Follow us on Twitter
twitter icon@FreshPatents


Cancer patents

      

This page is updated frequently with new Cancer-related patent applications.

Indian Institute Of Technology Bombay
. .

National University Corporation Hokkaido University
. .

Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels.
Universal Diagnostics, S.l.


Predictive baseline biomarkers for use of vascular disrupting agents
The present disclosure relates to the biological markers ferritin and il-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent..
Bionomics Limited


Pd-l1 antibodies and uses thereof
Provided herein are pd-l1 antibodies and methods for using the same for detecting human pd-l1 protein in biological samples. The pd-l1 antibodies and methods may be useful for diagnosing a medical condition associated with elevated pd-l1 levels (e.g., cancer) in subjects in need thereof and in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a pd-l1-related medical condition, among other uses..
Spring Bioscience Corporation


Biomarkers for ovarian cancer ctap3-related proteins
The present invention provides a protein-based biomarker that is useful qualifying ovarian cancer status to a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer.
The Johns Hopkins University


Methods and kits for detecting cancer
Kits for detecting cancer, including an agent for measuring lrrn1 antibody and a label indicating that the reagent for measuring lrrn1 antibody is for detecting cancer are disclosed. Methods for detecting cancer in a subject, including the steps of measuring the level of lrrn1 antibody, wherein a higher lrrn1 antibody level in the subject compare to a control sample, indicates the presence of cancer, are also provided..
Chang Gung Memorial Hospital, Linkou


Methods for determining prognosis of colorectal cancer
Provided herein are methods for determining the risk that a subject diagnosed with colorectal cancer will develop a recurrence of colorectal cancer and methods of predicting clinical outcome for a subject diagnosed with colorectal cancer by a) determining the level of expression for each marker of a panel of markers in a panel of tumor compartments in a tumor tissue sample from the subject, wherein the panel of markers comprises at least two of tem1, hif2α, caix, pdgfrβ, fibronectin, collagen i, collagen iv, and cd31 and wherein the panel of tumor compartments comprises at least three tumor compartments of pure stroma, tumor, stromal vessel, and tumor vessel; b) determining the tapps score for said subject; and c) comparing the tapps score of the subject to the tapps score of a population of subjects diagnosed with colorectal cancer. Also provided are related computer-implemented methods and systems, kits, and tumor microarrays..
Morphotek, Inc.


Phosphoproteins in extracellular vehicles as candidate markers for breast cancer
The state of protein phosphorylation and glycosylation can be key determinants of cellular physiology such as early stage cancer, but the development of phosphoproteins and/or glycoproteins in biofluids for disease diagnosis remains elusive. Here we demonstrate, for the first time, a strategy to isolate and identify phosphoproteins/glycoproteins in extracellular vehicles (evs) from human plasma as potential markers to differentiate disease from healthy states.
Purdue Research Foundation


Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
Methods are provided for detecting circulating tumor cells in a mammalian subject. Methods of diagnosing cancer in a mammalian subject are provided.
The Scripps Research Institute


Predictive biomarkers

The present disclosure relates to the biological markers sap, shbg, myoglobin, mmp-9, and scf that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent..
Bionomics Limited

Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model

Described are three-dimensional, engineered, biological breast tissues, adipose tissues, and tumor models, including breast cancer models.. .
Oregon Health & Science University

Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment

The present disclosure provides methods for predicting responsiveness of a subject having cancer to an ox40 agonist treatment by measuring the expression level of one or more biomarkers. Also provided are methods for monitoring pharmacodynamic activity of or responsiveness to an ox40 agonist treatment by measuring the expression level of one or more biomarkers.
Genentech, Inc.

Srm assay to indicate cancer therapy

The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the alk, ros, ron, ret, ts, and/or fgfr1 proteins that are particularly advantageous for quantifying the alk, ros, ron, ret, ts, and/or fgfr1 proteins directly in biological samples that have been fixed in formalin by the methods of selected reaction monitoring (srm) mass spectrometry, or as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Expression Pathology, Inc.

Single-molecule platform for drug discovery: methods and apparatuses for drug discovery, including discovery of anticancer and antiviral agents

The present application discloses methods and apparatuses for single molecule drug screening, discovery and validation. These methods and apparatuses allow a user to detect rapidly, using observation of single molecules, whether and how a drug candidate interferes with a target enzyme involved in a particular disease pathway.
Nanobiosym, Inc.

Compounds that target myc microrna responsive elements for the treatment of myc-associated cancer

Novel mir-330 agents and their methods of use are provided. Methods of treating myc-associated cancers are provided..
Beth Israel Deaconess Medical Center

Modified vaccinia virus strains for use in diagnostic and therapeutic methods

Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided.
Genelux Corporation

Device and obtaining immuno-stimulatory antigen-presenting cells

The present invention relates to methods for producing immuno-stimulatory antigen-presenting cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer..
Yale University

Binding molecules specific for cd73 and uses thereof

The present disclosure provides anti-cd73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with cd73-expression, e.g., cancer.
Medimmune Limited

Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Antagonistic tnfr superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory t cells (t-regs). For example, antibodies of the invention include antagonistic tnfr2 antibodies and antigen-binding fragments thereof, and can be used to suppress the t-reg-mediated deactivation of tumor reactive t-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases..
The General Hospital Corporation

Methods of treating fgfr3 related conditions

Provided herein are biomarkers and therapies for the treatment of pathological conditions, such as cancer, and method of using fgfr3 antagonists. In particular, provided is fgfr3 as a biomarker for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto..
Genentech, Inc.

Methods for tumor treatment using cd3xcd20 bispecific antibody

The present invention relates to a method (dosage regimen) for administering a cd3×cd20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating b cell (cd20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a cd3×cd20 bispecific antibody to a human patient.
Regeneron Pharmaceuticals, Inc.

Covalent diabodies and uses thereof

The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens.
Macrogenics, Inc.

Method for treating cancer metastasis and composition thereof

The present invention is related to a method for treating cancer metastasis and composition thereof. By using an il-35 antagonist, cancer metastasis can be effectively treated so that an increased cancer fee and overall survival can be achieved..
National Yang-ming University

Compositions and methods for treating cancer

One aspect of the invention provides a method for treating a cancer including administering to a subject in need of such treatment a composition including a therapeutically effective amount of an antibody directed against p40 monomer or an immunologically active fragment thereof. In various embodiments, the antibody is a polyclonal, monoclonal, human, humanized, and chimeric antibody; a single chain antibody or an epitope-binding antibody fragment.
Rush University Medical Center

Prevention of metastasis and recurrence after primary cancer treatment

There is provided methods for inhibiting metastasis or recurrence of a cancer in a patient after a primary treatment of the patient, and compositions for same. The method comprises administering a therapeutically effective amount of a composition for inhibiting cancer stem cell enrichment in other embodiments, the method comprises administering a therapeutically effective amount of a cancer therapy targeted towards a population of proliferating cancer stem cells in the patient..
Encyt Technologies, Inc.

Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer

This invention relates to ly6g6f, vsig10, tmem25 and lsr proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble ly6g6f, vsig10, tmem25 and lsr molecules, extracellular domains of ly6g6f, vsig10, tmem25 and lsr and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.
Compugen Ltd.

Combination immunotherapy

The invention is based on the disclosure provided herein that secondary lymphoid organ chemokine (slc) inhibits the growth of syngeneic tumors in vivo. Thus, the invention provides a method of treating cancer in a mammal subject by administering a therapeutically effective amount of an slc to the mammal in combination with a checkpoint inhibitor, including monoclonal antibodies and small molecule inhibitors.
The Regents Of The University Of California

Therapeutically active compositions and their methods of use

Provided are methods of treating a cancer characterized by the presence of a mutant allele of idh1/2 comprising administering to a subject in need thereof a compound described here.. .
Agios Pharmaceuticals, Inc.

Esters of steroidal lactam and bis(2-chloroethyl) aminophenoxy propanoic acid derivatives

Novel homo-aza-steroidal esters with alkylating bis(2-chloroethyl)aminophenoxy propanoic acid and substituted derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the treatment of cancer.. .
Energonbio Technologies S.a.

Progesterone-cationic lipid hybrid as anticancer agent and the process of synthesis thereof

The present invention relates to the development of the cationic progesterone compounds as a novel anti-tumor agent. The present invention provides a method for the preparation of novel series of progesterone derivatives.
Council Of Scientific & Industrial Research

Anticancer property studies of chiral palladium n-heterocyclic carbene complexes and process for preparation thereof

The present invention further investigates the influence of chirality on the anticancer activity, wherein the enantiomeric pairs of present chiral palladium n-heterocyclic carbene complexes of formula (ig, ih) shows no differential activity based on optical isomerism despite all of the palladium complexes exhibiting high anti-proliferative activity towards a variety of cancer cells. Also, provided herein is a process of preparation of the chiral palladium n-heterocyclic carbene complexes and a pharmaceutical composition comprising the chiral palladium n-heterocyclic carbene complexes.

Amino-triazolopyridine compounds and their use in treating cancer

And pharmaceutically acceptable salts thereof, where r1 and r2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent dna-pk mediated disease, including cancer.

Diaryl macrocycle polymorph

This disclosure relates to polymorphs of (7s,13r)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5h)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans..
Tp Therapeutics, Inc.

Bicyclic heterocyclic amide derivative

The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring q1 is optionally-substituted c6-10 aryl group, etc.; r1 and r2 are independently hydrogen atom, etc.; w1 is optionally-substituted c1-4 alkylene group; w2 is —nr3ac(o)—, etc. Wherein r3a is hydrogen atom or c1-6 alkyl group; cy1 is the following group of formula (11), etc.; ring q2 is optionally-substituted benzene ring, etc.; n and m are independently 0, 1 or 2, provided that n and m are not simultaneously 0; x is nr5, etc.; r5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; r4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent..
Sumitomo Dainippon Pharma Co., Ltd.

Bicyclic alkyne derivatives and uses thereof

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the map kinase interacting kinases mnk2a, mnk2b, mnk1a, and mnk1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g.
Agency For Science, Technology And Research

Antitumor derivatives for differentiation therapy

Wherein x is selected from ch, n, s, and o, y is selected from s, co, and o, r1 and optional r2 are independently selected from h, oh, substituted or unsubstituted c1-c6 alkyl, and substituted or unsubstituted c4-c6 cycloalkyl or cycloheteroalkyl, r3 is selected from h, oh, substituted or unsubstituted c1-c6 alkyl, and optional z is selected from oh, nh2, nh(co)r4, nh(so2)r4, guanidine, alkylguanidine, and fluoroguanidine, r4 is polyethylene glycol or substituted or unsubstituted c1-c6 alkyl, and pharmaceutically acceptable salt thereof. The imidazopyridine derivatives can be used for treatment of cancer in a subject..

Pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton's tyrosine kinase

Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics Llc

N2-phenyl-pyrido[3,4- d]pyrimidine-2, 8-diamine derivatives and their use as mps1 inhibitors

Wherein r1, r2, r3 and r4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of monospindle 1 (mps1—also known as ttk) kinases either directly or indirectly via interaction with the mps1 kinase itself.

Substituted quinazoline compounds and methods of use thereof

Or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein r, r1, r2a, r2b, r2c, a, b, l1 and e are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of g12c mutant kras protein for treatment of disorders, such as cancer, are also provided..

Parg inhibitory compounds

The present invention relates to compounds of formula i that function as inhibitors of parg (poly adp-ribose glycohydrolase) enzyme activity: wherein r1a, r1b, r1c, r1d, r1e, w, x1, x2, x3, x4, x5, x6, x7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which parg activity is implicated..
Cancer Research Technology Limited

Sulfinylphenyl or sulfonimidoylphenyl benzazepines

Wherein x and r1 to r6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

18f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.. .
Ruprecht-karls-universitaet Heidelberg

Pyrrolomycins and methods of using the same

Provided herein are pyrrolomycin derivatives, which can be used to modulate mcl-1, inhibit proliferation of bacteria and pathogens, as well as to treat infectious diseases and cancers.. .
Board Of Regents Of The University Of Nebraska

Cyanopyrrolidines as dub inhibitors for the treatment of cancer

The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (dubs). In particular, the invention relates to the inhibition of ubiquitin c-terminal hydrolase l1 (uchl1) and ubiquitin c-terminal hydrolase 30 or ubiquitin specific peptidase 30 (usp30).
Mission Therapeutics Limited

Lipids that increase insulin sensitivity and methods of using the same

The invention provides, inter alia, fatty acyl hydroxy fatty acid (fahfa; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, metabolic syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate fahfa levels, fahfa-mediated signaling, and fahfa-mediated biological effects.. .
President And Fellows Of Harvard College

System and multi-axis imaging of specimens

A specimen holding and positioning apparatus operable to substantially non-movably maintain a specimen (e.g., an excised tissue specimen) in a fixed or stable orientation with respect to the apparatus during imaging operations (e.g., x-ray imaging), transport (e.g., from a surgery room to a pathologist's laboratory), and the like for use in facilitating accurate detection and diagnosis of cancers and/or other abnormalities of the specimen.. .
Faxitron Bioptics, Llc

System and multi-axis imaging of specimens

A specimen holding and positioning apparatus operable to substantially non-movably maintain a specimen (e.g., an excised tissue specimen) in a fixed or stable orientation with respect to the apparatus during imaging operations (e.g., x-ray imaging), transport (e.g., from a surgery room to a pathologist's laboratory), and the like for use in facilitating accurate detection and diagnosis of cancers and/or other abnormalities of the specimen.. .
Faxitron Bioptics, Llc

Methods for better delivery of active agents to tumors

The present invention concerns delivery of agents through the skin. Methods for delivering agents such as bioactive agents are contemplated by the present invention.
Kimberly-clark Worldwide, Inc.

Antibodies for treatment and diagnosis

The invention relates to the diagnosis and treatment of diseases, including cancer and inflammatory disorders. The invention provides, and involves the use of, antibodies that bind: i) the iiics isoform of fibronectin, ii) matrix-metalloproteinase 3 (mmp3), iii) periostin, or iv) tenascin-w..
Philogen S.p.a.

Positron emitting radionuclide labeled peptides for human upar pet imaging

There is provided a positron-emitting radionuclide labelled peptide for non-invasive pet imaging of the urokinase-type plasminogen activator receptor (upar) in humans. More specifically the invention relates to human upar pet imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence..
Curasight Aps

Compound and pharmaceutical composition for tumor imaging and tumor therapy

A compound represented by formula (i) is provided, wherein in formula (i), r1 and r2 each independently represents hydrogen, o—r3 or s—r4, at least one of r1 and r2 is o—r3 or s—r4, and r3 and r4 are independently a c1 to c10 alkyl group, such that the c1 to c10 alkyl group is non-substituted or substituted with at least one selected from the group consisting of —oh, —nh2, halogen, ester, ether, and carboxylic acid, and m being a metal or a metal-containing compound. The compound represented by formula (i) is shown to have higher specificity to tumor cells, and is therefore suitable for carrying anti-cancer drugs and/or nuclear imaging agents..
Seecure Taiwan Co., Ltd.

Compositions and methods for treatment of autoimmune and other disease

Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates..
Cerulean Pharma Inc.

Nanoparticle composition for use in targeting cancer stem cells and treatment of cancer

There is disclosed a composition in the form of a nanoparticle. The nanoparticle composition has a diameter from 5 to 500 nanometers.
City University Of Hong Kong

Drug formulation based on particulates comprising polysaccharide-vitamin conjugate

The present disclosure provides formulations for pharmacologically active reagents, including formulations based on particulates formed from a biodegradable polymer (e.g., a polysaccharide such as dextran) linked to a vitamin or related agent (e.g., folic acid). Hydrophobic pharmaceutically active agents (such as anti-cancer drugs, e.g., paclitaxel) are encapsulated into the polysaccharide-vitamin conjugate for the administration of paclitaxel.
Zy Therapeutics, Inc.

Conjugated biological molecules, pharmaceutical compositions and methods

Antibody drug conjugates (adc's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics.
Obi Pharma, Inc.

Eribulin-based antibody-drug conjugates and methods of use

Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells.
Eisai R&d Management Co., Ltd.

Ckit antibody drug conjugates

The present invention relates to anti-ckit antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. .
Novartis Ag

Compositions and methods for the treatment of platinum-drug resistant cancer

Var2csa-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. Var2csa-drug conjugates (vdcs) comprise a var2csa polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofcs) and one or more toxins having anti-cancer activity conjugated to the var2csa polypeptide, either directly or via a linker..
Var2 Pharmaceuticals Aps

Treatment-resistance reducing agent for treatment-resistant cancer

[solution] a treatment-resistance reducing agent for treatment-resistant cancer that contains, as active ingredient(s), a substance specifically inhibiting the binding of interleukin-34 to colony stimulating factor-1 receptor and/or a substance suppressing the expression of interleukin-34 in a cancer cell. According to the present invention, the treatment resistance of cancer, which is resistant to a treatment method such as the administration of an anticancer agent or radiation therapy, can be reduced and, therefore, the efficacy of cancer treatment can be enhanced and the occurrence risk of a side effect can be suppressed..

Immunotherapy against melanoma and other cancers

A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has melanoma.
Immatics Biotechnologies Gmbh

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Compound and treating spasms, inflammation and pain

The disclosed invention generally relates to pharmaceutical and nutraceutical compounds and methods for reducing inflammation, muscle spasms, and pain associated with cancer, trauma, medical procedure, neurological diseases and disorders, as well as other conditions in subjects in need thereof. The disclosed invention further relates to mitragyna speciose and cannabis sativa-based compounds and synthetic analogs of the alkaloids found in said plants, where said compounds can also contain a pharmacologically inactive substance for modifying certain qualities of said compounds..

Compositions and methods related to multimodal therapeutic cell systems for cancer indications

The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer..
Rubius Therapeutics, Inc.

Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer

This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and nk-92 expressing fc receptor.. .
Nantkwest, Inc.

Methods of treating cancer, infectious disease, and autoimmune disease using cxc chemokines

The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using cxc chemokines and the receptors to which they agonize. It has been found that certain chemokines, including cxcl4, cxcl9, cxcl10, and cxcl12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention..
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery

Micro-rna for the treatment of malignant solid tumors and metastasis

Provided are compositions and methods for treating cancer, particularly solid tumors, and cancer metastasis, using micro-rnas mi r-96 and/or mi r-182.. .
Tel Hashomer Medical Research Infrastructure And Services Ltd.

Novel biomarker for diagnosing resistance to anticancer agent for billary tract cancer and use thereof

The present invention provides a novel molecule marker for resistance to an anticancer agent for biliary tract cancer, and diagnostic and therapeutic uses thereof. The marker, according to the present invention, shows significantly increased expression in an anticancer agent-resistant biliary tract cancer cell line compared to a non-anticancer agent-resistant biliary tract cancer cell line.
Cowell Biodigm Co., Ltd.

Method for prolonging the over survival of a cancer patient

The present invention relates to a method for treating a cancer with the combination of a topoisomerase ii inhibitor (top2 inhibitor) and a histone deacetylation inhibitor (hdaci), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (chk-1) is low.. .
National Yang-ming University

Methods and compositions for protection of cells and tissues from computed tomography radiation

Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and in cells affected by computed tomography (ct) radiation.
The University Of Chicago

Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer

The present disclosure is directed to methods of treating cancer comprising administering dihydrotestosterone, a dihydrotestosterone derivative, a dihydrotestosterone promoter, or a combination thereof to a patient in need of treatment.. .
Tyme, Inc.

Applications for estrone in preparing anti-ovarian cancer and/or breast cancer products

This invention discloses uses for estrone in preparing anti-ovarian cancer and/or breast cancer products. This invention provides uses for estrone in the preparation of products to treat ovarian cancer and/or breast cancer.
Shanghai Jiao Tong University

Combination therapy for treatment of hematological cancers and solid tumors

Provided herein are methods for treating, preventing, and/or managing hematological cancers and solid tumors using combination therapy of 3-(5-amino-2-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione and checkpoint inhibitors.. .
Celgene Corporation

Methods of treating cancer patients with farnesyltransferase inhibitors

The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (fti) that include determining whether the subject is likely to be responsive to the fti treatment based on genotyping and expression profiling of certain immunological genes and ras mutation status in the subject..
Kura Oncology, Inc.

Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors

The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the pim kinases and are useful in the treatment of diseases related to the activity of pim kinases including, e.g., cancer and other diseases..
Incyte Holdings Corporation

Indolotryptoline anticancer agents

Are disclosed. In these compounds r1 is chosen from hydrogen, halogen and oh; r2 is (c1-c4)alkoxy; and r3 is chosen from hydrogen and halogen the compounds are useful for treating cancer..

Novel methods for treating cancer

The invention provides thiazole-substituted indolin-2-ones as inhibitors of cancer stem cell pathway kinases (cscpk) and related kinases, and methods of using these compounds, to treat subjects in need thereof.. .
Boston Biomedical, Inc.

Spirocyclic hat inhibitors and methods for their use

Or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein r1, r2a, r2b, r3a, r3b, r4a, r4b, q1-q2, r6, r7, a, b, w, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various hat-related conditions or diseases, including cancer, by administration of such compounds are also provided..

Glucocorticoid receptor modulators to treat pancreatic cancer

The nonsteroidal sgrm may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a grm are disclosed.

Novel compounds and compositions for targeting cancer stem cells

The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.. .
Boston Biomedical, Inc.

Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same

Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, alzheimer's disease, parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided.
Concordia University

Dosage forms of halofuginone and methods of use

Oral and parenteral dosage forms comprising halofuginone, including enteric-coated solid oral dosage forms, subcutaneous dosage forms and intravenous dosage forms, for administration to subjects in need thereof, e.g., subjects having been identified with musculoskeletal disorders, fibrotic diseases, malaria, or cancer are described herein.. .
Akashi Therapeutics, Inc.

Exosomes for delivery of therapeutic agents

The present invention provides exosomes as drug delivery vehicles, compositions comprising a therapeutic agent encapsulated within such exosomes, methods of producing such exosomes and compositions thereof, as well as methods of delivering such exosomes and compositions to a specific patient tissue or organ. The present invention also provides methods of treating a disease, disorder, or condition such as cancer, an inflammatory disease, an infectious disease, an allergic disease, or an autoimmune disease, comprising administering to a patient in need thereof a provided therapeutic-loaded exosome or a pharmaceutical composition thereof..
Puretech Health Llc

Nanoliposomal formulation for targeting integrin-linked kinase (ilk) with small-interference rna and a treating ovarian cancer

The invention provides a nanoliposomal formulation that targets integrin linked kinase (ilk) with small-interfering rna (sirna) in cisplatin-resistant ovarian cancer. A reduction in cell proliferation and invasion was observed upon ilk depletion by sirna treatment.

Exosomal compositions and methods for the treatment of disease

An exosomal composition is provided that comprises a therapeutic agent encapsulated by an exosome. The therapeutic agent can be a phytochemical agent, a chemotherapeutic agent, or a stat3 inhibitor.
University Of Louisville Research Foundation, Inc.

Beverage composition comprising nanoencapsulated oxygen

The invention relates to a beverage composition comprising: water; oxygen bubbles; a surfactant in an amount of between about 0.1% (v/v) and about 0.5% (v/v); one or more viscosity modifying agent(s) in an amount of between about 0.5% (v/v) and about 2.5% (v/v); and optionally citric acid in an amount of between about 0.1% (v/v) and about 0.5% (v/v). The invention further relates to compositions, methods of treatment for cancer, the composition for use in treatment of cancer, and the manufacture of the composition..
Oxford University Innovation Limited

System and magnetically mediated plasma treatment of cancer with enhanced selectivity

A system and method of treating an area having cancerous cells. The system includes a plasma device to generate a plasma jet directed at the area having cancerous cells.
The George Washington University

Electronic cigarette

An electronic cigarette comprises nicotine without harmful tar. The cigarette includes a shell, a cell, nicotine solution, control circuit, and an electro-thermal vaporization nozzle installed in the air suction end of the shell.
Fontem Holdings 1 B.v.

Antibodies against phosphorylcholine in combination therapy with biologic agents

Antibodies against pc, pc conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are pc conjugates, pc or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells..
Suntory Flowers Limited

Method, apparatus and computer program for analysing medical image data

Medical image data is analysed to produce a biomarker. The data is filtered with a plurality of band-pass filters each having a different bandwidth.
Texrad Limited

Marker for heterogeneity of cancer tissue, and use thereof

A genetic marker is provided that can determine whether or not a cancer tissue contains a heterogeneous cancer cell population, the genetic marker being selected from the group consisting of calml3, bgn, clca2, csta, aldh1a1, ngfr, s100a8, eln, snurf, and lgals7.. .
Keio University

Septin proteins as novel biomarkers for detection and treatment of mÜllerian cancers

Provided herein, inter alia, are septin family proteins as novel biomarkers for the detection of müllerian cancers such as ovarian, fallopian tube, primary peritoneal, endometrial and uterine cancers as well as therapeutics targeting of septin-2 and other septin family genes and proteins via small molecule, antisense or antibody targeted treatment for treatment of the same. Thus, provided herein are molecular tools and methods for diagnosing müllerian cancers and for identifying subjects with an increased likelihood of having müllerian cancers..
University Of Rochester

Salivary biomarkers for gastric cancer detection

Disclosed herein are biomarkers related to gastric cancer. The presently identified salivary biomarkers create the basis for a gastric cancer detection bioassay with sensitivity and specificity.
The Regents Of The University Of California

Cancer diagnostic

Disclosed is the use of latrophilin expression as a biomarker for the diagnosis of haematopoietic cell cancer in a subject, together with methods for diagnosis and a kit for the detection of latrophilin expression on white blood cells collected from a subject.. .
University Of Kent, School Of Pharmacy

Methods for diagnosis and prognosis of epithelial cancers

The present invention is based on the discovery that three proteins, cystatin b, chaperonin 10, and profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples.
The General Hospital Corporation D/b/a Massachusetts General Hospital

Srm/mrm assays for cancer

Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by srm/mrm assay. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks.
Expression Pathology, Inc.

Gamma 9 delta 2 t-cell receptors

The current invention provides methods to identify γ9δ2t-cell receptors (γ9δ2tcr) that mediate anti-tumour responses. Surprisingly, it was now found that the cdr3 regions of the γ9-t-cell receptor chain and the δ2-t-cell receptor chain (δ2tcr chain) are of importance.
Gadeta B.v.

Phylogenetic analysis of mass spectrometry or gene array data for the diagnosis of physiological conditions

A universal data-mining platform capable of analyzing mass spectrometry (ms) serum proteomic profiles and/or gene array data to produce biologically meaningful classification; i.e., group together biologically related specimens into clades. This platform utilizes the principles of phylogenetics, such as parsimony, to reveal susceptibility to cancer development (or other physiological or pathophysiological conditions), diagnosis and typing of cancer, identifying stages of cancer, as well as post-treatment evaluation.

Cell classification based on mechanical signature of nucleus

The present invention relates to a method and system for identifying mechanical properties of a cell nucleus through a label-free cell analysis based on brillouin light scattering techniques. The present application additionally provides a method and system for identifying cancerous cells based on mechanical properties of the cell nucleus..
Canon U.s. Life Sciences, Inc.

Methods and materials for detecting colorectal cancer and adenoma

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long dna (e.g., quantified by alu pcr) and the presence and level of tumor-associated gene alterations (e.g., mutations in kras, apc, melanoma antigen gene, p53, braf, bat26, pik3ca) or epigenetic alterations (e.g., dna methylation) (e.g., cpg methylation) (e.g., cpg methylation in coding or regulatory regions of bmp-3, bmp-4, sfrp2, vimentin, septin9, alx4, eya4, tfpi2, ndrg4, foxe1) in dna from a stool sample obtained from the mammal..
Mayo Foundation For Medical Education And Research

Compositions, methods and kits for the diagnosis of carriers of mutations in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 genes

The present invention relates to diagnostic compositions methods and kits for the detection of carriers of mutations in the brca1 and brca2 genes. The detection is based on the use of detecting nucleic acids or amino acid based molecules, specific for determination of the expression of at least six marker genes of the invention, in a test sample.
Hadasit Medical Research Services And Development Ltd.

Fusion genes associated with progressive prostate cancer

The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: trmt11-grik2, slc45a2-amacr, mtor-tp53bp1, lrrc59-flj60017, tmem135-ccdc67 and ccnh-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence

The invention provides a kit for detecting the presence or absence of mutations in the selected regions of the target genes associated with colorectal cancer, comprising xna clamps and primers; wherein the xna clamps are capable of hybridizing with the selected regions having wild-type sequences in the target genes, and the primers are capable of amplifying the selected regions containing each of the mutations in the target genes. The invention also discloses a method of detecting a mutant gene associated with colorectal cancer, comprising: providing a sample containing dna and a xeno nucleic acid clamp capable of hybridizing to a wild-type gene; and detecting a mutant of the gene in the sample with a xeno nucleic acid probe capable of hybridizing to the mutant gene..

Methods of treating cancer patients with farnesyltransferase inhibitors

The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to methods of treating a subject with a farnesyltransferase inhibitor (fti) that include determining whether the subject is likely to be responsive to the fti treatment based on hras mutation status in the subject..
Kura Oncology, Inc.

Methods and compositions for correlating genetic markers with prostate cancer risk

The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (crr) for the subject based on the genotype determined in step (a). A crr of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early psa screening, prostate biopsy and/or chemoprevention..
Wake Forest University Health Sciences

Probes and a methylation in situ hybridization assay

The disclosure relates to the field of molecular pathology (for example, cancer diagnosis, prognosis, treatment and/or therapy prediction) through the detection of rna, mutations, copy number changes and determination of the methylation status of specific sequences of the genome of individual patients in hybridization assays (southern blot, ish, dot blot) including in situ determination of the methylation status of specific sequences of the genome of individual patients in individual cells. More specifically, this disclosure relates to: a) target-specific probes covalently attached to a labeled tail, b) the synthesis method of said the probe, c) the usage of said the probe such as an in situ hybridization-based method to correlate the methylation status of a promoter region of a gene in a biopsy or cytology specimen of a patient to the morphology and localization in that specimen, and d) kits comprising the target-specific probes.
Universiteit Gent

Accurate molecular deconvolution of mixture samples

The present disclosure relates to methods to deconvolute a mixture sample of genetic material from different origins or sources. The disclosed methods can be used in various applications, including, the non-invasive determination of a fetal genome, a fetal -ome (e.g.
Arima Genomics, Inc.

Multi-target modulation for treating fibrosis and inflammatory conditions

The present invention relates to compositions comprising one or more active agents that selectively modulate the expression of two or more genes, for example at the post-transcription level, that are involved in fibrosis and/or inflammatory conditions. Also provided are methods of using such compositions for treating fibrotic diseases, as well as other diseases including inflammatory diseases and cancer..
Aadigen, Llc

Cancer specific-splicing ribozyme and use thereof

The present invention relates to a recombination vector, a transformation cell into which the recombinant vector is introduced, a ribozyme expressed from the recombination vector, a prophylactic or therapeutic composition for liver cancer comprising the recombination vector and the ribozyme, and a therapeutic method for liver cancer using the composition, said recombination vector comprising: a tissue-specific promoter; and a ribozyme-target gene expression cassette comprising a trans-splicing ribozyme targeting a cancer-specific gene and a target gene connected to the 3′ exon of the ribozyme, wherein a splicing donor/splicing acceptor sequence (sd/sa sequence) is connected to the 5′ end of the ribozyme-target gene expression cassette, woodchuck hepatitis virus posttranscriptional regulatory element (wpre) is connected to the 3′ end of the ribozyme-target gene expression cassette, and a nucleic acid sequence recognizing a micro rna-122a (microrna-122a, mir-122a) is further connected to the 3′ end of the wpre.. .
Industry-academic Cooperation Foundation, Dankook University

Mumps virus as a potential oncolytic agent

This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent..
Mayo Foundation For Medical Education And Research

Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response

The present disclosure provides populations of cells comprising partially mature and optimally activated dendritic cells that can be used for administration to individuals having a cancer and/or tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 10 to about 19 hours, upon administration efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual.
Northwest Biotherapeutics, Inc.

Anti-fibroblast activation protein (fap) antibodies for treatment and diagnosis

The present invention relates to the diagnosis and treatment of diseases, such as cancer and inflammatory disorders. The invention provides, and involves the use of, antibodies that bind fibroblast activation protein (fap)..
Philogen S.p.a.

Anti-cd276 antibodies (b7h3)

Polypeptides and proteins that specifically bind to and immunologically recognize cd276 are disclosed. Chimeric n antigen receptors (cars), anti-cd276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed.
Biomed Valley Discoveries, Inc.

Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function

The present invention is directed to antibodies and fragments thereof having binding specificity for fzd7, which preferably do not substantially interact with (bind to) other fzd family members, and methods of making said anti-fzd7 antibodies and binding fragments thereof. Another embodiment relates to antibodies and binding fragments comprising sequences of vh, vl and/or cdr polypeptides described herein.
The Regents Of The University Of California

Human antibodies to pd-l1

The present invention provides antibodies that bind to the t-cell co-inhibitor ligand programmed death-ligand1 (pd-l1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-l1.
Regeneron Pharmaceuticals, Inc.

Antibody molecules to pd-l1 and uses thereof

Antibody molecules that specifically bind to pd-l1 are disclosed. Combination therapies comprising the anti-pd-l1 antibody molecules are also disclosed.
President And Fellows Of Harvard College

Anti-human tim-3 antibodies and methods of use thereof

An anti-human t-cell immunoglobulin domain and mucin domain 3 (tim-3) antibody, can bind the peptides, comprising the amino-acid sequence rkgdvsl (seq id no: 9) and/or ekfnlkl (seq id no: 10) of human tim-3 protein. The antibody can regulate immune cell activity.
Development Center For Biotechnology

Native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3

Novel monoclonal antibodies directed against immune checkpoint modulator (icm) proteins tim-3 and b7-h3 are useful in treating cancer and immune system disorders.. .
Trellis Bioscience, Llc

Chimeric receptors and methods of use thereof

The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.. .
Alector Llc

Antibody against human nrg1 protein

An object is to provide an antibody capable of specifically recognizing a human nrg1 protein isoform, and suppressing signal transduction in which the isoform is involved. An antibody capable of binding to a region at positions 221 to 234 of a human nrg1-α protein or an antibody capable of binding to a region at positions 213 to 239 of a human nrg1-β1 protein was successfully obtained.
Medical & Biological Laboratories Co., Ltd.

Novel peptide and use thereof

This invention relates to a peptide consisting of an amino acid sequence of seq id no:1 or a pharmaceutically acceptable salt thereof, and to the use thereof. According to this invention, cancer can be effectively prevented or treated..
Ensol Biosciences Inc.

Selective cysteine protease inhibitors and uses thereof

The present invention relates to compounds of formula i, ii, ia-va, iva1-iva5, iiia1-iiia5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases.
Genesis Technologies Limited

Cyclic di-nucleotides as modulators of sting

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer and as vaccine adjuvants..

Ectonucleotidase inhibitors and methods of use thereof

The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention..
Calithera Biosciences, Inc.

Pharmaceutical co-crystal composition and use thereof

The current invention relates to series of co-crystals of platinum analogues and their pharmaceutical use. The co-crystals of the subject invention may be used in the treatment or prevention of cancers and virus infections..
Syn-nat Products Enterprise Llc

Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer

The present application is directed to pharmaceutical compositions comprising derivatives of 6-(4-substitutedphenyl)-2-(substituted piperidine)imidazo[2,1-b][1,3,4]thiadiazol-2-yl], to a method of treating cancer using these compositions and to processes for preparing these derivatives.. .
Urifer Ltd.

Chiral diaryl macrocycles as modulators of protein kinases

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.

Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
Glaxosmithkline Llc

Brk inhibitory compound

The present invention relates to a compound represented by general formula (i) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof an n-oxide thereof, or a prodrug of any of these. Since the compound has a brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of brk-related diseases such as cancer, for example..
Ono Pharmaceutical Co., Ltd.

Heteroaryl substituted aminopyridine compounds

Disclosed are compounds of formula (i) or salts thereof, wherein het is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of formula (i) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 rb; a is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 ra; and r3, ra, and rb are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Compounds and uses thereof

The present invention refers to 4-amino-substituted pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives of formula i and iv able to target the src family kinases (sfks) such as src, fyn and hck tyrosine kinases as well as abl tyrosine kinase and uses and method of preparation thereof. In particular, the compounds of the invention are for use in the treatment and/or prevention of cancer, such as neuroblastoma (nb) or glioblastoma multiforme (gbm) or for use in the treatment and/or prevention of neurodegenerative diseases such as taupathies..
Lead Discovery Siena S.r.l.

Quinoxaline derivatives useful as fgfr kinase modulators

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. Cancer..
Astex Therapeutics Ltd

Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them

Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .

Disubstituted triazole analogs

The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of formula (i) are provided..
Bioventures, Llc

6-aminoisoquinoline compounds

6-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided.
Aerie Pharmaceuticals, Inc.

Histone methyltransferase inhibitors

The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases g9a and/or glp inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of g9a and/or glp such as cancers and hemoglobinpathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds..
Global Blood Therapeutics, Inc.

Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders

The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (compound 1) in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).. .
Arena Pharmaceuticals, Inc.

Polymorphic forms of rad1901-2hcl

Various polymorphic forms of rad1901-2hcl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of rad1901-2hcl for cancer treatment are also disclosed..
Radius Pharmaceuticals, Inc.

Multiple cation cancer therapy apparatus and use thereof

The invention comprises a method and apparatus for imaging and/or treating a tumor of a patient using multiple ion types, such as a cations with one, two, or more mass-to-charge ratios and/or electrons, where the multiple ion types are accelerated, at separate times, using a single accelerator, and the multiple ion types are used to treat different depths into a tumor of a patient, where the patient is optionally maintained in a single treatment position relative to a patient positioning system during treatment.. .

Human antibodies to pd-1

The present invention provides antibodies that bind to the t-cell co-inhibitor programmed death-1 (pd-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1.
Regeneron Pharmaceuticals, Inc.

Ceacam1 based cancer therapy and diagnosis

The invention relates to methods and compositions for the treatment and diagnosis of cancers. At least one aspect of the present invention relates to methods and compositions for enhancing the efficacy of tumor-infiltrating lymphocyte (til) therapy in the treatment of cancer by negatively modulating the activity of the ceacam1 protein..

Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors

The present invention relates to methods of treating cancers that over-express somatostatin receptors. More specifically, the invention provides a combined therapy in which a combination of peptide receptor radionuclide therapy (prrt) and immuno oncology therapy (i-o therapy) are administered for the treatment of neuroendocrine tumors..
Advanced Accelerator Applications

Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous dna sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer.
Trieza Therapeutics, Inc.

Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies

The present application relates to novel binder drug conjugates (adcs), to active metabolites of these adcs, to processes for preparing these adcs, to the use of these adcs for the treatment and/or prophylaxis of diseases and to the use of these adcs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures..
Bayer Pharma Aktiengesellschaft

Amatoxin-conjugates with improved linkages

The present disclosure relates to tumour therapy. In one aspect, the present disclosure relates to conjugates of an amatoxin and a target-binding moiety, e.g.
Heidelberg Pharma Gmbh

Methods of treating prlr positive breast cancer

Provided herein are methods of treating prolactin receptor positive breast cancer using an antibody drug conjugate (adc) comprising an anti-prlr antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent. In certain embodiments, the anti-prlr antibody or antigen-binding fragment thereof is conjugated to maytansinoid.
Regeneron Pharmaceuticals, Inc.

Prodrugs activated by caspase

Described are prodrug conjugates that release a chemotherapeutic agent upon activation by caspase, and methods using such prodrug conjugates to induce apoptosis, amplify apoptosis, and treat cancer.. .
Pharosgen Co., Ltd.

Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (odn) sequence conjugated to a short-activating rna (sarna) or an antisense oligonucleotide sequence (aso), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating cebpa, and method of reducing activity of stat transcription factor, by one of the disclosed compounds or compositions.. .
City Of Hope

Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer

The present disclosure describes combination therapies comprising an antagonist of programmed death 1 receptor (pd-1) and a listeria based strain that expresses prostate-tissue specific antigen (psa), and the use of the combination therapies for the treatment of prostate cancer.. .
Merck Sharp And Dohme Corp.

Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)

Provided is a natural killer (nk) cell killing of various tumors is inhibited in the presence of ligands of tigit, an inhibitory receptor present on all human nk cells and on various t cells. Monoclonal antibodies that recognize tigit and inhibit its suppressive activity on t-cells are provided as well as pharmaceutical compositions including them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders..
University Of Rijeka Faculty Of Medicine

A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy

An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, selected from a cell, protein, peptide, antibody or antigen binding fragment thereof, directed against ctla-4, pd-1, pd-l1 and combinations thereof, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator comprises a whole cell mycobacterium, for example, m.
Immodulon Therapeutics Limited

Drug regimen for treatment of cerebral ischemia

Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (vegf-rst) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity..
Shimojani, Llc

Pd-1 peptide inhibitors

This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (pd-1). These peptides block the interaction of pd-1 with its ligand pd-l1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis..
Leidos, Inc.

Allogenic tumor cell vaccine

The described invention provides a tumor cell vaccine comprising genetically modified tumor cell line of a particular tumor type that stably expresses high levels of two or more immunomodulators. According to some embodiments, an immunogenic amount of the tumor cell line variants may be selected for concomitant expression of two or more of recombinant membrane expressed igg1, cd40l, tnf-alpha, as well as membrane and soluble forms of gm-csf, and flt-3l peptides that are effective to elicit an anti-tumor immune response compared to the parent unmodified tumor cell line as measured in vitro by a one-way mixed lymphocyte tumor reaction assay using human peripheral blood mononuclear cells and the genetically modified allogeneic cell vaccine candidate.
Alloplex Biotherapeutics

Seaweed extracts with anti-cancer activity

The present invention provides extracts from red seaweeds such as: polysiphonia ureceolata or polysiphonia flexicaulis, as well as their use for inhibiting the growth of cancer cells, fractions from these seaweeds, and methods for their extraction.. .
Oceans Ltd.

Methods of diagnosing and treating cancer

A method of treating cancer in a subject includes determining the p53 status and the level of udg in cancer cells of the subject and administering an antimetabolite agent in combination with an ap endonuclease inhibitor or udg inhibitor if the determined level of udg in the cancer cells is increased relative to the control level and the cancer cells are p53 mutant or deficient cancer cells.. .
Case Western Reserve University

Anticancer agent

The present invention aims to provide a therapeutic drug for cancer having a superior treatment effect. A cancer treatment using a cbp/catenin inhibitor and an immune checkpoint inhibitor in combination not only increases a treatment effect on cancer, but also enables an effective treatment of cancer patients showing low sensitivity when an immune checkpoint inhibitor is used alone..
Eisai R&d Management Co., Ltd.

Pharmaceutical compositions and methods

This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [gr] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.. .
Pop Test Oncology Llc

Applications for levonorgestrel in preparing anti-ovarian cancer products

This invention discloses uses for levonorgestrel in preparing anti-ovarian cancer products. This invention provides uses for levonorgestrel in the preparation of products to treat ovarian cancer.
Shanghai Jiao Tong University

Applications for etonogestrel in preparing anti-prostate cancer products

This invention discloses uses for etonogestrel in preparing anti-prostate cancer products. This invention provides uses for etonogestrel in preparing anti-prostate cancer products.
Shanghai Jiao Tong University

Applications of desogestrel in the preparation of anti-colon cancer/breast cancer er-negative ah receptor-positive products

This invention discloses applications of desogestrel in the preparation of anti-colon cancer/breast cancer er-negative ah receptor-positive products. This invention provides applications for desogestrel in the preparation of products to treat colon cancer and/or breast cancer.
Shanghai Jiao Tong University

Applications for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products

This invention discloses uses for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products. This invention provides uses for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products.
Shanghai Jiao Tong University

Compositions and methods for treating cancer

A method of treating cancer in a subject in need thereof includes administering to the subject therapeutically effective amounts of a pp2a activator and a protein kinase inhibitor.. .
Icahn School Of Medicine At Mount Sinai

Applications for promethazine in preparing anti-liver cancer and/or colon cancer and/or lung cancer products

This invention provides uses for promethazine in the preparation of products to treat liver cancer and/or colon cancer and/or lung cancer. From carrying out cancer drug repositioning for the fda- and cfda-approved drug promethazine, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that promethazine has a new use as an anti-liver cancer and/or colon cancer and/or lung cancer medication, thus achieving a new purpose for an old drug..
Shanghai Jiao Tong University

Systems and methods for treating cancer

Embodiments of the invention provide a method of treating cancer, the method comprising providing a subject having cancer cells, and contacting the cancer cells with a therapeutically effective amount of a g2/m checkpoint inhibitor. Embodiments of the invention also provide a method of treating cancer in a subject, the method comprising the steps of: (a) receiving a sample of the cancer cells from the subject; (b) determining if at least a portion of the sample of the cancer cells is lkb 1 deficient; and (c) contacting the cancer cells with a therapeutically effective amount of a g2/m checkpoint inhibitor..
The Translational Genomics Research Institute

Pharmaceutical combinations

A pharmaceutical combination comprising (a) an alk inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one hdma-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one braf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.. .
Novartis Ag

Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy

Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a dihydropyrazino-pyrazine compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.. .
Signal Pharmaceuticals, Llc

Therapy of small-cell lung cancer (sclc) with a topoisomerase-i inhibiting antibody-drug conjugate (adc) targeting trop-2

The present invention relates to treatment of sclc with therapeutic adcs comprising a drug attached to an anti-trop-2 antibody or antigen-binding antibody fragment. Preferably, the drug is sn-38.
Immunomedics, Inc.

Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions

Compositions and methods for treatment of viral skin disease, precancerous and cancerous skin disease, and other neoplasms are disclosed.. .
The Trustees Of The University Of Pennsylvania

Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer

The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-cs1 antibodies in combination with one or more immunotherapeutic agents.. .
Bristol-myers Squibb Company

Applications for nicardipine in preparing anti-lung cancer products

This invention discloses uses for nicardipine in preparing anti-lung cancer products. This invention provides uses for nicardipine in the preparation of products to treat non-small cell lung cancer.
Shanghai Jiao Tong University

Treatment of brca1-defective cancer or resistant cancers

Provided herein are methods of treating cancer in a subject by administering coh29 ((n-(4-(3,4-diydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide)). The methods of treating include treating a brca1-defective subject, a parp1 inhibitor-resistant subject or a dna-damaging anti-cancer agent resistant subject.
City Of Hope

Compositions and methods of rit1 inhibition

Various compounds, compositions, and methods for inhibition of rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with rit1 signaling..
Nantbio, Inc.

Methods of treatment associated with the granulocyte colony-stimulating factor receptor

Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (gcfr) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a gcfr modulator to a subject in need thereof..
Ligand Pharmaceuticals Incorporated

Compositions and methods for diagnosis and treatment of inflammation

Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.. .
The United States Of America As Represented By The Secretary Of The Navy

Applications for sulindac in preparing anti-lung cancer products

This invention discloses uses for sulindac in preparing anti-lung cancer products. This invention provides uses for sulindac in the preparation of products to treat lung cancer.
Shanghai Jiao Tong University

Use of short chain fatty acids in cancer prevention

The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids.
Temple University-of The Commonwealth System Of Higher Education

Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer

A mechanism of monoamine oxidases (maos) driven epithelium-to-mesenchymal transition (emt) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing maos in cancer cells.
University Of Southern California

Milk-derived microvesicle compositions and related methods

A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum.
University Of Louisville Research Foundation, Inc.

Nanoliposomal c-myc-sirna inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer

The present invention discloses c-myc-sirna formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-myc with small interfering rna (sirna) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation.

Curcumin-loaded nanoemulsions, manufacture, and preventive treatment using the same

A oil-in-water curcumin nanoemulsion that includes curcumin dissolved in at least one miscible solvent and encapsulated in an oil core, wherein the oil core also comprises a stabilizer, wherein the oil core forms an organic phase which is dispersed in an aqueous solvent, and wherein the oil core is selected from a pharmaceutically acceptable oil. A method of manufacturing an oil-in-water curcumin nanoemulsion includes dissolving the curcumin in at least one miscible solvent; encapsulating the curcumin in the oil core to produce an organic phase solution; adding the stabilizer to the organic phase solution; dispersing the organic phase solution in the aqueous solvent; and evaporating the mixture.
Universidad De Chile

Imaging device and detection of disease

A system for testing a biological subject includes an imaging device and an imaging agent detectable by the imaging device, for detecting amount and location of a biomarker in the biological subject. The imaging agent includes a fluorescent microsphere and a targeting member attached to the fluorescent microsphere.
Vigilant Biosciences, Inc.

R-pharm Overseas Inc.

. .

Identifying and excluding blurred areas of images of stained tissue to improve cancer scoring

A method for identifying blurred areas in digital images of stained tissue involves artificially blurring a learning tile and then training a pixel classifier to correctly classify each pixel as belonging either to the learning tile or to a blurred copy. A learning tile is first selected from a digital image of stained tissue.
Definiens Ag

Methods of treating cancer by identification of patients sensitive to fgfr inhibitor therapy

Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring (srm) mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Expression Pathology, Inc.

Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers

The disclosure relates to use of the he4/he4a marker(s) to assess endometrial and uterine cancer in a patient. The disclosure also relates to using tumors marks for diagnosis, grading and staging of endometrial and uterine cancers.
Fujirebio America, Inc.

Means and methods for diagnosing pancreatic cancer in a subject based on a biomarker panel

The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising the steps of: (a) determining in at least one sample of said subject the amounts of a group of diagnostic biomarkers comprising (i) at least one diagnostic amino acid, said diagnostic amino acid being proline, histidine or tryptophan, preferably, being proline; (ii) at least one diagnostic ceramide, said diagnostic ceramide being ceramide (d18:1,c24:0) or ceramide (d18:2,c24:0), preferably being ceramide (d18:1,c24:0); (iii) at least one diagnostic sphingomyelin, said diagnostic sphingomyelin being sphingomyelin (35:1), sphingomyelin (d17:1,c16:0), sphingomyelin (41:2) or sphingomyelin (d18:2,c17:0), preferably being sphingomyelin (35:1); and (iv) ca19-9; and (b) comparing said amounts of the diagnostic biomarkers with a reference, whereby pancreatic cancer is diagnosed. Moreover, the present invention relates to a method for determining the probability for a subject to suffer from pancreatic cancer, and to devices and uses related to said methods..
Metanomics Health Gmbh

Method of detecting lung cancer

A biomarker panel for a urine test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of dma, c5:1, c10:1, adma, c5-oh, sdma, and kynurenine, or a combination thereof. A biomarker panel for a serum test for detecting lung cancer detects a biomarker selected from the group of biomarkers consisting of valine, arginine, ornithine, methionine, spermidine, spermine, diacetylspermine, c10:2, pc aa c32:2, pc ae c36:0, and pc ae c44:5; and lysopc a c18:2, or a combination thereof..
Biomark Cancer Systems Inc.

Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof

The present disclosure relates to a biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof. The present disclosure provides a marker, a composition, and a kit for predicting the sensitivity to a protein kinase inhibitor, and a prediction method thereof.
Cj Healthcare Corporation

Diagnosis and treatment of viral diseases

This disclosure relates to methods of diagnosing a viral disease such as idiopathic pulmonary fibrosis, castleman's disease, a lymphoma, a thymoma or a sarcoma in a patient by identifying one or more virus-specific elements such as a nucleic acid or a viral protein or a patient antibody to a virus-specific element, as well as to kits for diagnosing the viral disease in a patient. The disclosure further relates to methods of monitoring disease progression and/or the efficacy of therapy by measuring the levels of a virus-specific element in a sample from a patient.
Enzo Biochem, Inc.

Method for analyzing biological specimens by spectral imaging

A method for analyzing biological specimens by spectral imaging to provide a medical diagnosis includes obtaining spectral and visual images of biological specimens and registering the images to detect cell abnormalities, pre-cancerous cells, and cancerous cells. This method eliminates the bias and unreliability of diagnoses that is inherent in standard histopathological and other spectral methods.
Northeastern University

Allogeneic autophagosome-enriched composition for the treatment of disease

A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
Providence Health & Sevices-oregon

Cancer markers

Hence, the invention relates to a method for diagnosis and/or prognosis of cancer, comprising the steps of analyzing in a sample of a subject the dna methylation status of a genomic region of at least one member of the group of, (i) sfn according to seq id no. 1, (ii) slit2 according to seq id no.
Queen Mary And Westfield College University Of London

Histone modification agents for cancer treatment

Described herein are methods of cancer diagnosis through monitoring the presence and activity of the kansl1 gene, and particularly the effects of kansl1 overexpression on specific histone acetylation. Cancer treatment with histone acetyltransferase inhibitors and deacetylase agents is also described..
Mor Research Applications Ltd.

Targeted gene delivery for dendritic cell vaccination

Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (dc). The virus envelope comprises a dc-sign specific targeting molecule.
California Institute Of Technology

Medicine for treating cancer and treating cancer

An object of the present invention is to reveal a role of a stem cell control factor including matrin-3 in cancer exhibiting neural differentiation including small cell lung cancer, and develop a medicine useful for treating cancer and the like based on the role. Among cancers having the cancer stem cell controlling mechanism, in cancer exhibiting the differentiation potency, the peculiar balance where both of expression of a stem cell maintenance factor and expression of a differentiation promoting factor are higher as compared with normal cells is retained.
Tokyo Institute Of Technology

Compositions and methods for inhibiting cell proliferation

The present disclosure provides, among other things, compounds that inhibit the expression or activity of gene products having a synthetic lethal interaction with loss of tsc1 and/or tsc2. Also provided are applications, such as therapeutic and diagnostic methods, in which the compounds are useful.
President And Fellows Of Harvard College

Magnetic nanostructure for detecting and isolating cell-free dna comprising cationic polymer and magnetic-nanoparticle-containing conductive polymer

Provided is a magnetic nanostructure for detecting and isolating cell-free dna (cfdna) that including a cationic polymer and a magnetic-nanoparticle-containing conductive polymer. The magnetic nanostructure for detecting and isolating cfdna according to the subject matter can significantly improve detection and extraction efficiencies of dna present in a urine, csf, blood plasma, or blood sample, and exhibits an enhanced sensitivity.
National Cancer Center

Artificial immune cell emulating selected properties of granulocytes utilizing fenton-type reactions

An artificial immune cell emulating certain properties of the granulocytes is disclosed as a construct or aggregate of several constituent particles that possess the properties of catalysis therefore producing free radicals and reactive species of oxygen, nitrogen, halogens and the like in the classical fenton and fenton-like reactions with produced free radicals serving as signaling molecules and, in higher concentrations, as toxic factors for microorganisms, cancerous cells, abnormal tissue and other biological targets, emulating the production of free radicals by natural immune cells. Motility of the artificial immune cell is facilitated by magnetotactic and other means, as some or all of the constituent particles possess magnetic, especially superparamagnetic properties which may be provided by the same catalytic components since said particles such as those containing compounds such as magnetite, maghemite, and substituted ferrites are capable of catalyzing fenton-type reactions.

Bispecific antigen-binding constructs targeting her2

Provided herein are biparatopic antigen-binding constructs that specifically bind her2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ecd2 of her2, a second antigen-binding moiety that binds to ecd4 of her2, and an fc.
Zymeworks Inc.

Use of chimeric antigen receptor modified cells to treat cancer

The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (car) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding car.
Innovative Cellular Therapeutics Co., Ltd.

Binding molecules for the treatment of cancer

This invention relates to binding molecules that bind specifically to tnf-related apoptosis-inducing ligand receptor 2 (trailr2) and cadherin-17 (cdh17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.. .
Boehringer Ingelheim International Gmbh

Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways

This disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a combination of therapeutically effective amounts of an antibody or an antigen-binding portion thereof that binds specifically to programmed death-1 (pd-1) or to programmed death ligand-1 (pd-l1), and an antibody or an antigen-binding portion thereof that binds specifically to c-x-c chemokine receptor 4 (cxcr4) or to c-x-c motif chemokine 12 (cxcl12). The disclosure also provides a kit for treating a subject afflicted with a cancer, the kit comprising one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to pd-1 or to pd-l1, one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to cxcr4 or to cxcl12, and instructions for using the antibodies or portions thereof for treating the subject..
Bristol-myers Squibb Company

Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target

The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research

Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

The present invention provides compositions comprising an anti-cd7 chimeric activating receptor (car) and an anti-cd7 protein expression blocker, and methods of using such compositions in cancer therapy.. .
National University Of Singapore

Methods for treating inflammatory disorders or cancer metastasis by administering antibodies to connexin 43 (cx43) hemichannels

Methods for identifying compounds that positively regulate connexin 43 hemichannels.. .
Board Of Regents Of The University Of Texas System

Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers

The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158p1d7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158p1d7 and variants thereof.. .
Agensys, Inc.

Hpv vaccines

Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses.
Hookipa Biotech Ag

Pharmaceutical composition of carboplatin based co-crystals and use thereof

The current invention relates to series of co-crystals of carboplatin with cyclic amides as co-formers and their pharmaceutical use. The co-crystals of the current invention may be used in the treatment or prevention of cancers..
Syn-nat Products Enterprise Llc

Stat3 dimerization inhibitors

The subject matter disclosed herein relates to compositions and methods of making and using the compositions. In a further aspect, the subject matter disclosed herein relates to inhibitors of stat3 dimerization.
H. Lee Moffitt Cancer Center And Research Institute Inc.

Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of rory and the treatment of disease

The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting rory activity, increasing the amount of il-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.. .
Lycera Corporation

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Heteroaryl substituted aminopyridine compounds

Disclosed are compounds of formula (i) or salts thereof, wherein: het is a heteroaryl selected from imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of formula (i) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 rb; a is pyrazolyl, imidazolyl, or triazolyl, each substituted with zero or 1 ra; and r3, ra, and rb are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.
Bristrol-myers Squibb Company

Heterocyclic compounds as erk inhibitors

They are potentially useful in the treatment of diseases treatable by inhibition of erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula i and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier..

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

Heterocyclic compounds as immunomodulators

Disclosed are compounds of formula (i), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections..
Incyte Corporation

Heterocyclic compounds as immunomodulators

Disclosed are compounds of formula (i), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections..
Incyte Corporation

Heterocyclic compounds as immunomodulators

Disclosed are compounds of formula (i), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections..
Incyte Corporation

Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds

Compounds useful for the treatment of pain or cancer in a mammal.. .
Array Biopharma Inc.

Protein kinase c inhibitors and methods of their use

Pkc inhibitors are disclosed. The pkc inhibitors are useful for treating pkc associated diseases, including certain cancers.
Novartis Ag

Heterocyclic compounds as immunomodulators

Disclosed are compounds of formula (i), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections..
Incyte Corporation

Selective anti-cancer compounds

A compound of formula i, wherein the compound of formula i has the structure: wherein r1 to r5, y, l, z and x1 to x7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.. .
National University Of Singapore

Biaryltriazole inhibitors of macrophage migration inhibitory factor

The present disclosure describes biaryl triazole compounds, as well as their compositions and methods of use. The compounds inhibit the activity of macrophage migration inhibitory factor and are useful for the treatment of diseases, e.g., inflammatory diseases and cancer..
Yale University

Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anticancer ingredient, pharmaceutical composition, medicinal preparation, treating prostate cancer

R4 is c1-c4 alkyl or cyclopropyl.. .

Gpbp inhibition using q2 peptidomimetics

That inhibiting gpbp activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and er stress-mediated disorders, and aberrant apoptosis.. .

Columns for isolation, detection and use of biological cells

This invention relates to devices and methods for purifying, detecting and using biological cells. A variety of cell types including viable tumor, stem, immune and sperm cells can be purified from a complex biological sample using a column, including a pipette tip column.

Fiducial marker / cancer imaging and treatment apparatus and use thereof

The invention comprises a fiducial marker—fiducial detector based treatment room position determination/positioning system apparatus and method of use thereof. A set of fiducial markers and fiducial detectors are used to mark/determine relative position of static and/or moveable objects in a treatment room using photons passing from the markers to the detectors.

Multiple treatment beam type cancer therapy apparatus and use thereof

The invention comprises a method and apparatus for using a turning magnet of an accelerator of a cancer therapy system, the accelerator comprising first magnet coils and second correction coils wound about a magnet core where: (1) at a first time, the second correction coils are used to correct a magnetic field, resultant from the first magnet coils, used to turn cations and (2) at a second time, after reversing polarity of the correction coils, the correction coils are used to turn anions and/or electrons, the cations and electrons used to treat a tumor of a patient positioned in a treatment position relative to a treatment beam from the accelerator during the first and second time periods.. .

Radiation shielding implants and methods of use

A removable implant having a radiation shield adapted to reduce radiation exposure to one or more secondary radio-sensitive tissues during breast cancer radiation therapy is provided herein, the implant including: a radiation-absorbing core adapted to absorb at least a portion of cardiac impact zone radiation when compared to a control, wherein the radiation-absorbing core comprises: a flexible solid polymer; and a plurality of radiation-absorbing members dispersed throughout the flexible solid polymer, wherein the radiation-absorbing core comprises a plurality of zones, each of said zones comprising a distinct capacity for radiation absorption, wherein capacity for radiation absorption is proportional to a sensitivity of the secondary radio-sensitive tissues to radiation, such a zone that shields tissue comparatively more sensitive to radiation comprises a zone having a comparatively higher capacity for radiation absorption, and a zone that shields tissue comparatively less sensitive to radiation comprises a zone having a comparatively lower capacity for radiation absorption. Also provided is an implant having a breast tissue expander disposed on a top face of the flexible casing of the implant.

Compositions of nucleic acid-containing nanoparticles for in vivo delivery

Compositions comprising a polymeric micellar nanoparticle composition comprising a block or graft copolymer comprising at least one polycationic polymer and at least one polyethylene glycol (peg) polymer having an average molecular weight less than 1 kda, and at least one nucleic acid, wherein the graft or block copolymer and at least one nucleic acid are complexed and condensed into a shaped micellar nanoparticle that is stable in biological media are disclosed. The presently disclosed subject matter also provides a method for preparing the presently disclosed polymeric micellar nanoparticle compositions, a method for targeting at least one metastatic cancer cell in a subject, and a method for treating a disease or condition using the presently disclosed polymeric micellar nanoparticle compositions..
The Johns Hopkins University

Ligand-cytotoxic drug conjugate, preparation method thereof, and use thereof

Provide are ligand-cytotoxic drug conjugates with a general formula of pc-l-dr, a preparation method thereof, and uses of the ligand-cytotoxic drug conjugate and pharmaceutical compositions containing the same in preparing drugs for treating cancers by means of receptor regulation.. .
Shanghai Hengrui Pharmaceutical Co., Ltd.

Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies

The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin e (mmae) and monomethyl auristatin f (mmaf) are introduced, which have potent antitumor activity in vivo.
Georgetown University

Compounds for targeted immunotherapy

Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula tm-ln-am, wherein tm is a targeting moiety, am is an activating moiety that is capable of activating a human dendritic cell, nk cell, or tumor cell, or a combination thereof, ln is a linker, and n is an integer selected from 0 and 1..
Birdie Biopharmaceuticals, Inc.

Compounds for targeted immunotherapy

Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula tm-ln-am, wherein tm is a targeting moiety, am is an activating moiety that is capable of activating a human dendritic cell, nk cell, or tumor cell, or a combination thereof, ln is a linker, and n is an integer selected from 0 and 1..
Birdie Biopharmaceuticals, Inc.

Methods of treating cancer using compounds containing a vascular disrupting agent

The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (vda) associated with a mmp proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.. .
Incanthera Ltd

Multicomponent degradable cationic polymers

Degradable polymers were synthesized that self-assemble with dna to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner.
The Johns Hopkins University

Combination of pd-1 antagonist with an egfr inhibitor

The present invention relates to a pharmaceutical composition comprising pd-1 antagonist and an egfr inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of cancer.

Micro-rna-155 enhances the efficacy of dendritic cell vaccine for cancer

Engineered dendritic cell vaccines, and methods of forming and applying same, that may be used as effective immunotherapies for cancers.. .
University Of South Carolina

Compositions and methods for treating cancer with arginine depletion and immuno oncology agents

Methods of treating tumors or cancer include administration of an arginine depleting enzyme and an immune-oncology agent.. .
Aeglea Biotherapeutics, Llc

Compositions and methods for modulating pro-inflammatory immune response

Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (lilr) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a lilr protein..
Icahn School Of Medicine At Mount Sinai

Method for treatment or prevention of a cancer

The present invention is related to a method or a pharmaceutical composition for treatment or prevention of a cancer through blocking the interaction of β4 integrin and focal adhesion kinase (fak).. .

Uses of hypoxia-inducible factor inhibitors

The present invention relates to treating a hematologic cancer using a hypoxia-inducible factor (hif inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the hif inhibitor.
Oncoimmune, Inc.

Methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy

Methods are provided for identifying whether a lung tumor will be responsive to treatment with the combination of the therapeutic agents cisplatin and pemetrexed. Specified ercc1, ts, p16, and frα fragment peptides are precisely detected and quantitated by srm-mass spectrometry directly in lung tumor cells collected from lung tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with the combination of cisplatin and pemetrexed therapeutic agents..
Expression Pathology, Inc.

Therapeutic agent associated with suppression of proliferation and metastasis of tumor, which comprises exosomes released from cytotoxic t cells and targets cancer stromal/mesenchymal cells

Therapeutic agents effective for treating cell-proliferative diseases contain extracellular vesicles (exosomes) released from cytotoxic t cells or mirna obtained from extracellular vesicles (exosomes) released from cytotoxic t cells, such as human cd8+ t cells. Such therapeutic agents suppress the proliferation of mesenchymal cells surrounding cancer cells, e.g., by killing the mesenchymal cells, such that the cancer cells become isolated and unable to metastasize.
Kyoto University

Mirnas as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers

Disclosed are methods and compositions for using microrna (mirna) for treating cancer. The methods and compositions include hsa-mir-204 and homologs of hsa-mir-204..
The Board Of Regents Of The University Of Texas System

Method for treating cancer using chemokine antagonists

What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to cxcr1 and/or cxcr2 receptors by administering a therapeutically effective amount of an antagonist of cxcr1 and/or cxcr2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.. .
Syntrix Biosystems Inc.

Compositions and methods for treating patients with rtk mutant cells

Disclosed herein are compositions and methods for treating cancer patients who have been previously treated with one or more chemotherapeutic agents and have developed at least partial resistance to such chemotherapeutic agents. Also disclosed are methods for selecting compounds suitable for treatment of cancer in a patient who has become resistant to an inhibitor of a receptor tyrosine kinase (rtk)..
Ignyta, Inc.

Therapeutic compositions, combinations, and methods of use

This invention relates to methods comprising administering a fak inhibitor and an immunotherapeutic agent such as anti-pd-1 or anti-pd-l1; that are useful in the treatment of abnormal cell growth, such as cancer, in mammals, especially humans.. .
Verastem, Inc.

3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc

Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer

A method of treating prostate cancer in a subject with biochemically recurrent prostate cancer is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes phenelzine..
University Of Southern California

Heterocyclic compounds as immunomodulators

Disclosed are compounds of formula (i′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit pd-1/pd-l1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections..
Incyte Corporation

Combination therapy using belinostat and pralatrexate to treat lymphoma

The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.. .
Spectrum Pharmaceuticals, Inc.

Compositions for the treatment of cancer and uses thereof

The invention pertains to compositions comprising inhibitors of pi3k, akt and/or mtor, one or more 4-quinolinemethanols and a pharmaceutically acceptable excipient. These compositions can contain subtherapeutic amounts of each active ingredient (pi3k, akt, mtor, one or more 4-quinolinemethanols and various combinations thereof).
University Of Florida Research Foundation Incorporated

Biomarkers for nanoparticle compositions

The present invention provides methods and compositions for treating a hyperplasia (such as cancer, restenosis, or pulmonary hypertension) by administering a composition comprising nanoparticles that comprise an mtor inhibitor (such as a limus drug) and an albumin based upon the status of an mtor-activating aberration.. .
Abraxis Bioscience, Llc

1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase

The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.. .
Incyte Holdings Corporation

Methods and compositions to treat cancer

Embodiments provided herein relate to methods and compositions for treating cancer. Some embodiments include treating lung cancers and renal cancers..
Children's Hospital Medical Center

Kras g12c inhibitors and methods of using the same

Provided herein are kras g12c inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers..
Amgen Inc.

Combination of an antiandrogen with a vitamin k antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer

The present invention relates to the combination of an antiandrogen with a vitamin k antagonist or with a γ-glutamyl carboxylase inhibitor for use in the treatment or prevention of an androgen receptor positive cancer, such as prostate cancer, or a hyperactive androgen receptor signaling disease/disorder. The invention also relates to a vitamin k antagonist or a γ-glutamyl carboxylase inhibitor for use in resensitizing an antiandrogen-resistant prostate cancer to the treatment with an antiandrogen.
Cemm-forschungszentrum FÜr Molekulare Medizin Gmbh

Use of cyp expression to direct therapeutic intervention in cancer

Certain embodiments of the invention provide a method for identifying a cancer cell that is sensitive to a biguanide compound or other cyp epoxygenase inhibitor, comprising detecting increased expression of at least one cytochrome p450 (cyp) and/or decreased expression of soluble epoxide hydrolase (ephx2) in the cancer cell, wherein increased cyp expression and/or decreased expression of ephx2 in the cancer cell correlates with increased sensitivity of the cancer cell to the biguanide compound or other cyp epoxygenase inhibitor.. .
Regents Of The University Of Minnesota

Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment

The invention compositions comprising a continuous hydrophobic phase and liposomes as a vehicle for delivery of an antigen capable of inducing a cytotoxic t lymphocyte (ctl) response and methods for their use in the treatment of cancer.. .
Immunovaccine Technologies, Inc.

3d printed trans-modular scaffolds for grafting applications in segmental bone defects

A bone repair scaffold having two moduli that match those of the cancellous and cortical bone in a patient receiving a bone graft/implant. The bone repair scaffold possesses increased mechanical properties to sustain physiological loading and biologically active capability to facilitate bone fusion.
The Trustees Of The Stevens Institute Of Technolog Y

Establishing a machine learning model for cancer anticipation and a detecting cancer by using multiple tumor markers in the machine learning model for cancer anticipation

A method of establishing a machine learning model for cancer anticipation includes collecting test results of a plurality of tumor markers of a plurality of eligible individuals and corresponding conditions of cancer; performing a variable selection process on the collected data to select a plurality of robust variables; and using the selected variables, numerals, and conditions of cancer by cooperating with a machine learning method to establish a cancer anticipation model. A method of detecting cancer by using a plurality of tumor markers in a machine learning model for cancer anticipation is also provided..

Methods and materials for assessing hydrogen peroxide accumulation in cells

This document provides methods and materials for assessing hydrogen peroxide accumulation within cells (e.g., cancer cells) exposed to one or more test agents. For example, methods and materials for determining whether or not cancer cells (e.g., mm cells) from a mammal (e.g., a human) accumulate hydrogen peroxide following contact with a test agent (e.g., an imid) and exogenous h2o2 are provided..
Mayo Foundation For Medical Education And Research

Urinary polyamines as prostate cancer detection biomarkers

The present disclosure relates to urinary polyamines useful as prostate cancer biomarkers. In particular, the present disclosure provides a novel, highly-sensitive and specific, method for detecting and quantifying urinary polyamines using lanthanide complexes or citrate capped gold nanoparticles..
Hong Kong Baptist University

Bin1 expression as a marker of cancer

Provided are methods for screening a subject for cancer. The methods involve obtaining a blood sample from the subject and determining a level of bridging integrator 1 (bin1) isoforms comprising exon 12a in the sample.
Sarcotein Diagnostics, Llc

Methods for detecting and treating cancer

The invention generally features compositions and methods for the diagnosis, treatment, and monitoring of neoplasia in a subject, as well as methods of treatment selection.. .
Imperial College London

Method for improved hepatocellular cancer diagnosis

Methods are provided for determining the diagnosis of whether a liver mass is a benign hepatocellular adenoma or a pre-malignant hepatocellular dysplastic nodule and/or a malignant hepatocellular carcinoma. Specific protein fragment peptides are precisely detected and quantitated by srm-mass spectrometry directly in liver mass cells collected from liver mass tissue that was obtained from a patient suffering from the liver mass and compared to reference levels in order to determine if the liver mass is a benign growth or a pre-cancer and/or cancer..
Expression Pathology, Inc.

Methods for diagnosis of bladder cancer

Methods for diagnosis of bladder cancer are disclosed. In particular, the invention relates to the use of urinary biomarkers for aiding diagnosis, prognosis, and treatment of bladder cancer, and to a panel of biomarkers that can be used to distinguish high-grade bladder cancer from low-grade bladder cancer..
The Board Of Trustees Of The Leland Stanford Junior University

Profiling peptides and methods for sensitivity profiling

The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an mcl-1 binding domain, and optionally a cellular uptake moiety.
Tolero Pharmaceuticals, Inc.

Synthetic microfluidic systems for tumor metastasis

A method of assaying metastasis can include: providing a device of one of the embodiments; introducing the at least one cancer cell into the at least one internal chamber or at least one fluid channel; and studying metastasis of the at least one cancer cell. Optionally: introducing cancer cells into a first internal chamber; detecting escape of the cancer cell from the first internal chamber into the fluid channel; detecting migration of the cancer cell through the fluid channel; detecting adhesion of the cancer cell to a coating on the fluid channel; detecting invasion of the cancer cell into a second internal chamber from the fluid channel; or visualizing metastasis of the cancer cell with a visualization device..
Cfd Research Corporation

Hydrogel-based microfluidic chip for co-culturing cells

Provided are a hydrogel-based microfluidic chip for cell co-culture and a use thereof, wherein the microfluidic chip allows the co-culture of cancer cells and vascular endothelial cells; can be widely applied in various studies associated with cancer; is suitable in studies on the photothermal therapy effect on, especially, cancer cells; and has excellent biocompatibility, mechanical properties, and economical feasibility.. .
Sogang University Research Foundation

Variant libraries of the immunological synapse and synthesis thereof

Disclosed herein are methods for the generation of highly accurate nucleic acid libraries encoding for predetermined variants of a nucleic acid sequence. The nucleic acid sequence may encode for all or part of a tcr or a tcr-binding antigen.
Twist Bioscience Corporation

Detecting mutations and ploidy in chromosomal segments

The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus..
Natera, Inc.

Allogeneic autophagosome-enriched composition for the treatment of disease

A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
Providence Health & Sevices-oregon

Diagnostic for lung disorders using class prediction

The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis with bronchoscopy. The methods of the invention provide far superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis.
Trustees Of Boston University

Detection of single nucleotide polymorphisms in human kras

Disclosed herein are primers and probes for the detection of single nucleotide polymorphisms (snps) in the kras gene. These primers and probes may be used in a method of identifying the presence or absence of one or more snps in the kras gene.
Abbott Molecular Inc.

Distinguishing pca3 messenger rna species in benign and malignant prostate tissues

This invention concerns the discovery of two distinct pca3 mrna sequences. One of these sequences corresponds to a short pca3 mrna molecule whereas the other pca3 rna molecule is longer as it comprises an additional sequence between exon 3 and exon 4a.
Gen-probe Incorporated

Targeted therapies for cancer

Various embodiments provide compositions and methods for detecting cancers containing an nrg1 fusion event and treating a patient with a therapeutic agent that is targeted to the nrg1 fusion. Exemplary compositions for treating cancers containing the nrg1 fusion may comprise therapeutic agents inhibiting epidermal growth factor receptor and/or erbb2 such as cetuximab, panitumumab, sym004, mm-151, mab 806, mab 528, mehd794a, gefitinib, erlotinib, lapatinib, afatinib, pd153035, ag1478, trastuzumab, and pertuzumab.
Mayo Foundation For Medical Education And Research

Gfralpha1 as a biomarker for cisplatin-induced chemoresistance and metastasis

Certain embodiments are directed to methods and composition for detecting the level of gfrα1 in cancers and treating same.. .
The Board Of Regents Of The University Of Texas System

Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof

Methods and composition related to the engineering of a novel protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (cgl) comprising one or more amino acid substitutions and capable of degrading methionine.
Aemase, Inc.

Antisense oligonucleotides for treatment of cancer stem cells

The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial rna as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial rna as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory hpv-associated cancer)..
Andes Biotechnologies Global, Inc.

Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells

An apparatus and method for accelerating and/or inhibiting the migration of cells by applying a time-varying magnetic field to induce eddy currents that promote electrotaxis (galvanotaxis) of cells without the need for chemokines or glucose. The present invention can also be used to study and quantify the metastatic potential of different cell lines..
Ohio State Innovation Foundation

Cell structure, non-human model animal, producing non-human model animal, and evaluating test substance

An object of the present invention is to provide a non-human model animal rich in stromal tissue, a cell structure useful for producing the above-described non-human model animal, a method for evaluating a test substance in which the above-described non-human model animal is used, and a method for producing the above-described non-human model animal. According to the present invention, a cell structure is provided which contains a biocompatible macromolecular block and at least a cancer cell and a mesenchymal cell, and in which a plurality of the above-described biocompatible macromolecular blocks are arranged in gaps between a plurality of the above-described cells..
Fujifilm Corporation

Dendritic cell generator

Devices, systems, and methods can be used for the automated production of dendritic cells (dc) from dendritic cell progenitors, such as monocytes obtained from peripheral blood. The invention makes it possible to obtain sufficient quantities of a subject's own dc for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease..
Northeastern University

Methods of treating cancer

Compositions and methods of treating a subject with cancer are described. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound with the dual characteristics or restoring function of the c-cbl ubiquitin ligase in cancer cells and in also worsening sublethal lysosomal dysfunction, preferably in combination with an agent capable of making cancer cells more oxidized.
The University Of Rochester

Biomarkers related to treatment of cancer with her3 and egfr inhibitors

Provided herein are methods of treating cancers expressing specific biomarkers with her3 and/or egfr inhibitors, and provided herein are also biomarkers and uses thereof in determining likelihood of effective cancer treatment with her3 and/or egfr inhibitors. In one aspect, the disclosure provides methods for treating a cancer, comprising administering to a patient diagnosed with said cancer a therapeutically effective amount of a her3 inhibitor, an egfr inhibitor, or a combination of a her3 inhibitor and an egfr inhibitor.
Celldex Therapeutics, Inc.

Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody

The present invention describes combination treatment comprising a pd-1 axis binding antagonist and an anti-cd20 antibody and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.. .
Genentech, Inc.

Anti-tumor agents and methods of use

The present invention relates to anti-tumor agents that target certain tumor-associated macrophages. Also disclosed are methods of using such agents in treatment of cancer..
The Rockefeller University

Therapeutic antibodies and their uses

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to bcma (b-cell maturation antigen) and/or cd3 (cluster of differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the bcma antibodies, compositions comprising the bcma antibodies, and methods of using the bcma antibodies and their conjugates for treating conditions associated with cells expressing bcma (e.g., cancer or autoimmune disease).
Pfizer Inc.

Combined use of immune activators

The present invention is based on the finding that combined use of a multispecific antibody comprising: (1) a cancer-specific antigen-binding domain, (2) a cd3-binding domain, and (3) a domain comprising an fc region having decreased fcγ receptor-binding activity with a tumor necrosis factor (tnf) receptor superfamily agonist antibody can reduce side effects such as liver injury observed when the agonist antibody is prescribed alone, and achieve effective therapeutic effects.. .
Chugai Seiyaku Kabushiki Kaisha

Therapeutic cd47 antibodies

Provided are anti-cd47 monoclonal antibodies (anti-cd47 mabs) with distinct functional profiles as described herein, methods to generate anti-cd47 mabs, and to methods of using these anti-cd47 mabs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of cd47 in tissue samples.. .
Tioma Therapeutics, Inc.

Jam-c antibodies and methods for treatment of cancer

A novel method to reduce b-cell lymphoma cell migration to and engraftment of the spleen in patients with jam-c positive b-cell lymphomas is described. In certain aspects, a method for identifying and treating jam-c positive b-cell lymphoma patients with anti-jam-c antibodies is provided.
Research Development Foundation

Filamin a binding proteins and uses thereof

The present invention encompasses filamin a (flna) binding proteins. Specifically, the invention relates to antibodies to flna.
Berg Llc

Btla fusion protein agonists and uses thereof

The present invention is based on the seminal discovery that btla agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind btla enhancing btla signaling the present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a btla agonist fusion protein as described herein..
Pfizer Inc.

Car t cells recognizing cancer-specific il 13ra2

Provided are specific binding molecules, or fragments thereof, that bind to an epitope of il13rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an il13rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a t cell signaling protein, a peptide modulator of t cell activation, or an enzymatic component of a labeling system.
Baylor College Of Medicine

Cancer antigen helper peptide

The present invention relates to a wt1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a wt1 protein and induces wt1-specific helper t cells by binding to an mhc class ii molecule, a pharmaceutical composition comprising them and the like.. .
International Institute Of Cancer Immunology, Inc.

Novel polypeptide capable of binding to vascular endothelial growth factor, and use thereof

The present disclosure relates to a novel polypeptide capable of binding specifically to vascular endothelial growth factor, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a recombinant microorganism including the expression vector, a method of producing the polypeptide using the recombinant microorganism, a composition for treating or preventing cancer, which comprises the polypeptide, and a method for preventing or treating cancer, which comprises administering the composition for treating or preventing cancer, which comprises the polypeptide. The disclosed polypeptide is capable of binding to vascular endothelial growth factor to inhibit the activity thereof, and thus can be widely used as an agent for treating and preventing various diseases associated with vascular endothelial growth factor (vegf)..
Korea Advanced Institute Of Science And Technology

Compositions and methods for treating diseases by inhibiting exosome release

A multipartite peptide that inhibits release of exosomes in a cell, comprising an n-terminal end and a c-terminal end and comprising at least one secretion modifying region (smr) peptide from hiv-1 nef and at least one clusterin (clu)-binding peptide (clu-bp). Pharmaceutical compositions comprising these peptides alone or in synergistic combinations with other active agents in methods for treating cancers and/or infectious diseases are further provided herein..
Morehouse School Of Medicine

Prototype systems of theranostic biomarkers for in vivo molecular management of cancer

The present invention relates to a theranostic system comprising a beacon and a compound selected from the group consisting of a quinazoline-based tyrosine kinase inhibitor and a natural product. The theranostic systems have use in the therapy and diagnosis of tyrosine kinase related malignancies..
Epos-iasis Research And Development, Ltd

Compounds targeting proteins, compositions, methods, and uses thereof

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, ck1α, gspt1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses.
Biotheryx, Inc.

Inhibitors of ptp4a3 for the treatment of cancer

The invention provides protein tyrosine phosphatase inhibitor compounds, their pharmaceutical compositions, uses, and methods of use, such as in the treatment of various cancers, and process for making the compounds. Also disclosed is an improved synthesis of protein tyrosine phosphatase inhibitor and precursor compound thienopyridone (5)..

Use of the fl-one hundred eighteen core chemical structure platform to generate fl-one hundred eighteen derivatives for treatment of human disease

Described herein, are fl118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the fl118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as obama called precision medicine) through application of a series of structural relevant individual fl118 platform-derived analogues..
Canget Biotekpharma, Llc

Piperidine derivative and preparation method and pharmaceutical use thereof

The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (i) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer.
Shanghai Hengrui Pharmaceutical Co., Ltd.

Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (cns) disorders. In particular, it relates to the use of a α5-containing gabaa receptor agonist (e.g., a α5-containing gabaa receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (cns) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, mild cognitive impairment (mci), amnestic mci (amci), age-associated memory impairment (aami), age related cognitive decline (arcd), dementia, alzheimer's disease(ad), prodromal ad, post traumatic stress disorder (ptsd), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (als), cancer-therapy-related cognitive impairment, mental retardation, parkinson's disease (pd), autism spectrum disorders, fragile x disorder, rett syndrome, compulsive behavior, and substance addiction.
Agenebio, Inc.

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Pyrimidine-2,4-diamine derivatives for treatment of cancer

Or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of mth1..

Compounds for the treatment of cancer

Wherein a and b are as defined herein, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention and/or delay of progression of cancer.. .

5-bromo-indirubins

Disclosed herein inter alia are compositions and methods for treating cancer using 5-br-indirubin derivatives.. .
National And Kapodistrian University Of Athens

Salicylate inhibitors of melk and methods of use

Wherein x and r1-r3 are defined in the specification. The compounds are useful for treating cancer and other conditions or diseases associated with aberrant melk expression.

Pyrrolcarboxamide derivatives for the inhibition of erk5

Or a tautomer, stereoisomer, n-oxide, pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the prophylaxis or treatment of a disease state or condition mediated by erk5, in particular cancers..

Salts of a pim kinase inhibitor

The present invention relates to salt forms of the pim kinase inhibitor n-{(7r)-4-[(3r,4r,5s)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5h-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of pim kinase-related diseases such as cancer.. .
Incyte Corporation

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds

Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents.
Aerie Pharmaceuticals, Inc.

Human glut5 specific inhibitors and methods of treatment

The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human glut5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of glut5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through glut5, including such disease states and conditions as glut5 deficiency syndrome, diabetes (type i and ii), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others..
Rosalind Franklin University

Mitochondria-targeted lapachone compounds and uses therefor

Compounds, compositions and methods useful for treating cancer and neiirodegeneration are provided. The compounds comprise a mitochondria-targeting moiety linked to β-lapachone or a β-lapachone derivative..
University Of Pittsburgh-of The Commonwealth System Of Higher Education

Hsp70 modulators and methods for making and using the same

The present invention, among other things, provides compounds and compositions thereof for use in the modulation of hsp70. In some embodiments, the present invention provides a method for inhibiting hsp70 activity.
Memorial Sloan Kettering Cancer Center

Heterocyclic compound

The present invention relates to a compound which can be useful for the treatment or prevention of spt-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including niemann-pick disease).. .
Takeda Pharmaceutical Company Limited

5-bromo-indirubins

Disclosed herein are compositions and methods for treating cancer, flt3-aml, and cml.. .
City Of Hope

Resorcinol derivatives

The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.. .
Sutter West Bay Hospitals

Cancer therapy treatment beam / scanning control apparatus and use thereof

The invention comprises a method and apparatus for controlling tumor treatment, comprising the steps of: (1) a control system controlling a cancer therapy system, the control system comprising a set of modular control units, the cancer therapy system comprising a set of subsystem elements, (2) altering a first subsystem of the set of subsystem elements; and (3) updating a first modular control unit, of the set of modular control units, corresponding to the first subsystem without a necessitated change of remaining code elements of the set of modular control units corresponding to non-altered subsystem elements of the set of subsystem elements with an optional step of altering main subsystem controller code configured to control the set of subsystem control modules. Optionally the control system directly controls each of the subsystem elements and/or communicates with each of the set of subsystem elements without direct communication between the set of subsystem elements..

Radiation therapy with immune response monitoring

A method of treating cancer includes administering a first dose of radiation to a subject; determining a level of a biomarker obtained from the subject, the level indicating an immune response of the subject to the first dose; and not administering a second dose of radiation to the subject unless and until the level of the biomarker is beyond a threshold value.. .
Klinikum Mannheim Gmbh

Treatment of cancer by manipulating the immune system

The present invention relates to the treatment of cancers. Specifically, the invention pertains to a method for the extracorporeal treatment of one or more body fluids (e.g., blood or cerebrospinal fluid, csf) in two stages characterized by removing a body fluid (e.g., blood or csf) from a living body diseased with a type of cancer, passing the body fluid through a first stage of applying a treatment to at least one antigen in the body fluid.
Marv Enterprises, Llc

Armed replication-competent oncolytic adenoviruses

Disclosed are replication-competent oncolytic adenoviruses, comprising chimeric human/mouse cd40 ligands. The oncolytic adenoviruses may be replication competent.
Dnatrix

Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis

Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis.
Cornell University

Glycan-dependent immunotherapeutic molecules

The present invention relates to compositions and methods for treating cancer. The invention makes use of peptides, nucleic acids encoding such peptides, and cells expressing such peptides, where the peptide comprises a tumor-associated carbohydrate antigen (taca)-binding domain..
The Regents Of The University Of California

Anti-ntb-a antibodies and related compositions and methods

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to ntb-a. Also disclosed are methods for using the anti-ntb-a antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an ntb-a-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with ntb-a-expressing cells, such as multiple myeloma, non-hodgkin lymphoma and acute myeloid leukemia..
Seattle Genetics, Inc.

Methods for treating cancer

The present invention relates to a method of treating cancer in a subject.. .
Bicycle Therapeutics Limited

Agtr1 aptamer-anticancer drug complex for cancer cell chemotherapy

This invention relates to a complex for cancer cell chemotherapy and, more particularly, to an agtr1 aptamer-anticancer drug complex for chemotherapy of cancer cells, which includes a nucleic acid aptamer specifically binding to agtr1 and an anticancer drug linked with the nucleic acid aptamer, so that agtr1-positive (overexpressed) breast cancer cells are selectively targeted and killed.. .
Korea University Research And Business Foundation

Pharmaceutical combination for cancer treatment and the therapeutic use thereof

A pharmaceutical combination for sensitizing a subject to a cancer treatment comprises an amount of metformin and an amount of statin. The amount of metformin and the amount of statin together constitute an effective amount of the pharmaceutical combination.
Shiner Pharm Corp.

Armed oncolytic viruses

Disclosed are oncolytic viruses comprising chimeric human/mouse cd40 ligands. The chimeric human/mouse cd40 ligand may be mem40.
Memgen, Llc

Methods of treating cancer using tigit inhibitors and anti-cancer agents

The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits tigit expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits tigit expression and/or activity, or both, as well as instructions for use thereof..
Genentech, Inc.

Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective

The present invention provides a method for determining the efficacy of a gpc3-targeting therapeutic agent for a liver cancer patient and a gpc3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the gpc3-targeting therapeutic agent is effective. The present invention provides, for example, a method for determining that a gpc3-targeting therapeutic agent is effective when the expression level of gpc3 per tumor cell is a predetermined value, and a gpc3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the gpc3-targeting therapeutic agent is effective..
Chugai Seiyaku Kabushiki Kaisha

Antibodies against lif and uses thereof

Described herein are antibodies that target leukemia inhibitory factor (lif). Also described herein are uses of these antibodies for the treatment of cancer..
FundaciÓ Privada InstituciÓ Catalana De Recerca I Estudis AvanÇats

Pd-l1 antagonist combination treatments

The present disclosure describes combination therapies comprising an antagonist of programmed death ligand 1 receptor (pd-l1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.. .
Pfizer Inc.

Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane

Methods and compositions for treating ovarian cancer in a human patient with ascites by administering a therapeutically effective amount of an ang2 inhibitor in combination with a taxane.. .
Amgen Inc.

Combination cancer therapies

The disclosure provides methods of treatment for cancer in patients using bispecific anti-igf-1r, anti-erbb3 antibodies in combination with one or more therapeutic agents that impede regulatory t-cell agents. In certain embodiments, said one or more therapeutic agent may be an antagonistic anti-receptor antibody that immunospecifically binds human pd-l1..
Merrimack Pharmaceuticals, Inc.

Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer

The present disclosure describes combination therapies comprising an antagonist of programmed death 1 receptor (pd-1) and a toll-like receptor 9 (tlr9) agonist that is a cpg-c type oligonucleotide, and the use of the combination therapies for the treatment of cancer.. .
Dynavax Technologies Corporation

Methods for enhancing antigen-specific immune responses

Described herein are methods comprising administering to a mammalian subject an effective amount of an annexin chimeric fusion protein, wherein the annexin chimeric fusion protein comprises at least one immunogenic antigen, thereby enhancing the antigen specific immune response relative to administration of the immunogenic antige alone. Methods and kits for treating or preventing recurrence of hyper proliferating diseases, e.g., cancer, are described.
The Johns Hopkins University

Partner of sld five 1 (psf1)-derived peptide

A partner of sld five 1 (psf1)-derived peptide that can induce a cytotoxic t-cell (ctl) response useful for a specific immunotherapy for cancer patients and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention are described.. .
Vasculead Inc.

Combination of vaccination and inhibition of the pd-1 pathway

The present invention relates to a vaccine/inhibitor combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one pd-1 pathway inhibitor, preferably directed against pd-1 receptor or its ligands pd-l1 and pd-l2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination.
Curevac Ag

Combination of vaccination and inhibition of the pd-1 pathway

The present invention relates to a vaccine/inhibitor combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one pd-1 pathway inhibitor, preferably directed against pd-1 receptor or its ligands pd-l1 and pd-l2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination.
Curevac Ag

Method for inducing early t memory response with short peptides anti-tumor vaccine

The present invention relates to a therapeutic peptide t specific immune therapy for use in the treatment of a cancer of an hla-a2 (human leukocyte antigen a2) positive patient, said treatment comprises a priming period consisting in two to three administrations of said therapeutic peptide t specific immune therapy, thereby inducing a memory t cell response.. .
Ose Immunotherapeutics

Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and producing antigen presenting cell

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of seq id nos: 1 to 15 and consisting of 11 or less amino acid residues.. .
Cytlimic Inc.

Beta-casein a2 and antioxidant capacity

Improving the antioxidant capacity in an animal by increasing the level of glutathione in the blood or tissue of the animal comprising providing a composition containing beta-casein to the animal for consumption, where the beta-casein comprises at least 75% by weight of one or more beta-caseins not capable of producing beta-casomorphin-7 on enzymatic digestion. Uses include as an oxidant, for treating or preventing the symptoms of cancer, inflammation, kwashiorkor (protein deficiency), seizure, autism, down's syndrome, chronic fatigue syndrome, alzheimer's disease, parkinson's disease, sickle cell anaemia, liver disease, cystic fibrosis, hiv, aids, infection, heart attack, stroke, and diabetes, avoiding or reducing the effects of aging, promoting the recovery of tissue following physical exercise, and promoting fertility..
The A2 Milk Company Limited

Compound and reducing appetite, fatigue and pain

The disclosed invention generally relates to pharmaceutical and nutraceutical compounds and methods for reducing appetite, muscle fatigue and spasticity, enhancing athletic performance, and treating pain associated with cancer, trauma, medical procedure, and neurological diseases and disorders in subjects in need thereof. The disclosed invention further relates to kratom compounds where said compound contains at least some pharmacologically inactive component..

Anticancer composition containing mixed herbal medicine extract as active ingredient

The present invention relates to a composition containing, as an active ingredient, a mixed extract of astragalus membranaceus, angelica gigas, and trichosanthes kirilowii, for preventing or treating cancer. The mixed extract of astragalus membranaceus, angelica gigas, and trichosanthes kirilowii according to the present invention does not impact normal cell growth, while having an anticancer effect which specifically inhibits the proliferation of cancer cells, and an excellent effect of inhibiting metastasis of cancer cells, and thus can be useful in preventing or treating cancer and supplementing cancer treatment..
University-industry Cooperation Group Of Kyung Hee University

Cancer treatment and diagnosis

The present disclosure provides, in general, a method for selecting a therapy for treating cancer in a human subject and subsequently treating cancer in a subject, which includes isolating a cancer cell from a human subject having cancer, determining the functional activity of sting or cgas in the cell; and selecting a therapy for the cancer based on the functional activity of the sting or cgas in the cell. Also provided, if the functional activity of sting and/or cgas is determined to be defective in the cell, the therapy selected is one that is effective at killing sting-deficient and/or cgas-deficient cancer cells, e.g., therapy including administering to the subject an oncolytic virus..
University Of Miami

Oral cancer vaccine

A cancer vaccine that can be orally administered can be provided through the use of a transformed bifidobacterium capable of expressing and displaying a wt1 protein. The wt1 protein expressed and displayed by the transformed bifidobacterium is a protein covering most of a wt1 protein unlike a wt1 peptide vaccine restricted to a certain hla.
Osaka University

Combination therapy with a flavagline and 2-deoxyglucose

The present invention relates to a combined preparation comprising 2-deoxyglucose and a flavagline and to the use of said combined preparation as a medicament or in the treatment of cancer. Moreover, the present invention relates to a flavagline for use in a combination therapy against cancer comprising administration of 2-deoxyglucose; and to 2-deoxyglucose for use in a combination therapy against cancer comprising administration of a flavagline.
Deutsches Krebsforschungszentrum

Combination therapy including sapc-dops for the treatment of pancreatic cancer

Disclosed herein, according to the present invention, are methods of treating pancreatic cancer comprising administering a first pharmaceutical composition comprising saposin c and dioleoylphosphatidylserine (sapc-dops) and administering a second pharmaceutical composition comprising an anti-neoplastic agent. Optionally, additional pharmaceutical compositions may be administered.
University Of Cincinnati

Methods for reducing cellular proliferation and treating certain diseases

Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (csa), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein..
Brigham Young University

Methods for treating cancer

Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject by administering to the subject a therapeutically effective amount of a combination of palbociclib and rad1901.. .
Radius Pharmaceuticals, Inc.

Cancer stem cell targeting compounds

The present invention provides compounds of formula (i), compositions, uses thereof and methods for inhibiting proliferation or obliterating cancer stem cells which includes killing; and/or inducing apoptosis in cancer stem cells. Included within the scope of such compounds, compositions, uses thereof and methods are those in which proliferation of cancer stem cells are selectively eradicated or inhibited..
Godavari Biorefineries Limited

Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors

Also provided are methods of using the compounds of this invention as akt protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.. .

Combination therapy of transcription inhibitors and kinase inhibitors

The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone.
Dana-farber Cancer Institute, Inc.

Pyrimidine pyrazolyl derivatives and their use as irak inhibitors

The present invention provides compounds of formula (ii) for the treatment of cancer, rheumatoid arthritis and other diseases.. .
Merck Patent Gmbh

Small molecule analogs of the nemo binding peptide

The invention is directed to a method of inhibiting, within a living cell, the interaction between nf-κb essential modulator (“nemo”) with iκb kinase-β (ikk-β) at the nemo binding domain (nbd), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a nemo-binding domain analog (nbda). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between nf-κb essential modulator (“nemo”) with iκb kinase-β (ikk-β) at the nemo binding domain (nbd) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention.
The Scripps Research Institute

Combination drug therapies for cancer and methods of making and using them

In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices for treating, preventing or ameliorating a tumor or a cancer, and methods and uses for treating, preventing or ameliorating a tumor or a cancer. In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices comprising: a beta adrenergic receptor antagonist (a “beta blocker”) such as propranolol; a non-steroidal anti-inflammatory drug (a nsaid) such as etodolac; and, a sorafenib or nexavar™ or equivalent thereof in alternative embodiments, the therapeutic combinations further comprise an anti-cancer or anti-tumor antibody, a cytokine, and/or an additional chemotherapeutic agent.
Vicus Therapeutics, Llc

Aziridine containing dna alkylating agents

Provided herein are compounds of formula (i)-(vi), wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.. .
Threshold Pharmaceuticals, Inc.

Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy

Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and/or chemotherapy, the composition comprising an active agent, said active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is comprised in the range 4.3 to 5.3.. .
Professional Dietetics S.p.a.

Dual assembly nanoparticles

Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the chitosan nanoparticles are coated with polylactic acid. Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease are also disclosed.
Board Of Regents, The University Of Texas System

Methods and compositions for treating proliferative diseases

The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime..
Abraxis Bioscience, Llc

Cavitation seed for drug delivery, and drug delivery method using same

A cavitation seed for drug delivery, and a drug delivery method using the same are disclosed. The cavitation seed according to the present invention comprises: a shell which forms the outer surface thereof to maintain the outer shape thereof within a fluid; and a core which is located inside the shell to determine buoyancy of the cavitation seed within the fluid.
Pacific System Co., Ltd.

Image guidance system

It is an object of the invention to provide for a system that can be used to improve a cancer related clinical workflow compared to the current cancer related clinical workflow. This object is achieved by an image guided system configured for supporting a combined biopsy and treatment procedure using image guidance to bring a needle from a defined location to a predetermined end location in a subject of interest.
Koninklijke Philips N.v.

Electronic cigarette

An electronic cigarette comprises nicotine without harmful tar. The cigarette includes a shell, a cell, nicotine solution, control circuit, and an electro-thermal vaporization nozzle installed in the air suction end of the shell.
Fontem Holdings 1 B.v.

. .

Forma Therapeutics, Inc.

. .

The Medical Research, Infrastructure And Health Services Fund Of The Tel Aviv Medical Center

. .

Computer vision for cancerous tissue recognition

A system includes an imager, a processor, and an output module. The imager is configured to provide a plurality of tissue images.

Prostate cancer-associated secreted proteins

Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules agr2, agr3, crisp3, ccl3, ceacam5, ceacam6, il24, mmp9, cxcl14, cd90, postn, and sfrp4. The methods can include administering at therapy to a subject with prostate cancer.
University Of Washington

Anti-gitr antibodies for cancer diagnostics

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (gitr). Such antibodies are useful for methods of detecting the expression of gitr in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-gitr immunotherapy or predicting whether a cancer patient will respond to anti-gitr immunotherapy..
Bristol-myers Squibb Company

Method for diagnosis of colorectal cancer using mass spectrometry of n-glycans

The present invention relates to a method of diagnosing colorectal cancer by detection of glycan changes, and more particularly to a method of diagnosing colorectal cancer using mass spectrometry, in which, when specific glycan structures increase, decrease or significantly change due to a change in n-linked glycosylation of a colorectal cancer patient-derived glycoprotein, as detected by mass spectrometry, the glycan structures are selected as diagnostic markers.. .
Korea Advanced Institute Of Science And Technology

Methods, kits, and systems for treatment of metastatic papillary thyroid cancer

Provided herein are methods for identifying a subject with an increased likelihood of developing or having metastatic papillary thyroid cancer (ptc), or a subject with an increased likelihood of developing or having recurrent ptc, and the treatment of such a subject.. .
The Governors Of The University Of Alberta

Novel t cell receptors and immune therapy using the same

The present invention relates to antigen recognizing constructs against a tumor associated antigen (taa) derived from the target protein ddb1 and cul4 associated factor 4-like 2 (dcaf4l2). The invention in particular provides novel t cell receptor (tcr) based molecules which are selective and specific for the taa of the invention.
Immatics Biotechnologies Gmbh

Methods for monitoring polymorphonuclear myeloid derived suppressor cells

A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (pmn-mdscs) comprises isolating from a cell suspension those cells which express lox-1 to provide a population of cells enriched with pmn-mdscs. A method of monitoring the population of lox-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer.
The Wistar Institute Of Anatomy And Biology

Immune cell trapping devices and methods for making and using the same

Embodiments herein described provide devices for identifying and collecting rare cells or cells which occur at low frequency in the body of a subject, such as, antigen-specific cells or disease-specific cells. More specifically, the devices are useful for trapping immune cells and the devices contain a physiologically-compatible porous polymer scaffold, a plurality of antigens, and an immune cell-recruiting agent, wherein the plurality of antigens and the immune cell recruiting agent attract and trap the immune cell in the device.
President And Fellows Of Harvard College

Method and determining a probability of colorectal cancer in a subject

A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed. The method comprises, for each gene of a set of one or more genes selected from the group consisting of anxa3, clec4d, il2rb, lmnb1, prrg4, tnfaip6 and vnn1: determining a level of rna encoded by the gene in blood of the test subject, thereby generating test data; providing positive control data representing levels of rna encoded by the gene in blood of human control subjects having colorectal cancer, and providing negative control data representing levels of rna encoded by the gene in blood of human control subjects not having colorectal cancer; and determining a probability that the test data corresponds to the positive control data and not to the negative control data, where the probability that the test data corresponds to the positive control data and not to the negative control data represents the probability that the test subject has colorectal cancer as opposed to not having colorectal cancer..
Genenews, Inc.

Breast cancer biomarkers and methods of using same

The present invention provides breast cancer markers based on recql mutations, and related methods, uses, agents, and kits. The invention includes methods for determining the susceptibility of a subject to developing breast cancer, and methods for detecting, diagnosing, treating, and predicting responses to treatment for breast cancer..
Women's College Hospital

Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity

In one embodiment, the subject invention relates to a method for treatment of a breast or ovarian cancer patient that includes receiving assay results stating that the patient's tumor exhibits loh, and administering a parp inhibitor. In one embodiment, the subject invention comprising: classifying said cancer patient, with the computer system, as being likely to respond to a parp inhibitor if the data comprises i) one or more deleterious mutations in brca1 or brca2, or ii) a percentage of the genome having greater than 10 percent loh as determined by the sum of the lengths of each individual loh region divided by the total genome length, wherein an loh region is defined as the presence of homozygosity at multiple contiguous single nucleotides, but excludes whole chromosome or chromosome arm loh..
Clovis Oncology, Inc.

Bioprobes and methods of use thereof

Disclosed are biomolecule based bioprobes that exhibit improved water solubility and mono layer-forming properties with substantially little or no aggregation that can appreciably interfere with binding of the bioprobes to a target nucleotide. The bioprobes may be used in conjunction with a suitable reporter system to detect very small quantities of biological markers.
The Governing Council Of The University Of Toronto

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Antitumor agent

This invention provides a composition and a method for treating or preventing a subject having a tumor that more highly expresses a tug1 gene than in normal tissues (e.g., brain tumor, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, or lymphoma), which composition comprises, as an active ingredient, a nucleic acid that inhibits the high expression of the tug1 gene in tumor stem cells.. .
Public University Corporation Nagoya City University

Assays to identify genetic elements affecting phenotype

The present invention comprises generally applicable methods for identifying endogenous physiologically relevant genetic elements that affects a intracellular phenotype of interest. In the methods, non-living cells that have been subjected to a mutagenesis treatment are sorted based on phenotype and analyzed to identify the genetic element.
Stichting Het Nederlands Kanker Instituut-antoni Van Leeuwenhoek Ziekenhuis

Alk4:actriib heteromultimers and uses thereof

In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an alk4 receptor and an extracellular domain of actriib. In certain aspects, such soluble alk4:actriib complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells.
Acceleron Pharma Inc.

Modified nk-92 cells for treating cancer

Provided herein are nk-92 cells expressing at least one car and at least one fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with nk-92 cells, such as cancer, comprising administering to the patient nk-92-fc-car..
Nantkwest, Inc.

Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1

The present invention relates to an attenuated mutant strain of salmonella comprising a recombinant dna molecule encoding wilms' tumor protein i. In particular, the present invention relates to the use of said attenuated mutant strain of salmonella in cancer immunotherapy..
Vaximm Ag

Treatment with anti-erbb2 antibodies

The present invention concerns the treatment of cancer with anti-erbb2 antibodies.. .
Genentech, Inc.

Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds cd138 attached to an interferon or to a mutant interferon.
The Regents Of The University Of California

Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies

The present invention concerns compositions and methods of use of anti-hla-dr antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease.
Immunomedics, Inc.

Novel anti-pd-l1 antibodies

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (pd-l1), which can block the binding of pd-l1 to pd-1, and therefore block the inhibitory function of pd-l1 on pd-1 expressing t cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function..
Wuxi Biologics (shanghai) Co. Ltd.

Gm-csf/cd40l vaccine and checkpoint inhibitor combination therapy

A method is disclosed for treating a cancer in a subject. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of a tumor vaccine.
H. Lee Moffitt Cancer Center And Research Institute, Inc.

Anti-ceacam6 antibodies and uses thereof

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and macaca fascicularis ceacam6 (carcinoembryonic antigen-related cell adhesion molecule 6, cd66c, non-specific crossreacting antigen, nca, nca-50/90), and which do not significantly cross-react with the closely related human ceacam1, human ceacam3, and human ceacam5. The invention further provides methods to generate this kind of antibodies.
Bayer Pharma Aktiengesellschaft

Antibodies specific for claudin 6 (cldn6)

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin-6 (cldn6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.. .
Johannes Gutenberg-universitat Mainz

Compositions and methods relating to inhibiting cancer cell growth and/or proliferation

The present invention determined that egfl6 functions as a tumor vascular regulator of ovarian cancer stem cells (csc). In addition, the present invention determined that a novel egfl6 blocking antibody was able to restrict cancer cell growth and delay disease recurrence.
The Regents Of The University Of Michigan

B1sp fusion protein therapeutics, methods, and uses

Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a b1sp fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer.
The University Of British Columbia

Cytokine

A novel cytokine, u83a, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and hiv/aids, are described..
London School And Hygiene And Tropical Medicine

Tyrosine kinase inhibitors

The present disclosure provides compounds that are tyrosine kinase inhibitors, in particular bruton tyrosine kinase (“btk”) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of btk such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds..
Principia Biopharma Inc.

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

Novel compounds

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (dubs). In particular, the invention relates to the inhibition of ubiquitin c-terminal hydrolase l1 (uchl1).
Mission Therapeutics Limited

Compounds for the modulation of myc activity

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject..
Syros Pharmaceuticals, Inc.

Substituted anilines as ccr(4) antagonists

Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.

Enhancer of zeste homolog 2 inhibitors

This invention relates to novel compounds according to formula (i) which are inhibitors of enhancer of zeste homolog 2 (ezh2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.. .
Glaxosmithkline Intellectual Property (no.2) Limited

3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc

Tricyclic derivative compound, preparing same, and pharmaceutical composition comprising same

The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against parp-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against parp-1, tankyrase-1, or tankyrase-2, and thus can be effectively used for the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, or cancer..
Je Il Pharmaceutical Co., Ltd.

2-(2,4,5-substituted-anilino)pyrimidine compounds

The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the l858r activating mutant, the exon19 deletion activating mutant and the t790m resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers.
Astrazeneca Ab

Radiomitigating pharmaceutical formulations

The present disclosure relates to compounds of formula (i) and (ii), compositions containing the compounds (alone or in combination with other agents), and their use to prevent, mitigate or treat a) damage induced by ionizing radiation, b) inflammation or c) cancer.. .
The Regents Of The University Of California

Process methods for phosphatidylinositol 3-kinase inhibitors

A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed..
Gilead Calistoga Llc

211-astatine containing radiotherapeutics for the treatment of cancer

Described herein is an alpha-emitting radionuclide, 211at, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (i), wherein r1-r4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model.
The Trustees Of The University Of Pennsylvania

Automated cancer therapy treatment beam / scanning apparatus and use thereof

The invention comprises a method and apparatus for proton treatment of a tumor, comprising the steps of a central control system: (1) receiving an initial cancer treatment irradiation plan; (2) directing a treatment of the tumor using the positively charged particles; (3) during a treatment session and after the step of directing the treatment of the tumor, receiving imaging input from an imaging system; (4) generating an updated cancer treatment irradiation plan using the imaging input; (5) continuing the treatment session using the updated cancer treatment irradiation plan; and (6) optionally, while the patient remains in the treatment room and under approval of a medical professional not in line of sight of the patient, repeating at least three times the steps of: receiving imaging input from the imaging system; generating an updated cancer treatment irradiation plan; and continuing the treatment session using the updated cancer treatment irradiation plan.. .

Reducing absorption of radiation by healthy cells from an external radiation source

A semi-flexible rod may have a rounded tip having exposed metal conductor elements that produce an adaptive electrical field or an adaptive magnetic field. The adaptive electrical field or the adaptive magnetic field may be adjusted in order to capture a stray x-ray photon near an in-vivo target area of cancer cells..
Hj Laboratories, Llc

Diagnostic imaging agent for early bone metastasis from cancer

There is provided a diagnostic imaging agent for early bone metastasis from cancer, containing trans-1-amino-[18f]fluorocyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.. .
Nihon Medi-physics Co., Ltd.

Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.. .
Arbor Therapeutics, Llc

Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells

Methods for treating cancer, e.g., in conjunction with anti-cancer therapy, like immunotherapy, and for identifying candidate therapeutic agents, by targeting myeloid derived suppressor cells expressing tspan33.. .
Beth Israel Deaconess Medical Center Inc.

Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer

The present disclosure describes combination therapies comprising an anti-il-10 antibody or antigen-binding fragment thereof and a cpg-c type oligonucleotide, and the use of the combination therapies for the treatment of cancer.. .
Dynavax Technologies Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Methods to treat diseases with protein, peptide, antigen modification and hemopurification

The current invention discloses methods to modify protein and peptide and antigen to treat disease such as pathogen infection, autoimmune diseases and cancer. The method involves increasing the molecular weight of the protein by connecting multiple peptide units with site specific conjugation to extend the in vivo half life.

Treatment of cancer with immune stimulators

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject.
Sciclone Pharmaceuticals, Inc.

Novel t cell receptors and immune therapy using the same

The present invention pertains to antigen recognizing constructs against tumor associated antigens (magea1). The invention in particular provides novel t cell receptor (tcr) based molecules which are selective and specific for the tumor expressed antigen of the invention.
Immatics Biotechnologies Gmbh

Engineered natural killer cells and uses thereof

Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (cars). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites.
Onkimmune Limited

Compositions for cellular immunotherapy

The present disclosure relates to compositions and methods for using cells having cellular immunotherapies comprising a composition of chimeric antigen receptor (car)-modified cd4+ t cells and a composition of cd8+ t cells modified with a distinct car in that the intracellular signaling component of the each car is different, wherein the modified cd4+ and cd8+ t cells have enhanced helper and effector functions, respectively, and together more effectively augment the immune response. Such cellular immunotherapies are useful in treating disease, such as cancer..
Fred Hutchinson Cancer Research Center

Methods of obtaining mononuclear blood cells and uses thereof

Methods of obtaining mononuclear blood cells are provided. Also provided are methods of using the obtained cells for treating diseases such as cancer, infectious disease, autoimmune disease, allergy, and graft rejection..
Biolinerx Ltd.

Methods and compounds for treatment of lymphocyte-related diseases and conditions

Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein r1, l1, x, y and z are as defined herein..
Sarepta Therapeutics, Inc.

Compositions and methods for treating cancer

Also provided are pharmaceutical compositions comprising same and methods of using same for treating cancer.. .

Thieno- and pyrrolopyrimidine analogues as anticancer agents and methods of use thereof

The present invention provides for the design and synthesis of halogenated thieno- and pyrrolopyrimidine compounds that exhibit cancer proliferation inhibitory activity and the use thereof for cancer treatment.. .
University Of Maryland, Baltimore County

Treatment of cancer and benign proliferative disorders

Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided.
The University Of Manchester

Pac-1 combination therapy

The invention provides compositions and methods for the induction of cancer cell death. The compositions and methods of using them include use of compositions in therapy for the treatment of cancer and for the selective induction of apoptosis in cancer cells.
The Board Of Trustees Of The University Of Lllinois

2-(azaindol-2-yl) benzimidazoles as pad4 inhibitors

Compounds of formula (i) wherein; r1 is hydrogen or c1-6alkyl; r2 is hydrogen, c1-6alkyl, perhalomethylc0-5alkyl-o—, or c1-6alkoxy; r3 is hydrogen, c1-6alkyl, or c1-6alkoxyc1-6alkyl; r4 is hydrogen, c1-6alkyl, perhalomethylc1-6alkyl; or unsubstituted c3-6cycloalkylc1-6alkyl; a is c—r5 or n; b is c—r6 or n; d is c—r7 or n; with the proviso that at least one of a, b, and d, is n; r5 is hydrogen or c1-6alkyl; r6 is hydrogen or c1-6alkyl; r7 is hydrogen, c1-6alkyl, c1-6alkoxy, or hydroxy; r8 is hydrogen or c1-6alkyl, with the proviso that one of r4 and r8 is hydrogen; r9 is hydrogen or hydroxy; r1o is hydrogen or c1-6alkyl; and salts thereof are pad4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.. .
Glaxo Group Limited

Inhibitors of mcl-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors

The present invention includes compositions and methods for inhibiting mcl-1, including novel inhibitors of mcl-1, and compositions and methods for treating a subject with cancer that is refractory to one or more mapk pathway protein inhibitors.. .
Texas Tech University System

Pharmaceutical combination and uses thereof

The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor bnc105, and an immunotherapeutic agent, in particular an anti-pd-l1, pd-1 or ctla-4 antibody, and use thereof in the treatment of cancer.. .
Bionomics Limited

Citrin inhibitors for the treatment of cancer

Provided are methods, pharmaceutical compositions and kits for treating cancer in a subject in need thereof, by administering to the subject a therapeutically effective amount of an agent which downregulates a mitochondrial aspartate-dependent pyrimidine synthesis, thereby treating the cancer.. .
Yeda Research And Development Co., Ltd.

Liposomal nanoconstructs and methods of making and using the same

Provided herein is a liposome comprising: a) a conjugate comprising a lysophospholipid and a photosensitizer; b) a first derivatized phospholipid comprising a first phospholipid and a strained cyclooctyne moiety; c) a second derivatized phospholipid comprising a second phospholipid and a polyethylene glycol polymer; and d) a cationic or anionic lipid. Also provided herein is a liposome comprising: a) a conjugate comprising a lysophospholipid and a photosensitizer; b) a first derivatized phospholipid comprising a first phospholipid and a targeting moiety; c) a second derivatized phospholipid comprising a second phospholipid and a polyethylene glycol polymer; and d) a cationic or anionic lipid.
The General Hospital Corporation

Seoul National University R&db Foundation

. .

. .

Radius Pharmaceuticals, Inc.

. .

Bambam: parallel comparative analysis of high-throughput sequencing data

The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, aids, autism, alzheimer's, and/or parkinson's disorder. The methods can also be used to monitor and track changes in a patient's dna and/or rna during and following a clinical treatment regime.
The Regents Of The University Of California

Algorithms for disease diagnostics

The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis..
Veracyte, Inc.

Method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation

The present inventors demonstrated that the relb subunit of nfκb plays a crucial role in promoting cell migration. More precisely, they identified that this pro-migratory activity is mediated by the activation of the nfκb pathway through relb phosphorylation at serine 472.
Institut National De La Sante Et De La Recherche M Edicale (inserm)

Aie luminogens for visualization and treatment of cancer

The present subject matter relates to ate luminogens for visualization and treatment of cancer, particularly aie luminogenic probes for cancer cell visualization and discrimination, lysosome-targeting aiegens for imaging and autophagy visualization, highly fluorescent aie-active theranostic agents for monitoring drug distribution and having anti-tumor activity to specific cancer cells, probes comprising aie luminogens for cancer cell imaging and staining, aie luminogens having clusteroluminogenic features and applications thereof, and methods of preparing thereof.. .
The Hong Kong University Of Science And Technology

Methods for diagnosis and prognosis of cancers of epithelial origin

Adam 12 expression and activity are up regulated in patients that have cancers of epithelial origin, such as breast cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, and skin cancer, as well as others: accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. In particular, the presence of adam 12 in a biological sample is indicative of cancer of epithelial origin.
Children's Medical Center Corporation

Diagnostics of gyneacological diseases, especially epithelial ovarian cancer

The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of ca125. More specifically, said altered glycosylation pattern relates to that recognizable by mgl..
Turun Yliopisto

Use of he4 and other biochemical markers for assessment of ovarian cancers

The disclosure relates to use of the he4/he4a marker(s) together with one or more other markers to assess ovarian cancers in a patient.. .
Fujirebio America, Inc.

Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics

Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a vegf targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ang-2, sdf-1 and vegf-d in a sample from the subject and using the expression levels to determine whether the vegf targeting agent will be effective to treat the cancer in the subject.
Duke University

P53 biomarkers

The present invention relates to the identification of p53 biomarker profiles that predict response in patients with hyperproliferative disease such as cancer to a therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy.. .
Multivir Inc.

Methods of treating lung cancer by administration of an alk inhibitor

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of anaplastic lymphoma kinase (alk) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. Non-small cell lung carcinoma (nsclc).
Cell Signaling Technology, Inc.

Use of circulating tumor cell mitotic index in cancer stratification and diagnostics

Circulating tumor cells (ctcs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that ctcs exhibit cell cycle phase variability and that there is a strong correlation between the number of ctcs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained.
Creatv Microtech Inc.

Screening methods for targets for cancer therapy

In vitro and in vive methods for screening for targets for cancer therapy are provided herein. Methods contemplate screening for targets that contribute to the immunosuppressive environment for the tumor cells, especially those targets that are associated with radiation treatment.
Board Of Regents, The University Of Texas System

Protein-protein interaction as biomarkers

The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.. .
H. Lee Moffitt Cancer Center And Research Institute, Inc.

Compositions and methods for modulating oncogenic mirna

Provided herein are compositions and methods related to modulation of progenitor micrornas (pro-mirnas), such as for the treatment of cancer.. .
Children's Medical Center Corporation

Classification and actionability indices for cancer

The disclosure provides compositions, kits, and methods for detecting a plurality of genes and associated variants in a sample from a subject with cancer. The compositions, kits, and methods include a set of oligonucleotides, typically primers and/or probes that can hybridize to identify a gene variant.
Life Technologies Corporation

Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)

The disclosure provides methods correlating intra-patient genomic heterogeneity of single ctcs with phenotypic heterogeneity in each of a population of prostate cancer (pca) patients.. .
Epic Sciences, Inc.

Genomic alterations in the tumor and circulation of pancreatic cancer patients

Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients.
The Johns Hopkins University

Use of an mirna to reduce proliferation of a cancer cell

A method is provided for decreasing at least one of the proliferation and the migration of a cancer cell comprising contacting a cancer cell with an effective amount of a pharmaceutically acceptable composition comprising a microrna (mirna) having a nucleotide sequence having at least 80% sequence similarity to the nucleotide sequence of mir-3189-3p derived from the mir-3189 mitron of the growth differentiation factor 15 (gdf15) gene. The methods and compositions are advantageous for inhibiting proliferation and migration of, but not limited to, glioblastoma cells, melanoma cells, and breast cancer cells..
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Microrna compounds and methods for modulating mir-21 activity

Described herein are compositions and methods for the inhibition of mir-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of mir-21 activity.
Regulus Therapeutics Inc.

Method for preparing natural killer cells using irradiated pbmcs, and anti-cancer cell therapeutic agent comprising the nk cells

Provided is a method for preparing natural killer cell with high efficiency using irradiated peripheral blood mononuclear cells, more particularly to a method for proliferating highly activated nk cells using a combination of irradiated peripheral blood mononuclear cells (pbmcs) and a cd16 antibody and an anti-cancer cell therapeutic composition containing the natural killer cells (nk cells) prepared thereby. Further provided is a method for large-scale proliferation of activated nk cells with high efficiency using a combination of irradiated peripheral blood mononuclear cells (pbmcs) and a cd16 antibody without the use of cancer cells or genetically modified feeder cells having safety issues as feeder cells.
Korea Institute Of Radiological & Medical Sciences

Hormone responsive tissue culture system and uses thereof

The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” the genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples..

Bispecific heterodimeric diabodies and uses thereof

Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the p-cadherin tumor cell associated antigen and the cd3 t cell antigen..
Pfizer Inc.

Anti-adam28 antibody for treating cancer

The present invention provides an antibody that specifically binds to human adam28, inhibits enzyme activity of human adam28, and has an activity to suppress metastasis of a cancer cell that expresses human adam28. The antibody of the present invention can be a human antibody..
Keio University

Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta

This disclosure relates to compositions and conjugates comprising an interleukin, e.g., il-15 and a polypeptide that specifically binds tgf-beta. Typically the polypeptide that specifically binds tgf-beta is a type ii tgf-beta receptor.
Children's Healthcare Of Atlanta, Inc.

Diagnosis and treatment of cancer using anti-itm2a antibody

Disclosed is a monoclonal antibody binding to an itm2a protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as ewing's sarcoma, t cell leukemia, t cell lymphoma, acute myeloid leukemia, b cell tumor, and multiple myeloma.
Chugai Seiyaku Kabushiki Kaisha

Antibodies against human and canine il-13ra2

Provided herein are monoclonal antibodies that specifically bind il-13ra2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers..
Wake Forest University Health Sciences

Inhibitors of prototypic galectin dimerization and uses thereof

Agents that inhibit the dimerization of a prototypic galectin such as galectin-7 are described. These agents, for example antibodies and peptides, bind to a domain corresponding to residues 13-25, 86-108 and/or 129-135 of human galectin-7.
Institut National De La Recherche Scientifique

Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody

This disclosure provides a method for treating a subject afflicted with a pd-l1 positive non-squamous non-small cell lung cancer (nsclc). The method comprises administering to the subject a therapeutically effective amount of an anti-pd-1 anti-body or anti-pd-l1 antibody.
Bristol-myers Squibb Company

Antibody molecules to pd-1 and uses thereof

Antibody molecules that specifically bind to pd-1 are disclosed. The anti-pd-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders..
President And Fellows Of Harvard College

Compositions and methods to enhance the immune system

The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g.
Stichting Sanquin Bloedvoorziening

Cancer targets and uses thereof

Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“cat”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using cat.
Celera Corporation

Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras

The present invention pertains to anti-mif antibodies, preferably in combination with cancer therapeutics, i.e. Chemotherapeutic agents, in the treatment of cancers containing mutant tp53 and/or mutant ras..
Baxalta Incorporated

Multimeric constructs

Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
Genzyme Corporation

Anti-activin a antibodies and uses thereof

The present invention provides antibodies that bind to activin a and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to activin a with high affinity.
Regeneron Pharmaceuticals, Inc.

Sirp polypeptide compositions and methods of use

Provided herein are sirp-gamma, sirp-beta or sirp-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.. .
Ab Initio Biotherapeutics, Inc.

Histone anti-cancer vaccines

The present invention pertains to novel immunogenic peptide sequences that can be used as vaccines in the treatment of cancer diseases such as brain cancers and specifically glioma. The cancer vaccines of the invention are designed based on the k27m mutated variant of the human histone 3.
Deutsches Krebsforschungszentrum

Structure-based peptide inhibitors of p53 aggregation as a new approach to cancer therapeutics

This invention relates, e.g., to an inhibitory peptide or cpp inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or cpp inhibitor (e.g.
The Regents Of The University Of California

Peptidomimetics for imaging the ghrelin receptor

The present invention concerns compositions comprising and methods of identification and use of imaging agents. The imaging agents comprise a growth hormone secretagogues having a conjugated fluoride.
London Health Sciences Centre Research Inc.

Cancer cell-targeting peptide and use thereof

The present invention relates to a peptide targeting a tumor cell and use of the peptide, and more particularly, to a peptide consisting of seq id no: 1 to seq id no: 4 and specifically binding to a tumor cell, a composition including the peptide as an effective ingredient for detecting a tumor cell, a composition including the peptide as an effective ingredient for delivering a drug, and a composition including the peptide as an effective ingredient for imaging. The peptide of the present invention can be used for detection or imaging of a tumor cell in vitro and in vivo by specifically binding to a tumor cell..
Kyungpook National University Industry-academic Cooperation Foundation

Progesterone antagonists

Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.. .
Evestra, Inc.

Nucleotides for the treatment of cancer

The present invention relates to novel nucleoside derivatives, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.. .
Idenix Pharmaceuticals Llc

Cytotoxic platinum complex, its preparation and therapeutic use

Platinum(iv) complexes especially suitable for antitumor therapy and methods for their preparation. Further provided is a method for treating a subject, in particular a human, suffering from a disease comprising administering a platinum(iv) complex of the present invention, which disease is especially preferably but not exclusively a cancer.
City University Of Hong Kong

Etp derivatives

Provided herein, inter alia, is the synthesis of etp derivatives. The uses of the etp derivatives described herein include treatment of cancer..
The Regents Of The University Of California

Mcl-1 inhibitors and methods of use thereof

And enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions..

Palladium-mediated ketolization

Provided herein are palladium-mediated coupling reactions useful in the preparation of ketone-containing organic molecules. The provided methods can be used for the preparation of natural products and pharmaceutical agents, including eribulin, halichondrins, and analogs thereof.
President And Fellows Of Harvard College

Ether analogues of galiellalactone

Ether analogues of galiellalactone, methods of preparing the analogues, and use of the analogues in the treatment of cancer are disclosed. The analogues are of formula (i) or (ii):.
Glactone Pharma Development Ab

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Pyrrolopyrimidine compounds and their uses

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases.
Astex Therapeutics Ltd.

Inhibitors of kras g12c mutant proteins

Or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein b, w, x, y, r1, r2a, r2b, r3a, r3b, r4a, r4b, g1, g2, m1, m2, l1, l2 and e are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of g12c mutant kras protein for treatment of disorders, such as cancer, are also provided..

Pharmaceutical compositions comprising perillyl alcohol derivatives

A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer..
Neonc Technologies Inc.

Salt and crystal forms of plk-4 inhibitor

A fumarate salt and a maleate salt of compound (i) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (i) fumarate and 1:1 compound (i) maleate are characterized by a variety of properties and physical measurements.
University Health Network

Small molecule based antibody-recruiting compounds for cancer treatment

The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (upar) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (adcc) and/or complement dependent cytotoxicity (cdc) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer..
Yale University

N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors

A compound of formula (i), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between si 00a9 and interaction partners such as rage, tlr4 and emmprin and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders..
Active Biotech Ab

Isoquinolin-3-yl carboxamides and preparation and use thereof

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc

2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of pdk1

The present invention concern a 2-oxo-1,2-dihydropyridine-3-carboxamide compound of formula (i) and new 2-oxo-1,2-dihydropyridine-3-carboxamide compounds of formula (ii) in the treatment of pathologies which require an inhibitor of pdk1 enzyme such as diabetes, neurodegenerative diseases such as alzheimer's and prion diseases, and tumours such as breast, and pancreatic cancers and glioblastoma, particularly glioblastoma.. .
International Society For Drug Development S.r.l.

Ribonucleotide reductase inhibitors and methods of use

Provided herein are novel compounds that inhibit ribonucleotide reductase (rr) by binding to rrm2 and interfering with the activity of the rrm1/rrm2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit rr activity and to treat various conditions associated with rrm2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases..
City Of Hope

Pyrimidine compounds containing acidic groups

The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via tlr7 which are useful in the treatment of viral infections and cancers.. .
Apros Therapeutics, Inc.

Inhibitors of ack1/tnk2 tyrosine kinase

Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ack1 tyrosine kinase and their use in the treatment of cancer.
H. Lee Moffitt Cancer Center And Research Institute, Inc.

New crystal form of lenvatinib methanesulfonate salt and preparation method thereof

The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer.
Crystal Pharmatech Co., Ltd

Antibiotic sensitivity-restoring and photosensitive agents

The present disclosure describes a method to treat conditions, including bacterial infections and cancer, using a photosensitive compound that, upon exposure to white light, can be activated. The photosensitive compound can also interact synergistically with antibiotics used concomitantly to kill drug-resistant bacteria.
New Mexico Tech Research Foundation

3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones

Compounds of formula (i) as described hereinprocesses for their production and their use as anti-cancer agents.. .
Bayer Pharma Aktiengesellschaft

Aryl ethers and uses thereof

The present disclosure relates to hif-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in hif-2α scintillation proximity assay, luciferase assay, and vegf elisa assay, and led to tumor size reduction and regression in 786-o xenograft bearing mice in vivo..
Peloton Therapeutics, Inc.

Normal tissue toxicity reducing microbeam-broadbeam radiotherapy, skin's radio-response immunotherapy and mutated molecular apheresis combined cancer treatments

Normal tissue complications limit curative broadbeam radiotherapy to tumors including lung cancer. Radiation retinitis causing blindness limits quality of life and long term survival for patients with ocular melanoma.

Extracting protobeams for cancer radiation therapy

A method and system are provided. The method includes condensing, by a processor, an original voxel-beamlet matrix stored in a memory device into a reduced dataset for proton beam simulation and therapy.
International Business Machines Corporation

De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy

The present invention generally provides compositions methods and composition relating to the diagnosis and/or treatment of cancers having a cell surface de-n-acetylated sialic acid antigen, e.g., an at least partially de-n-acetylated ganglioside and/or a de-n-acetylated sialic acid-modified cell surface protein.. .
Children's Hospital & Research Center At Oakland

Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.

Cancer immunotherapeutic

The invention relates to immunotherapeutic compositions and methods for treating specifically solid tumours and cells of the tumour microenvironment.. .
Rubicon Biotechnology Llc

Methods of treatment with arginine deiminase

The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase.. .
Polaris Group

Blocking il-9 signaling in conjunction with chemotherapy to treat cancer

This document provides methods and materials related to using inhibitors of il-9 signaling in conjunction with chemotherapy to treat cancer (e.g., solid tumors). For example, methods and materials for using inhibitors of il-9 signaling (e.g., anti-il9 antibody preparations) in conjunction with chemotherapy to treat cancer (e.g., solid tumors such as breast cancer tumors or colon cancer tumors) or to reduce the growth rate of cancer (e.g., solid tumors such as breast cancer tumors or colon cancer tumors) within a mammal are provided..
Mayo Foundation For Medical Education And Research

Compositions and methods related to cell systems for penetrating solid tumors

The present disclosure provides, e.g., compositions and method for treating cancers, e.g., solid tumors. In embodiments, the compositions comprise an erythroid cell expressing an exogenous polypeptide, e.g., a polypeptide that promotes penetration of the erythroid cell into the solid tumor..
Rubius Therapeutics, Inc.

Compositions, methods and kits for eliciting an immune response

The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one cmv antigen expressed by a cancer cell, in particular for treating and preventing cancer. Cmv determination methods, compositions, and kits also are provided..
Duke University

Novel cmv pp65 targeting dna vaccine for cancer immunotherapy

The present invention relates to an attenuated strain of salmonella comprising a dna molecule encoding cmv pp65. In particular, the present invention relates to the use of said attenuated strain of salmonella in cancer immunotherapy..
Vaximm Ag

Shared neoantigens

Disclosed herein in one aspect is a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier, each neoantigenic peptide comprising a tumor-specific neoepitope capable of binding to an hla protein in a subject, each tumor-specific neoepitope comprising a tumor-specific mutation present in a tumor, wherein (a) the composition comprises neoantigenic peptides comprising tumor-specific mutations present in at least 1% of subjects in a population of subjects suffering from cancer; (b) the composition comprises neoantigenic peptides comprising tumor-specific neoepitopes which bind to hla proteins present in at least 5% of subjects in the population; and (c) the composition comprises at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects in the population of subjects suffering from cancer.. .
The General Hospital Corporation

Composition comprising ka11 polypeptide or gene encoding the same for inhibiting angiogenesis, and use thereof

Provided is a composition including a kai1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a kai1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, kai1h, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases kai1 or in which kai1 is forcefully increased, a method using a kai1 protein, or a method for inhibiting a src-pkc pathway provoking the degradation of kai1.
Seoul National University R & Db Foundation

Methods of treating pancreatic cancer using gpcr antagonists

Provided herein are, inter alia, compositions and methods for the treatment of cancer and inhibition of metastasis. The compositions include a μ-opioid receptor (mor) polypeptide and a somatostatin receptor 2 (sstr2) polypeptide, wherein the mor polypeptide is bound to a mor antagonist and the sstr2 polypeptide is bound to a sstr2 antagonist.
City Of Hope

Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment

The present invention relates to oncolytic adenoviruses with functional deletions of immunodominant t-cell epitopes of adenovirus proteins, as well as to methods of using the oncolytic adenoviruses for the treatment of diseases, such as cancer. The oncolytic adenoviruses may also contain one or more heterologous nucleic acid sequences each encoding a tumor antigen or epitope.
Vcn Biosciences Sl

Nk cells and antibodies for cancer treatment

Treatment of cancer in a patient comprises administering to the patient an effective amount of an antibody and an effective amount of nk cells, wherein the antibody binds an antigen on the surface of the nk cells and the antibody binds to an fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the nk cell on the cancer cell now binding the antibody via r-adcc..
University Health Network

Arsenic trioxide for treatment of pin1-associated disorders

The present invention relates to the treatment of pin1-associated disorders (e.g., disorders characterized by elevated pin1 activity) with arsenic trioxide, optionally in combination with a retinoic acid compound. Pin1-associated disorders may include, for example, proliferative disorders (e.g., cancers), inflammatory conditions, and autoimmune disorders associated with aberrant levels of pin1 activity..
Beth Israel Deaconess Medical Center, Inc.

Method for maintaining increased intracellular p53 level, induced by platinum-based anticancer drug, and application thereof

According to the method of the present invention, the increased intracellular p53 expression level can be maintained for a long period of time in spite of the treatment with a low-concentration platinum-based anticancer drug, thereby effectively inducing the apoptosis of cancer cells and minimizing the drug side effect caused by the administration of the platinum-based anticancer drug, and thus the present invention can be favorably used in the prevention of cancer or the development of cancer medicines.. .

Antitumoral combination comprising cabazitaxel and cisplatin

The present invention relates to a combination comprising cabazitaxel and cisplatin. The present invention relates also to a pharmaceutical composition containing such a combination and to a pharmaceutical kit comprising: (i) a first galenic formulation comprising cabazitaxel; and (ii) a second galenic formulation comprising cisplatin.
Aventis Pharma S.a.

Organic compositions to treat kras-related diseases

The present disclosure relates to rnai agents useful in methods of treating kras-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (cfc) syndrome and noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a rnai agent to kras.. .
Arrowhead Pharmaceuticals, Inc.

Prostate cancer treatment via synergistic inhibition of aryl hydrocarbon receptor (ahr) and src

Simultaneous inhibition of the aryl hydrocarbon receptor (ahr) and src abolishing androgen receptor (ar) signaling in prostate cancer cells is disclosed herein as an effective treatment for prostate cancer. Provided herein is a therapeutic composition that comprises an aryl hydrocarbon receptor (ahr) antagonist and an src inhibitor.
Clark Atlanta University

Fused bicyclic pyrimidine derivatives and uses thereof

The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.

Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus

An axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.. .
Bergenbio Asa

Combination compositions for immunotherapy

The present invention relates to therapeutic combinations comprising wnt inhibitors and methods for treating cancers using combination therapy.. .
Curegenix Corporation

Aza spiro alkane derivatives as inhibitors of metalloproteases

Enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of formula i and ii are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions..

Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases due to mutations in wnt signaling components.
Samumed, Llc

Biperiden for treating cancer

The present invention relates to the use of the compound biperiden as a malt1 inhibitor in the treatment of a cancerous disease. The invention in particular relates to a combination of biperiden and a phenothiazine for use in the treatment of a cancerous disease.
Universitätsklinikum Hamburg-eppendorf

Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent

Methods for treating breast cancer comprising administering to a subject in need thereof a bromodomain inhibitor concomitantly with a second agent. The second agent may be an aromatase inhibitor, a selective estrogen receptor modulator, or a selective estrogen receptor down-regulator.
Gilead Sciences, Inc.

Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent

Methods for treating prostate cancer comprising administering to a subject in need thereof a bromodomain inhibitor concomitantly with a second agent. The second agent may be an androgen receptor antagonist.
Gilead Sciences, Inc.

Inhibition of cancer cell motility

Provided herein are compositions and methods for inhibiting cancer cell motility and/or metastasis. In particular embodiments, kbu2046 (or an analog thereof) and one or more additional therapies (e.g., cancer therapies (e.g., hormone therapies and chemotherapies) are provided to inhibit cancer cell motility, inhibit metastasis, and/or treat cancer (e.g., prostate cancer, lung cancer, breast cancer, colon cancer, etc.)..
Northwestern University

Compositions and methods for treatment of cancer

Methods and compositions are provided for treatment of cancer, including prostate cancer. In one aspect, the present invention provides a composition comprising a taxane and a drug that reduces efflux of the taxane from a cell.
The Regents Of The University Of California

Multi-drug combinations that act as potent radiosensitizers

Provided is a method of treatment including administering to lung, brain or esophageal cancer cells an effective amount of radiation in conjunction with a micelle composition that includes an effective amount of paclitaxel, and one or both of 17-aag, and rapamycin, wherein the micelle includes poly(ethylene glycol)-block-poly(lactic acid) (peg-b-pla).. .
Wisconsin Alumni Research Foundation

Cabazitaxel fat emulsion, and preparation method and use thereof

Provided in the present invention is a cabazitaxel fat emulsion injection, wherein the cabazitaxel fat emulsion injection contains cabazitaxel, a medium chain triglyceride for injection, and lecithin. Also provided in the present invention are the method for preparing the cabazitaxel fat emulsion injection and the use thereof in preparing a drug for treating prostate cancer..
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene

This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (bmd), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (bmd), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (bmd), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (bmd), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof.. .
Aspen Park Pharmaceuticals, Inc.

Methods for treating cancer

Or a salt or solvate thereof.. .

Treating vasculature related diseases or disorders using nanoparticles

The present invention relates to prevention and/or treatment of diseases or disorders associated with a damaged or leaky vasculature in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating a disease or disorder associated with a damaged or leaky vasculature in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, an outer surface comprising a cellular membrane derived from a platelet; and optionally an agent for preventing, treating, diagnosing, or prognosing the disease or disorder and/or monitoring prevention or treatment of the disease or disorder.
The Regents Of The University Of California

Methods of treating pancreatic cancer

Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine.. .
Abraxis Bioscience, Llc

Combination liposomal pharmaceutical formulations

Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, dc-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (api) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second api comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel.
Cureport, Inc.

Methods of treating cancerous tissue

In one aspect, methods of treating cancerous tissue are described herein. In some embodiments, a method of treating cancerous tissue comprises inducing necrotic cell death in cancer stem cells in vivo during hyperthermic treatment of the tissue, wherein inducing necrotic cell death comprises positioning nanoparticles adjacent to the cancer stem cells and irradiating the nanoparticles with electromagnetic radiation resulting in membrane damage to the cancer stem cells..
Wake Forest University Health Sciences

Humanized mice and uses thereof

The invention relates to methods for generating, expanding and maintaining a culture of leukocytes in heterologous animals. The invention also relates to the use of these animals as models of human immune system for testing molecules in order to treat a disease or disorder such as cancer..
Champions Oncology, Inc.

Tumor antigen peptide

The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by yo-xo-zo; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing ctl; etc..
Suphatchatwong Innovation Co., Ltd.

Antibodies against phosphorylcholine in combination therapy with biologic agents

Antibodies against pc, pc conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are pc conjugates, pc or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells..
Suphatchatwong Innovation Co., Ltd.

Liposomal preparations for non-invasive-prenatal or cancer screening

Disclosed are controls for use in identifying any of a number of genotypes and/or for use in identifying or characterizing a disease or condition. The controls may be particularly useful for diagnostic tests that utilize circulating cell-free dna or microrna.
Seracare Life Sciences, Inc.

Methods and kits for cancer antigen and heparan sulfate imaging

An in vitro method of imaging a cancer antigen includes providing a cell sample including a cancer antigen selected from the group consisting of a tn antigen, a t antigen, a sialylated-tn antigen, and a sialylated-t antigen, treating the sample with a glycosyltransferase to incorporate a carbohydrate with a click chemistry moiety into the cancer antigen, adding a label to the sample that includes a click chemistry moiety that reacts to the click chemistry moiety of the carbohydrate such that the label attaches to the carbohydrate to form a labeled cancer antigen, and imaging the sample with a camera.. .
Bio-techne Corporation

Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells

Described herein are compositions and methods of use of anti-trop-2 antibodies or antigen-binding fragment thereof to isolate, enrich, detect, diagnose and/or characterize circulating tumor cells (ctcs) from patients with a trop-2 positive cancer. Preferably, the antibody is an rs7, 162-46.2 or mab650 antibody.
Immunomedics, Inc.

Biosensors and methods for detection of lysophosphatidic acid for signaling of ovarian cancer

The present disclosure relates to biosensors, kits and methods for detecting and/or quantifying lysophosphatidic acid (lpa) in a liquid sample such as a serum sample from a subject. The present disclosure also relates to linker compounds that are useful, for example, in the biosensors, kits and methods of the present disclosure and to methods for preparing a biosensor for detecting and/or quantifying lysophosphatidic acid (lpa) in a liquid sample..
Econous Systems Inc.

Compositions and methods for diagnosing breast cancer

The invention provides methods and compositions for distinguishing breast cancer.. .
Trustees Of Tufts College

Electrical cell-substrate impedance sensor (ecis)

A method for detection and monitoring a spreading stage of a biological cell for cancer diagnosis is disclosed. The method includes steps of removing biological cell lines from a material; culturing the cell lines via maintaining the removed biological cell lines in an appropriate medium at a controlled set of conditions; seeding the cultured biological cells lines on silicon nanowire electrode arrays of an electrical cell-substrate impedance sensor (ecis); and measuring an electrical impedance of the seeded biological cell lines to detect and monitor a spreading state of the seeded biological cell lines for cancer diagnosis..

Analysis of cell-free dna in urine and other samples

Diseases (e.g., cancer) of a particular organ can be detected by analyzing cell-free dna. Some embodiments may use an organ-associated sample that is from a particular organ or passes through the particular organ, as may occur, for example, in urine, saliva, blood, and stool samples.
The Chinese University Of Hong Kong

Methods of prostate cancer prognosis

The present invention relates to methods for diagnosing, monitoring or prognosticating prostate cancer or the progression state of prostate cancer wherein said method determines the state of the prostate cancer, based on the expression level of phosphodiesterase 4d (pde4d) variants. The invention further relates to a method of identifying an individual for eligibility for prostate cancer therapy.
Koninklijke Philips N.v.

Methods of prostate cancer prognosis

The present invention pertains to methods for determining gene expression signatures for diagnosing patients with prostate cancer, e.g., to establish a prognosis for such patients, for determining the predisposition of said patient to develop aggressive or indolent disease, for example after primary treatment, and/or for identification and stratification of patients for available therapies. The invention also relates to products used in such methods, e.g.
Koninklijke Philips N.v.

Biomarkers and uses thereof for selecting pancreas cancer intervention

The instant disclosure provides methods for using biomarkers for identifying therapeutic regimens to treat pancreas cancer, or to reduce the risk of pancreas cancer, pancreas cancer metastasis, pancreas cancer proliferation, or pancreas cancer recurrence. For example, such therapeutic regimens can be based on the level of runx3 expression in the context of a particular dpc4 genotype, or based on the level of runx3 expression in combination with the level of col6a1 expression, spp1 expression or both.
Fred Hutchinson Cancer Research Center

Methods for treating and assessing tumor invasion and metastasis

Provided herein are methods, such as diagnostic methods, for evaluating a tissue sample, such as a biopsy or cytology specimen of a subject to determine a likelihood of metastasis, a risk of tumor or cancer occurrence, or combinations thereof and provided herein are methods, such as a screening method, for determining the efficacy of a drug in reducing cell invasiveness. Also provided are methods of treatment, drugs, primers, and kits..
University Of Southern California

A predicting risk of recurrence of cancer

A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of foxm1, uhrf1, pttg1, e2f1, mybl2, hmgb2, atad2, e2f8, znf367 and tcf19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.. .
University College Dublin, National University Of Ireland, Dublin

Methods and compositions for determining ploidy

The invention provides improved methods, compositions, and kits for detecting ploidy of chromosome regions, e.g. For detecting cancer or a chromosomal abnormality in a gestating fetus.
Natera, Inc.

Assays to determine dna methylation and dna methylation markers of cancer

Methods are provided for determining a genomic methylation profile in a dna sample. In certain aspects, the methods can be used to determine if a subject has, or is at risk for developing, a bladder cancer or other cancers of the urinary tract.
Zymo Research Corporation

Methods, compositions, and kits for nucleic acid analysis

Aspects of the invention relate to methods and kits for assessing cancer. Some aspects of the invention relate to methods and kits for preparing a sample library for sequencing.
Toma Biosciences, Inc.

Oncolytic virus therapy for resistant tumors

Disclosed herein is a recombinant oncolytic virus comprising a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (trail). One such oncolytic virus is ohsv.
The General Hospital Corporation

Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood

Disclosed are methods of isolating t cells and tcrs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, tcrs, pharmaceutical compositions, and methods of treating or preventing cancer..
The United States Of America,as Represented By The Secretary,department Of Health And Human Service

Fusion proteins that facilitate cancer cell destruction

Provided is a fusion protein comprising a polypeptide component that blocks binding of cd47 to sirp alpha and a polypeptide that binds to and triggers a trail receptor or fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment..
Thomas Jefferson University

Methods of using bispecific cd33 and cd3 binding proteins

Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.

Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies

The present invention provides compositions comprising an anti-cd7 chimeric activating receptor (car) and an anti-cd7 protein expression blocker, and methods of using such compositions in cancer therapy.. .
National University Of Singapore

Anti-folate receptor alpha antibodies and uses thereof

Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits to detect folate receptor alpha.
Morphotek, Inc.

T cell receptor-like antibodies specific for a prame peptide

The presently disclosed subject matter provides antigen-binding proteins that specifically bind to preferentially expressed antigen of melanoma (prame), including humanized, chimeric and fully human antibodies against prame, antibody fragments (e.g., scfv, fab and f(ab)2), chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a prame peptide/hla class i molecule complex.
Eureka Therapeutics, Inc.

Tgf-beta 3 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (tgf-β3) are provided, particularly recognizing human and mouse tgf-β3, particularly antibodies and fragments that do not recognize or bind tgf-β1 or tgf-β2. Particular antibodies are provided which specifically recognize and neutralize tgf-β3.
Ludwig Institute For Cancer Research Ltd.

Monomeric cxcl121 peptide and use thereof

The present invention provides a cxcl121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and hiv/aids.. .
The Medical College Of Wisconsin, Inc.

Human cell lines mutant for zic2

Human cell lines mutant for zic2 with altered cellular phenotype are disclosed, including hek 293t, ln prostate cancer, and pc-3 cell lines. Method of making the human cell lines mutant for zic2 using gene editing tools such as crispr/cas9 is also disclosed herein.
Clark Atlanta University

Anti-cancer fusion polypeptide

The disclosure provides a fusion polypeptide specific for both cd137 and gpc3, which fusion polypeptide can be useful for directing cd137 clustering and activation to gpc3-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors.
Pieris Pharmaceuticals Gmbh

Novel proteins specific for cd137

The present disclosure provides human lipocalin muteins that bind cd137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making cd137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins.
Pieris Pharmaceuticals Gmbh

Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy

The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for using synthetically enhanced t-cells to treat cancer.
The Johns Hopkins University

Cholic acid derivative, and preparation method and medical use thereof

The present invention relates to a cholic acid derivative, and a preparation method and a medical use thereof. In particular, the present invention relates to a cholic acid derivative of formula (i), a stereoisomer, or a pharmaceutically acceptable salt thereof.
Shanghai Hansoh Biomedical Co., Ltd.

Novel prodrugs and methods of use thereof

The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human akr1c3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds..
Health Innovation Ventures B.v.

Tricyclic fused thiophene derivatives as jak inhibitors

The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of janus kinase (jak) and are useful in the treatment of diseases related to the activity of jak including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Incyte Holdings Corporation

4-((2-acrylamidophenyl)amino)thieno[3,2-d]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors

The present invention relates to a novel 4-((2-acrylamidophenyl)amino)thieno[3,2-d]pyrimidine-7-carboxamide compound, an anticancer agent containing the compound as an active ingredient and an intermediate compound for preparing the compound.. .
Korea Institute Of Science And Technology

Notch pathway signaling inhibitor compounds

The present invention provides the following compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing said compounds useful as a notch pathway signaling inhibitor for the treatment of named cancers, sensorineural hearing loss caused by auditory hair cell loss, and inducing auditory hair cell generation.. .
Audion Therapeutics

2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc

Cycloalkyl-linked diheterocycle derivatives

Or pharmaceutically acceptable salts thereof, wherein a, l, d, r1-r15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals.

Novel ezrin inhibitors and methods of making and using

The invention encompasses compound and pharmaceutical composition comprising the compound of the following formula (i): or pharmaceutically acceptable salts or prodrugs thereof, that are useful for inhibiting ezrin protein in a cell or for inhibiting the growh of a cancer cell.. .
Georgetown University

2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibotors and therapeutic uses thereof

Indazole compounds of formula (i) as cyclin-dependent kinase (cdk) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular cdk4/6, including but not limited to various cancers and inflammation-related diseases or conditions..
Beta Pharma, Inc.

Phenol derivatives to treat cancer

Wherein r1-r8 take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly for the treatment and/or prophylaxis of cancer.. .

Compounds and methods for treating cancer

The present application relates to compounds comprising an ester, a thioester, or a hydrazide moiety and methods of synthesizing these compounds. The present application also relates to pharmaceutical compositions containing the compounds and methods of treating cell proliferative disorders mediated by the hh signaling pathway, such as cancer, by administering the compounds and pharmaceutical compositions to subjects in need thereof..
Dana-farber Cancer Institute, Inc.

Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators

A method of identifying compounds as direct inhibitors of keap1-nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of keap1-nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, alzheimer's, and parkinson's.
The Broad Institute, Inc.

Compounds and methods of use thereof for treating tumors

The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated with abnormal cell growth, for example, treating or preventing cancer or tumor growth, which methods include administering to a mammal in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof..
Georgetown University

Gene therapy vector system and prodrug genes

The present invention relates to a replication retrovirus vector system comprising thymidine kinase (hsv-tk) gene and cytosine deaminase (cd) gene which make gene transfer to cancer cell tissue for the efficient treatment of cancer. Particularly, the hsv-tk/cd combined self-replicating retrovirus vector system of the present invention characteristically contains both hsv-tk and cd genes; has no worries about losing a therapeutic gene because recombination does not occur in this system during virus infection; and has an excellent stability, and also is able to induce cancer cell death by using the prodrug gcv or 5-fc and can apply a therapeutic gene or a prodrug thereof selectively to such cancer that shows resistance against cancer treatment using either tk or cd, so that this system of the invention can be advantageously used as a pharmaceutical composition for the treatment of cancer..
The Industry & Academic Cooperation In Chungnam National University (iac)

Antibody-drug conjugates, compositions and methods of use

Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.. .

Combination therapy for non-small cell lung cancer positive for egfr mutation

The present invention features methods of treating lung cancer (e.g., nsclc) with an anti-pd-l1 antibody and a tyrosine kinase inhibitor in a subject identified as having an egfr mutation-positive tumor.. .
Medimmune Limited

Anti-ror1 chimeric antigen receptors

The invention provides improved compositions for adoptive cell therapies for cancers that express ror1.. .
Eureka Therapeutics, Inc.

Nanoparticles for use as a therapeutic vaccine

The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer.. .
Nanobiotix

Combination therapy using pdk1 and pi3k inhibitors

The present invention relates to methods and compositions for inhibiting growth and proliferation of cancer cells resistant to pi3k inhibition using a combination of pdk1, sgk1 and pi3k inhibitors. The present invention is also directed to methods of treating cancer in a subject exhibiting cancer cells resistant to pi3k inhibition, comprising administering inhibitors of pi3k in combination with inhibitors of pdk1 and/or sgk1 to the subject..
Memorial Sloan-kettering Cancer Center

Method for treatment and prognosis of colorectal cancer

The invention relates to the treatment and prognosis of colorectal cancer, especially proximal colorectal cancer. It also relates to identifying patients with colorectal cancer who are likely to respond to therapy with an inhibitor of interleukin 22 signalling..
Oxford University Innovation Limited

Materials and methods for treating bacterial infections using c-1 gentamicin

Various aspects relate to the use of c-1 gentamicin as an antibiotic effective for the treatment of a bacterial infection, a genetic disorder, or cancer in a subject.. .
Indiana University Research And Technology Corporation

Methods and assays for combination treatment of cancer

The technology described herein is directed to the treatment of cancer, e.g. Methods and assays relating to selecting and administering a chemotherapy with or without an ezh2 inhibitor..
Children's Medical Center Corporation

Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy

Disclosed are compositions, kits, and methods for treating cancer in a subject in need thereof. The compositions, kits, and methods may be used to treat a tumor in a subject in situ.
University Of Iowa Research Foundation

Glycan therapeutic compositions and related methods thereof

Preparations of glycan therapeutics, pharmaceutical compositions, dietary supplements and medical foods thereof are provided, and methods of using said gycan therapeutics, e.g. In cancer therapy..
Kaleido Biosciences, Inc.

Methods of treating pancreatic cancer

Described herein are methods and compositions for the treatment of pancreatic cancer in a subject in need thereof. The pancreatic cancer may be resistant to other therapeutic regimens.
University Of Maryland, Baltimore

Compositions and methods for therapy of prostate cancer using drug combinations to target polyamine biosynthesis and related pathways

Provided are compositions and methods for treating prostate conditions. The methods involve administering to an individual in need thereof a composition that contains i) an inhibitor of methionine salvage pathway in prostate of the individual and ii) a polyamine analogue.
The Johns Hopkins University

Cerdulatinib for the treatment of b-cell malignancies

Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a b-cell malignancy, chronic lymphocytic leukemia (cll), follicular lymphoma (fl), diffuse large b-cell lymphoma (dlbcl) or other transformed fl and/or have relapsed or not responded to a prior chemotherapy..
Portola Pharmaceuticals, Inc.

Combinations of pfkfb3 inhibitors and immune checkpoint inhibitors to treat cancer

Provided herein is a method of treating cancer and stimulating anti-tumor immunity in a subject in need thereof, the method including administering to the subject a synergistic, therapeutically effective amount of a pfkfb3 inhibitor, such as pfk-158, in combination with an immune checkpoint inhibitor. Also provided is a method of synergistically increasing activity of an immune checkpoint inhibitor, the method including administering to a subject in need thereof a combination therapy including pfk-158 and the immune checkpoint inhibitor.
University Of Louisville Research Foundation, Inc.

Chloroquine induction of par-4 and treatment of cancer

Described herein are methods for treating cancer in a subject in need thereof by administering chloroquine, or a salt or prodrug thereof, optionally with another agent that promotes par-4 production to induce prostate apoptosis response-4 (par-4) production by host cells, particularly non-cancerous host cells, to promote apoptosis in cancer cells, including androgen insensitive prostate cancer cells.. .
University Of Kentucky Research Foundation

Novel compounds as rearranged during transfection (ret) inhibitors

This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. .
Glaxosmithkline Intellectual Property Development Limited

Pharmaceutical composition of mek inhibitor and preparation method thereof

The present application provides a pharmaceutical composition comprising 6-(2-chloro-4-iodophenylamino)-n-(2-hydroxyethoxy)-5-methyl-4-oxo-4,5-dihydrofuro[3,2-c]pyridine-7-carboxamide or a pharmaceutically acceptable salt, a binder, a surface stabilizer and a dispersant, wherein the pharmaceutical composition can be dispersed in water to form a pharmaceutical suspension having a median particle size, x50, of 0.5 μm to 4.0 μm. Also disclosed are a preparation method thereof and the use thereof for treating cancers..
Chia Tai Tainqing Phamaceutical Group Co., Ltd.

Bendamustine derivatives and methods of using same

The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.. .
Ignyta, Inc.

Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function

The invention relates to the field of medicine and concerns an agent that stimulates tissue regeneration and the recovery of diminished tissue and organ function. A medicinal agent for the treatment and/or prophylaxis of a pathological condition selected from the group including metabolic syndrome, impaired glucose tolerance, hepatitis, particularly chronic hepatitis and toxic hepatitis, idiopathic pulmonary fibrosis (ipf), emphysema of the lungs, chronic obstructive pulmonary disease (copd) and cachexia, particularly as a result of impaired glucose tolerance, pulmonary fibrosis, chronic obstructive pulmonary disease, cancer and other diseases, is proposed in the form of an agent based on treamide.
Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises"

Breast cancer therapeutic agent containing 5'-hydroxy-5-nitro-indirubin-3'-oxime as active ingredient

A breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as active ingredient has been disclosed. Further, a breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as cyclin-dependent kinase (cdk) inhibitor, wherein said breast cancer is triple negative breast cancer (tnbc) and/or an estrogen receptor (er) positive breast cancer including the tamoxifen-resistant estrogen receptor (er) positive breast cancer has been disclosed..
Anygen Co., Ltd.

Compositions comprising 15-hepe and methods of treating or preventing cancer and neurologic disease

The present disclosure provides compositions comprising 15-hepe and methods of using same for treating and/or preventing cancer and neurological diseases in a subject in need thereof.. .
Afimmune Limited

Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids

Described herein are methods to purify alkaloids and amino acids. Also described are compositions and methods to treat or prevent a disease using the purified amino acids and alkaloids.

Thermal therapy systems and methods

Devices and methods can be used to deliver thermal therapy to treat tissue. For example, this document provides devices and methods for treating varices, varicosity, other bleeding vessels, polyps, and cancer using microwave-delivered thermal therapy in a minimally invasive fashion.
Mayo Foundation For Medical Education And Research

Cutaneous blood flow monitoring device

A method and a device for diagnostic of skin cancer and other mammalian skin tissue pathologies are described. The method relies on determination of pathological changes in tissue vascularization and capillary blood flow.
Veriskin, Inc.

Mmtv-sv40-spy1a and spy1a-ptre transgenic mouse models

In one aspect, the invention provides a transgenic non-human animal model having germ cells and somatic cells containing an endogenous mmtv-sv40-spy1a gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage, wherein said gene sequence comprises a mouse mammary tumor virus gene (mmtv), a functionally disrupted sv40 gene (sv40) and a human spy1a gene. In another aspect, the present invention provides a transgenic non-human animal model whose germ cells and somatic cells contain an endogenous spy1a-ptre-tight gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage.

Network for medical image analysis, decision support system, and related graphical user interface (gui) applications

Described herein is a platform and supported graphical user interface (gui) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.. .
Progenics Pharmaceuticals, Inc.

Methods and systems for predicting dna accessibility in the pan-cancer genome

Techniques are provided for predicting dna accessibility. Dnase-seq data files and rna-seq data files for a plurality of cell types are paired by assigning dnase-seq data files to rna-seq data files that are at least within a same biotype.
Nant Holdings Ip, Llc

Bambam: parallel comparative analysis of high-throughput sequencing data

The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, aids, autism, alzheimer's, and/or parkinson's disorder. The methods can also be used to monitor and track changes in a patient's dna and/or rna during and following a clinical treatment regime.
The Regents Of The University Of California

Biomedical sensing methods and the detection and prevention of lung cancer states

The present invention relates to methods and apparatus to monitor and potentially prevent occurrences of lung cancer in patients. The invention includes apparatus and methods to determine a patient's pre-disposition or propensity to acquire lung cancer.
Johnson & Johnson Vision Care, Inc.

Methods of identifying glioblastoma patients as susceptible to anti-angiogenic therapy using quantitative imaging features and molecular profiling

The present invention provides methods to predict the treatment response of brain tumors such as glioblastoma multiforme to anti-angiogenic therapy based on quantitative perfusion-weighted mri that can optionally be combined with intra-tumor specific molecular profiling. Since only a subset of brain cancer patients will benefit from anti-angiogenic therapy, identification of this subset is critical so that the effectiveness of the patient's current anti-cancer treatment regimen and the patient's survival likelihood can be increased by the inclusion of an anti-angiogenic agent..
The Board Of Trustees Of The Leland Stanford Junior University

Method for detecting differentially methylated cpg islands associated with abnormal state of human body

Disclosed is a method for detecting differentially methylated cpg islands associated with an abnormal state of a human body, characterized by detecting very minute amounts of methylated cpg short tandem nucleic acid sequences in highly fragmented dna samples with genome scale, identifying differentially methylated cpg islands associated with abnormal state of human body and determining the corresponding abnormal state of human body. Sequencing libraries are constructed by using cpg short tandem sequences as primers to perform three steps of pcr reactions on dnas which are conversed by nodifiers, and detections of very minute amounts of methylated cpg short tandem nucleic acid sequences are implemented with high throughput sequencing technology.
Beijing Shijitan Hospital, Capital Medical University

Atomic therapeutic indicator

The present invention relates to the generation of an atomic therapeutic indicator (ati) for a test sample by the quantification of manganese; in voxels of a 3d region of the sample, wherein the 3d region is topographically defined by co-ordinates x′×y′×z. The ati is used to assess the radio-responsiveness i.e.
Atomic Oncology Pty Ltd

Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination

Method for the determination of adrenomedullin immunoreactivity in biological fluids for diagnostic purposes, in particular in sepsis, cardiac and cancer diagnosis, in which the midregional partial peptide (mid-proam; seq id no:3) of proadrenomedullin, which comprises the amino acids (45-92) of the complete preproadrenomedullin (pre-proam; seq id no:1), is measured in particular by means of an immunoassay which operates with at least one labelled antibody which specifically recognizes a sequence of mid-proam.. .
B.r.a.h.m.s Gmbh

Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a trk inhibitor, methods of predicting the efficacy of a trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a trk inhibitor-resistant cancer, and methods of determining the presence of a trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in ntrk1 and/or ntrk2 and/or ntrk3.. .
Array Biopharma, Inc.

Methods for diagnosis, prognosis and treatment of primary and metastatic basal-like breast cancer and other cancer types

In one embodiment, methods of theranostic classification of a breast cancer tumor are provided, wherein the classification is determined by detecting an expression level of foxc1. In other embodiments, methods for predicting a prognosis of a basal-like breast cancer and methods of treating a basal-like breast cancer are provided.

Compositions and methods for screening solid tumors

The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes.
Quest Diagnostics Investments Incorporated

Methods and compositions for diagnosing or detecting lung cancers

A multi-analyte composition for the diagnosis of lung cancer or lung disease comprises a ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an mrna gene transcript from a mammalian blood sample, and an additional ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an mirna of a gene from a mammalian blood sample. Each ligand and additional ligand binds to a different gene transcript or mirna and the gene transcripts and mirna identified form a characteristic profile of a stage of lung cancer or lung disease.
The Wistar Institute Of Anatomy And Biology

Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes

Disclosed are targeted lipid based particles for delivery of nucleic acid molecules (such as sirna) to leukocytes (such as t-cells and b-cells). Further disclosed are uses of the targeted lipid based particles for treating leukocytes-associated diseases, such as, cancer..
Ramot At Tel-aviv Unlversity Ltd.

Methods and compositions for the activation of gamma-delta t-cells

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
American Gene Technologies International Inc.

Methods and compositions for the activation of gamma-delta t-cells

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
American Gene Technologies International Inc.

Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells.

Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of forkhead box protein 1 (foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of forkhead box protein 1 (foxp1) expression, viral vectors containing such molecules, t cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate foxp1.
The Wistar Institute Of Anatomy And Biology

Methods and compositions for the treatment of cancer or other diseases

The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function.
City Of Hope

Compositions and methods for treatment of cancer

Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.. .
Aleta Biotherapeutics Inc.

Cancer therapy using cldn6 target-directed antibodies in vivo

The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing cldn6, in particular cancer and cancer metastasis using antibodies which bind to cldn6. The present application demonstrates that the binding of antibodies to cldn6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients.
Johannes Gutenberg-universitat Mainz

Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof

Antibodies are provided which specifically bind human and macaca fascicularis lysosomal-associated membrane protein 1 (lamp1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as lamp1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool.
Sanofi

Antibodies to cd40

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human cd40. Such antibodies optionally comprise fc regions with enhanced specificity for fcγriib.
Bristol-myers Squibb Company

Anti-cmet antibody

The invention also relates to a composition comprising such an antibody antagonist to c-met and its use as a medicament for treating cancer.. .

Therapeutic cd47 antibodies

Provided are anti-cd47 monoclonal antibodies (anti-cd47 mabs) with distinct functional profiles as described herein, methods to generate anti-cd47 mabs, and to methods of using these anti-cd47 mabs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of cd47 in tissue samples.. .
Tioma Therapeutics, Inc.

Anti-ror1 antibodies

The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for receptor tyrosine kinase-like orphan receptors (ror), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules.
Eureka Therapeutics, Inc.

Cancer neoepitopes

Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent..
Nant Holdings Ip, Llc

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein

Novel nucleic acid vectors comprising sequences encoding (a) an antigen, (b) a signal peptide, and (c) a heat shock protein, are disclosed, as are methods for using such vectors to induce antigen-specific immune responses and to treat tumors.. .
The Johns Hopkins University

Compositions and methods for inhibiting cd279 interactions

Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed death-1 protein (also known as cd279) and (2) programmed death-ligand 1 (pd-l1) and/or programmed death-ligand 2 (pd-l2) are disclosed. In addition, methods and compositions for increasing il-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed..

Pentapeptide associated with integrin receptor alpha vbeta3

A pentapeptide associated with integrin receptor αvβ3, which has a sequence of arginine-tryptophan-arginine-asparagine-methionine. The pentapeptide targets tumor cells highly expressing αvβ3, but not tumor cells lowly expressing αvβ3 and normal cells.
China Pharmaceutical University

Autotaxin inhibitors and uses thereof

Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, also described are uses thereof, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases)..
National And Kapodistrian University Of Athens

3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc

Fused heteroaromatic pyrrolidinones

And pharmaceutically acceptable salts thereof, wherein g, l1, l2, r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of syk is indicated..

Purine inhibitors of human phosphatidylinositol 3-kinase delta

The instant invention provides compounds of formula i which are pi3k-delta inhibitors, and as such are useful for the treatment of pi3k-delta-mediated diseases such as inflammation, asthma, copd and cancer.. .
Merck Sharp & Dohme Corp.

Imidazo-pyrimidone compounds, and preparation method and application thereof

Compounds of formula (i), imidazopyrimidine ketones, as well as preparations and applications thereof. Compounds and pharmaceutically acceptable salts thereof which stimulate the body to produce tumor necrosis factor-related apoptosis-inducing ligands, while avoiding the drawbacks of existing cancer treatments based on recombinant proteins and antibodies.
Nanjing Gator Meditech Company, Ltd.

Inhibitor compounds

Wherein r1, r4, ar, w, x and z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of monospindle 1 (mps1—also known as ttk) kinases either directly or indirectly via interaction with the mps1 kinase itself.

Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

And pharmaceutically acceptable salts thereof, where r1, r2, r3, r4 and r5 have any of the meanings defined herein. The specification also relates to the use of compounds of formula (i) and salts thereof to treat or prevent atm mediated disease, including cancer.

Inhibitors of kras g12c mutant proteins

Or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein r1, r2, r3a, r3b, r4a, r4b, g1, g2, l, m1, m2 and e are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of g12c mutant kras protein for treatment of disorders, such as cancer, are also provided..

Functionalised benzopyran compounds and use thereof

Benzopyran compounds, the preparation thereof, and their use in methods for treating cancer and reducing the incidence or risk of cancer recurrence. The cancer can be one or more of pancreatic cancer, colorectal cancer, melanoma, prostate cancer, brain cancer (including paediatric and adult), ovarian cancer, breast cancer, lung cancer, liver cancer, uterine cancer, neuroblastoma, mesothelioma, malignant ascites or peritoneal cancer..
Novogen Limited

Therapeutic compounds

The invention provides compounds and compositions that are useful for treating conditions including alzheimer's disease, parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.. .
Arizona Board Of Regents On Behalf Of Arizona State University

Tetrasubstituted alkene compounds and their use

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an er-positive breast cancer and/or the subject in need of treatment may express a mutant er-α protein..
Eisai R & D Management Co., Ltd.

Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-idh) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the formula (i) where a, b, u, v, z, w1, w2, w3, and r1-r6 are described herein.. .
Forma Therapeutics, Inc.

Imaging of tumor-associated macrophages

Presented herein are methods and compositions for non-invasive imaging of tams with discoidal high-density lipoproteins to assess prognosis and therapy outcome. Tams are increasingly investigated in cancer immunology, and are considered a promising target for better and tailored treatment of malignant growths.
Memorial Sloan Kettering Cancer Center

Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer

Tumor deliverable iron (tdi) drugs and pharmaceutical compositions and kits comprising them are provided and methods for delivering iron to tumors specifically, either intracellularly or extracellularly. As a result, tdi drugs are useful as a sensitizer for radiation therapy, radio-diagnosis, and chemotherapy, and are of interest.
The Trustees Of Columbia University In The City Of New York

Self assembling molecules for targeted drug delivery

Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin..
The General Hospital Corporation

Duocarmycin adcs showing improved in vivo antitumor activity

The present invention relates to duocarmycin-containing antibody-drug conjugates (adcs) for use in the treatment of human solid tumours and haematological malignancies expressing her2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing adcs for use in the treatment of human solid tumours with her2 ihc 2+ or 1+ and her2 fish negative tissue status.
Synthon Biopharmaceuticals B.v.

Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor

The present invention is directed to a combination therapy involving an anti-her2 antibody-drug conjugate and a selective bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a her2-expressing cancer.. .
Genentech, Inc.

Novel compounds

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Combination use of wt1 antigen peptide and immunomodulator

The invention relates to a combination use of a wt1 antigen peptide or a pharmaceutically acceptable salt thereof and an immunomodulator for treating or preventing cancer.. .
International Institute Of Cancer Immunology, Inc.

Enzymatic immunomodulation of solid tumors and uses thereof

In some embodiments the present disclosure pertains to a method of activating an anti-tumor immune response for the treatment of a cancer. In some embodiments, such a method comprises detecting cd26 expression in a subject in need thereof.
University Of Houston System

Modulation of axl receptor activity in combination with cytoreductive therapy

Compositions and methods are provided for treating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits axl protein activity, for example by inhibition of the binding interaction between axl and its ligand gas6. The treatment may be combined with a cytoreductive therapy..
The Board Of Trustees Of The Leland Stanford Junior University

Enhanced melanoma cancer prevention by novel melanotropins

A gamma-melanocyte stimulating hormone (γ-msh) derivative having improved stability, selectivity and bioavailabilty. The γ-msh derivative is selective for the melanocortin-1 receptor (mc1 r) and is deliverable to skin cells via topical or transdermal delivery.
The Arizona Board Of Regents On Behalf Of The University Of Arizona

Compositions, articles of manufacture and methods for treating cancer

A method of treating cancer in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in seq id no: 1 or an analog or derivative thereof; and an anti-cancer agent, thereby treating the cancer in the subject..
Bioline Rx Ltd.

Ubiquitin ligase kpc1 promotes processing of p105 nf-kappab1 to p50, eliciting strong tumor suppression

The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of kpc1, a peptide which is at least about 70% homologous to the kpc1 or an agent which up-regulates kpc1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50..
Rappaport Family Institute For Research In The Medical Sciences

Immunomodulatory & oncolytic minicells and methods of use

Disclosed herein are compositions comprising immunomodulatory and oncolytic eubacterial minicells, and the use of the composition in immunomodulatory therapies for cancer. In some embodiments, the minicells are used in combination of immune checkpoint inhibitors in treating cancer..
Vaxiion Therapeutics, Llc

Peptide inhibitors of twist

The disclosure provides, inter alia, compositions comprising twist peptide inhibitors and optionally one or more anti-cancer agents, and methods of using the compositions for the treatment of cancer.. .
City Of Hope

Compositions and methods for treating cancer

Use of a cxcr4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in seq id no: 1 or an analog or derivative thereof; and a therapeutically effective amount of a pd1 antagonist, a pdl-1 antagonist, a ctla-4 antagonist, a lag-3 antagonist, a tim-3 antagonist, a kir antagonist, an ido antagonist, an ox40 agonist, a cd137 agonist, a cd27 agonist, a cd40 agonist, a gitr agonist, a cd28 agonist or an icos agonist, thereby treating the cancer in the subject.
Biolinerx Ltd.

Compositions and methods for treating cancer and persistent viral infections

The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic t cell proliferation agent, or a nk cell proliferation agent; and a therapeutic peptide of the invention.
Susavion Biosciences, Inc.

Oncolytic adenovirus encoding a b7 protein

The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a dna sequence encoding a b7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.. .
Psioxus Therapeutics Limited

Composition for preventing or treating cervical cancer including gypenoside lxxv

Provided are a pharmaceutical composition for preventing or treating cervical cancer including gypenoside lxxv or a pharmaceutically acceptable salt thereof as an active ingredient, a method of preventing or treating cervical cancer including administering the pharmaceutical composition to a subject excluding humans, a health functional food composition for preventing or improving cervical cancer including gypenoside lxxv as an active ingredient, and a feed composition for preventing or improving cervical cancer including gypenoside lxxv as an active ingredient.. .
Intelligent Synthetic Biology Center

Anticancer adjuvant containing panaxadiol ginsenocide compound

The present invention relates to an anticancer adjuvant containing, as an active ingredient, protopanaxadiol (ppd) or a compound-k, which are types of panaxadiol ginsenoside compounds, and a pharmaceutical composition for treating cancer containing the anticancer adjuvant and an anticancer agent having mitochondria-mediated anticancer activity. The anticancer adjuvant containing the ppd or compound-k provided in the present invention as an active ingredient damages mitochondria in cancer cells, thereby aiding mitochondria-mediated anticancer activity, and thus can be widely used in safer treatment or alleviation of cancer using anticancer agents that exhibit mitochondria-mediated anticancer activity..
Intelligent Synthetic Biology Center

Metal delivery agents and therapeutic uses of the same

The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels).
The University Of Melbourne

Methods of diagnosing and treating cancer

A variety of different point mutations in ntrk1, ntrk2, and ntrk3 were identified in biopsy samples from a subjects having a variety of different cancers. Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment including a therapeutically effective amount of a trk inhibitor for a subject, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a trk inhibitor, methods of predicting the efficacy of a trk inhibitor in a subject having a cancer, methods of determining a subject's risk for developing a cancer, and methods of assisting in the diagnosis of cancer that are based on the identification of a subject having a cell that has at least one of the point mutations in ntrk1, ntrk2, and/or ntrk3, or the determination that a subject has a cell that has at least one of the point mutations in ntrk1, ntrk2, and/or ntrk3.
Loxo Oncology, Inc.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.

Macropinocytosis in cancer

Disclosed herein are compositions and methods for detecting and treating cancer. In some embodiments, the cancer is characterized by activation of ras..
Memorial Sloan Kettering Cancer Center

Metabolically programmed metal chelators and uses thereof

The present invention provides compounds of formula (i), which are “metabolically programmed” metal chelators, e.g., lipophilic, absorbable (e.g., orally absorbable), and effective metal chelators that are converted in vivo to their hydrophilic, nontoxic metabolites. The present invention also provides compounds of formula (ii), which are also “metabolically programmed” metal chelators.
University Of Florida Research Foundation, Incorporated

Methods and compositions for the diagnosis and selective treatment of cancer

In one aspect, provided herein are methods for treating cancer in a subject, comprising: (1) identifying in the subject the presence of a mutation in a splicing factor selected from the group consisting of u2af1, sf3b1, srsf2, and zrsr2; and/or determining in the subject an increased amount of dcaf15 compared to a control, and (2) inhibiting an activity of rbm39 in the subject. In some embodiments, the inhibiting step can include promoting rbm39 degradation, preferably in a dcaf15-dependent manner.
Board Of Regents Of The University Of Texas System

Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer

Disclosed herein are methods for use in treating cancer comprising administering at least one cancer sternness inhibitor, for example, at least one stat3 pathway inhibitor such as 2-acetylnaphtho [2, 3-b] furan-4, 9-dione, in order to sensitize or re-sensitive a cancer that is naive, resistant, or/and refractory to at least one immunotherapeutic agent, such as at least one immune checkpoint modulator.. .
Boston Biomedical, Inc.

Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (nsclc) and ovarian cancer, as well as other types of malignancy, including brain metastases of nsclc. Dianhydrogalactitol acts as an alkylating agent on dna that creates n7 methylation.
Delmar Pharmaceuticals, Inc.

Cell culture systems for producing il-33 induced t9 cells and methods of using the cells

Cell culture systems for producing il-33 induced t9 cells and methods of using the il-33 induced t9 cells (t9il-33 cells) in a cell therapy for increasing anti-tumoral activity following allogeneic hematopoietic cell transplantation (hct) and/or treating graft-versus-host disease (gvhd) are disclosed herein. Further, methods of using the t9il-33 cells, alone or in combination with allogeneic hematopoietic cell transplantation, are described herein for cancer treatment..
Indiana University Research And Technology Corporation

Contrast agents for applications including perfusion imaging

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds mc-1, and an imaging moiety, and scanning the subject using diagnostic imaging.. .
Walters Gardens, Inc.

Chimeric receptors and uses thereof in immune therapy

Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the fc portion of an immunoglobulin molecule (ig), an fc-binding domain; a transmembrane domain; at least one co-stimulatory signaling domain; and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (itam). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors.
Walters Gardens, Inc.

Forma Therapeutics, Inc.

. .

Curis, Inc.

. .

Igisu Co., Ltd.

. .

Method, array and use for determining the presence of pancreatic cancer

The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in table iii, wherein the expression in the test sample of one or more biomarkers selected from the group defined in table iii is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention..
Immunovia Ab

Aptamer specific to ovarian cancer and detection ovarian cancer

An aptamer specific to ovarian cancer and a detection method for ovarian cancer are provided. The aptamer includes a following nucleotide sequence: 5′-ncaaannncnnnnanncnnnimnnnnngaannnannngg-3′, wherein n is a nucleotide independently selected from “a,” “t,” “c,” and “g.”.
National Tsing Hua University

Epithelial quantitation of histologically normal prostate tissue predicts the presence of cancer in tissue biopsies

A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial percentage of the tissue, wherein an epithelial percentage greater than 39% indicates the presence of prostate cancer or a prostate cancer field defect.. .
Wisconsin Alumni Research Foundation

Test support supporting prediction of pathological complete response (pcr) using fluorescent nanoparticles

The present invention relates to a test support method which is a means for predicting whether or not pathological complete response (pcr) will be attained when a preoperative chemotherapy with an anticancer drug is performed, the method using a sample (breast cancer tissue section) collected from a breast cancer patient to be subjected to the preoperative chemotherapy. The test support method includes: [1] the step of acquiring a fluorescence image of a breast cancer tissue section, which fluorescence image shows bright spots of fluorescent nanoparticles labeling one or more kinds of breast cancer-related proteins; [2] the step of acquiring at least one index relating to the expression level(s) of the breast cancer-related protein(s) on the basis of the bright spots of the fluorescence image; and [3] the step of acquiring information for predicting pcr by performing an analysis using the above-described at least one index..
Konica Minolta, Inc.

Method for screening for cancer therapeutic agent

The invention aims to provide a method of screening for a therapeutic drug for cancer as a molecular-targeted drug targeting some protein from a number of candidate target proteins, without identifying the true target protein. In particular, the invention provides a method of screening for a therapeutic drug for cancer, including (i) a step of expressing an exogenous cell regulatory factor in a target cancer cell under contact or no contact with a test substance, (ii) a step of confirming change in the cancer cell, and (iii) a step of selecting the test substance as a therapeutic drug for cancer when the change of cancer cell increased under contact with the test substance as compared to no contact therewith..
Chugai Seiyaku Kabushiki Kaisha

Electrical cell-substrate impedance sensor (ecis)

A method for detection and monitoring a therapeutic effect of a cancer treatment drug is disclosed. The method includes steps of removing a malignant biological cell lines from a tumor; culturing the removed biological cell lines in a controlled set of conditions; seeding the cultured biological cell lines on silicon nanowire electrode arrays of an electrical cell-substrate impedance sensor (ecis); adding a cancer treatment drug to the seeded biological cell lines to treat the seeded biological cell lines; and measuring an electrical impedance of the treated biological cell lines for detection and monitoring a therapeutic effect of the cancer treatment drug..

Method of correcting a fluorescence image

A method for correcting a fluorescence image of an object, for example a biological tissue that can include fluorescent agents. The distance between a fluorescence probe generating the fluorescence image and the object examined is measured.
Fluoptics

A system for generating data relating to a tissue core biopsy, and the use of the system to detect tissue abnormalities, in particular cancerous tissue, in a patient

A system for generating data relating to a tissue core comprises a core needle biopsy module configured to obtain a tissue core from a locus within the body, and a tissue disintegration module operably connected to the core needle biopsy module and configured to receive a tissue core from the core needle biopsy module and convert at least a portion of the tissue core into gaseous tissue molecules. The system also comprises first vacuum pump means configured to convey a tissue core from the needle biopsy module to the tissue disintegration module, and second vacuum pump means configured to convey gaseous tissue molecules from the tissue disintegration module to an analyser module..

Method for evaluating health condition and predicting long-term efficacy of anticancer agent

A method for evaluating a health condition, includes: measuring a test amount of cell free dna per unit amount of a body fluid sample collected from a subject after tumor resection; and comparing the measured test amount of cell free dna with a reference value so as to evaluate a health condition of the subject. The reference value is one of a predetermined threshold value; an amount of cell free dna per unit amount of a body fluid sample collected from the subject before tumor resection; an amount of cell free dna per unit amount of a body fluid sample collected from the subject between 1 week and 3 months after tumor resection; and an amount of cell free dna per unit amount of a body fluid sample collected from the subject by the time of collecting the body fluid sample for measuring the test amount of cell free dna..
Nippon Medical School Foundation

Nucleic acid probes

The present embodiments relate to nucleic acid probes for detecting pten, zbtb20-lsamp, and lsamp mutations. The nucleic acid probes are particularly useful for detecting deletions in the pten and lsamp genes as diagnostics for prostate cancer, especially aggressive forms of prostate cancer for which treatment is indicated.
Cytotest, Inc.

Unbiased dna methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer

A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic dna from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of pla2g16, cav1, evx1, mcf2l, fgf1, ncr2 and wnt2 and ext1 and spag4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.. .
Wisconsin Alumni Research Foundation

Methods for detecting dna mutations using mitra tip extraction

The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., mitra tip).
Quest Diagnostics Investments Llc

Targeted selection of patients for treatment with cortistatin derivatives

A method for the targeted selection and treatment of patients with a tumor or cancer, comprising (i) determining whether the patient has a runx1 pathway impairment; and if so (ii) administering an effective amount of a cortistatin or its pharmaceutically acceptable salt or oxide, optionally in a pharmaceutically acceptable composition.. .
President And Fellows Of Harvard College

Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer

Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method includes the steps of determining the expression levels of the marker genes s1oop and pcsk6 and mathematically combining the expression level values to yield a combined score and comparing said combined score to a reference-value, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen..
Sividon Diagnostics Gmbh

Chromosome copy number gain as a biomarker of urothelial carcinoma lethality

Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2.
Dana-farber Cancer Institute, Inc.

Neuroendocrine tumors

The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (ffpe) samples.. .
Biotheranostics, Inc.

Novel methylation site regulating expression of mda-9/syntenin

Methods of prognosing the outcome of cancer and/or cancer treatment are provided. The methods involve quantitating the level of methylation at a site that regulates expression of the mda-9/syntenin gene, site cg17197774.
Virginia Commonwealth University

Comprehensive methods for detecting genomic variations

The invention can be used, for example, to analyze the complicated underlying genomic defects in diseases and conditions such as autism spectrum disorders (asd), cancers, alzheimer's disease, and other neurological disorders.. .

Labeled circular dna molecules for analysis of dna topology, and topoisomerases and for drug screening

The present invention provides labeled circular plasmid dna molecules for studying dna topology and topoisomerases. The molecules of the present invention also provide tools for high throughput drug screening for inhibitors of dna gyrases and dna topoisomerases for anticancer drug discovery and antibiotics discovery..
The Florida International University Board Of Trustees

Delivery of therapeutic agent

A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a dna sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g.
Codiak Biosciences, Inc.

Composition for cancer cell sensitization containing as active ingredient substance inhibiting expression of oncogene of hpv virus

The present invention relates to a composition for cancer cell sensitization containing as an active ingredient a substance inhibiting the expression of an oncogene of a hpv virus, and more specifically, to a composition for radiosensitization which is used for the treatment of cancer induced by hpv infection and contains as an active ingredient oligonucleotide having any one nucleic acid sequence selected from the group consisting of sequence numbers 1 to 10. The oligonucleotide of the present invention inhibits the expressions of e6 and e7 which are hpv virus oncoproteins, thereby inhibiting the proliferation of tumor cells, and enhances the sensitivity of tumor cells to radiation, thereby exhibiting an excellent effect as a sensitizer that can maximize the cell death effect..
Abion Inc.

Aptamers against glioma cells

Provided are aptamers able to bind to ligands associated with cancer cells. The ligands may particularly be associated with brain cancers, such as gliomas.
University Of Central Lancashire

Non-unique barcodes in a genotyping assay

The present disclosure involves ctdna assays that interrogate many regions from a single sample with high precision and accuracy, while evaluating multiple forms of cancer-related genomic alterations including sequence mutations and structural alterations. The disclosure provides simplified yet robust methods that achieve high sensitivity and specificity by analyzing cancer genes using a limited pool of non-unique barcodes in combination with endogenous barcodes.
Personal Genome Diagnostics, Inc.

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Selection and cloning of t lymphocytes in a microfluidic device

Methods of expanding t lymphocytes in a microfluidic device are provided. The methods can include introducing one or more t lymphocytes into a microfluidic device; contacting the one or more t lymphocytes with an activating agent; and perfusing culture medium through the microfluidic device for a period of time sufficient to allow the one or more t lymphocytes to undergo at least one round of mitotic cell division.
Berkeley Lights, Inc.

Lgr5+ somatic stem cells

A method for treating a condition, comprising administering to a subject in need thereof a composition that contains somatic stem cells that are 2 to less than 6 micrometers in size and lgr5+, wherein the condition is selected from the group consisting of neurodegenerative disorder, muscle-degenerative disease, cancer, metabolic disorder, autoimmune disorder, inflammatory disorder, heart disorder, circulatory disorder, a condition associated with aging, and damaged tissue.. .
Stembios Technologies, Inc.

Treatment of her2-positive breast cancer

Methods for the treatment of her2-positive breast cancer are provided by neoadjuvant administration of pertuzumab and trastuzumab in combination with anthracycline-based chemotherapy. In particular, the methods concerns the treatment patients with her2-positive, locally advanced, inflammatory, or early-stage breast cancer by neoadjuvant administration of pertuzumab and trastuzumab following anthracycline-based chemotherapy, wherein the combined administration of pertuzumab and trastuzumab increases pathological complete response (pcr) relative to administration of trastuzumab as a single agent, without significant increase in adverse events, such as cardiac toxicity, relative to neoadjuvant anthracycline-based chemotherapy..
F. Hoffmann-la Roche Ag

Method for treating a gd2 positive cancer

The present invention relates to a method for treating a gd2 positive cancer by administering a preparation comprising an anti-gd2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.. .
Apeiron Biologics Ag

Human monoclonal antibodies specific for glypican-3 and use thereof

Described herein is the identification of human monoclonal antibodies that bind gpc3 or heparan sulfate (hs) chains on gpc3 with high affinity. The antibodies described herein are capable of inhibiting hcc cell growth and migration.
The U.s.a., As Represented By The Secretary, Department Of Health And Human Services

Antibodies, pharmaceutical compositions and uses thereof

The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof.
Obi Pharma, Inc.

Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies

The invention provides methods of dosing for the treatment of cancers, such as b cell proliferative disorders, with anti-cluster of differentiation 20 (cd20)/anti-cluster of differentiation 3 (cd3) bispecific antibodies.. .
Genentech, Inc.

Il13ra2 binding agents and use thereof in cancer treatment

Provided are specific binding molecules, or fragments thereof, that bind to an epitope of il13rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an il13rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a t cell signaling protein, a peptide modulator of t cell activation, or an enzymatic component of a labeling system.
The University Of Chicago

Cd123 specific multi-chain chimeric antigen receptor

The present invention relates to a new generation of chimeric antigen receptors (car) referred to as multi-chain cars, which are made specific to the antigen cd123. Such cars aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen cd123.
Cellectis

Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof

Provided herein are antibodies and bispecific antigen-binding molecules that bind met and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human met.
Regeneron Pharmaceuticals, Inc.

Antibodies that bind to axl proteins

Antibodies that bind to axl protein and variants thereof are described herein. Axl exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in table i.
Agensys, Inc.

Antibodies that bind to axl proteins

Antibodies that bind to axl protein and variants thereof are described herein. Axl exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in table i.
Agensys, Inc.

Antibodies reactive with b7-h3 and uses thereof

The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human b7-h3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized b7-h3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers..
Macrogenics, Inc.

Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas

The present disclosure relates to methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas (hcc in abbreviation, the term “hepatocellular carcinoma” has its general meaning in the art and refers to the cancer developed in hepatocytes see page 2 lines 24-30 of the present application) comprising administering to the subject a therapeutically effective amount of an inhibitor of ntsr1 (neurotensin receptor 1) activation or expression. The examples show the expression of ntsr1 in hcc cell lines and the role of the nts/ntsr1 complex in these cell lines, thereby showing the role of the complex in tumour progression..
Universite Paris Descartes

Cancer cell specific anti-podocalyxin antibody and producing same

The present invention provides a method for producing an antibody against podocalyxin expressed specifically in cancer cells. The method includes a step of introducing a nucleic acid encoding all or a portion of podocalyxin into cells expressing a cancer cell-specific sugar chain structure to cause cancer cell-specific podocalyxin or a portion thereof to be expressed therein, a step of immunizing a non-human mammal with the cancer cell-specific podocalyxin or portion thereof to obtain antibodies, and a step of purifying the antibodies by primary screening using purified cancer cell-specific podocalyxin or a portion thereof..
Tohoku University

Novel immunomodulatory therapeutic strategies targeting tumors in cancer

The present invention discloses a method of treating, preventing or ameliorating tumor growth by immune response modulation via targeting abcb5 and an immune checkpoint molecule related pathways using various therapeutic agents such as antibody or small molecule. The present invention also provides use of an abcb5 inhibitor and an immune checkpoint inhibitor(s) for enhancing, increasing, promoting, expressing, modulating desirable immune response for prevention and treatment of tumors..
Bioxcel Corporation

Immunomodulatory fusion proteins

Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a tgfβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders..
Epicentrx, Inc.

Analogues of vdac1-derlved peptides

The present invention relates to peptides comprising analogues of vdac1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (nafld) and symptoms associated thereto. .
The National Institute For Biotechnology In The Negev Ltd.

Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, an isolated peptide comprising the amino acid sequence lrrfstapfafidindvinf, which exhibits anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models is disclosed.
The Johns Hopkins University

Par1 and par2 c-tail peptides and peptide mimetics

The present invention concerns isolated par1 cytoplasmic tail (c-tail) peptides and isolated par2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.. .
Hadasit Medical Research Services And Development Ltd.

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Novel peptide and composition containing the same

The present invention relates to a novel peptide and a composition including the same, and more particularly, to a novel peptide effective in anti-inflammation, anti-fibrosis, wound healing, and anti-cancer treatment, and a composition including the same. The novel peptide according to the present invention and the composition including the same exhibit an effect of alleviating, preventing, or treating inflammation, fibrosis, wounds, and symptoms of diseases such as cancer including these symptoms, and thus may provide a method of preventing or treating associated diseases..
Gemvax & Kael Co., Ltd.

Methods of synthesizing substituted purine compounds

The present invention provides an efficient process for the synthesis of (2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-((((1r,3s)-3-(2-(5-(tert-butyl)-1h-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which dot1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also provides novel crystalline forms of (2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-((((1r,3s)-3-(2-(5-(tert-butyl)-1h-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof (form a, form b, and form c), characterized by a unique x-ray diffraction pattern and differential scanning calorimetry profile, as well as a unique crystalline structure..
Epizyme, Inc.

Methods of synthesizing substituted purine compounds

The present invention provides an efficient process for the synthesis of (2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-((((1r,3s)-3-(2-(5-(tert-butyl)-1h-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which dot1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also provides novel crystalline forms of (2r,3r,4s,5r)-2-(6-amino-9h-purin-9-yl)-5-((((1r,3s)-3-(2-(5-(tert-butyl)-1h-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof (form a, form b, and form c), characterized by a unique x-ray diffraction pattern and differential scanning calorimetry profile, as well as a unique crystalline structure..
Epizyme, Inc.

Mito-honokiol compounds and methods of synthesis and use thereof

The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.. .
Aix-marseille Universite

Improved process for preparing boryl 7-azaindole compounds

The present disclosure relates to an improved process for the preparation of 3-boryl substituted azaindole compounds in high yields and high selectivity. Such azaindole compounds may be used as intermediates to form compounds with cytotoxic, anticancer, and antiviral activities..
Boropharm Inc.

Methods and compositions of substituted 5h-[1,2,5] oxadiazolo [3',4':5,6] pyrazino[2,3-b] indole analogs as inhibitors of beta-catenin/t-cell factor protein-protein interactions

In one aspect, the invention relates to substituted 5h-[1,2,5]oxadiazolo [3′,4′:5,6]pyrazino[2,3-b]indole analogues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and a methods of treating disorders, e.g., various tumors and cancers, associated with a β-catenin/t-cell factor interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
University Of Utah Research Foundation

Inhibitors of rad52 recombination protein and methods using same

The present invention includes novel rad52 inhibitors for preventing or treating cancers in a subject in need thereof. The present invention further includes a method of preventing or treating cancers in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention.
Drexel University

Cortistatin analogues, syntheses, and uses thereof

New cortistatin compounds and pharmaceutically acceptable salts and pharmaceutically acceptable compositions thereof are provided. These compounds can be used to treat a disorder mediated by cdk8 and/or cdk19 kinase or by the mediator complex generally.
President And Fellows Of Harvard College

Aza-phenalene-3-ketone derivative, preparation method thereof, and its application as parp inhibitor

Wherein r is hydrogen, methyl, ethyl, isopropyl, benzyl or 3-methyl-3-butenyl. The aza-phenalene-3-ketone derivative has very high activity for inhibiting parp, thereby providing a good basis for new drug research of developing a nitrogen-doped phenalene-3-ketone compound as parp inhibitor to treat cancer..

Ethynyl derivatives

The present invention relates to positive allosteric modulators (pams) of metabotropic glutamate receptor 4 (mglur4) that may be used for the treatment of conditions such as parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.

Pyrrolobenzodiazepines and conjugates thereof

Conjugates and compounds for making conjugates which are pbd molecules linked via the n10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.. .
Medimmune Limited

Compounds and methods for inhibiting mitotic progression

This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer..
Millennium Pharmaceuticals, Inc.

Bromodomain inhibitors

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease..
Celgene Quanticel Research, Inc.

Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

And pharmaceutically acceptable salts thereof, where q, r1, r2, r3, r4 and r5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent atm kinase mediated disease, including cancer.

Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1

In which y, y1, r1, r2, r3 and r4 are defined in the summary of the invention; capable of inhibiting the tyrosine kinase enzymatic activity of the abelson protein (abl1), the abelson-related protein (abl2) and related chimeric proteins, in particular bcr-abl1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers..

1,4-pyridone bicyclic heteroaryl compounds

The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Epizyme, Inc.

Barbiturate and thiobarbiturate compounds for use in cancer therapy

Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell.
Nuhope, Llc

Therapeutic compounds and methods of use thereof

The invention provides compounds that are useful for treating or preventing cancer.. .
Kuality Herbceutics Llc

Compounds for the treatment or prevention of breast cancer

It discloses compounds for the treatment and prevention of breast cancer, which are specifically 2-phenyl benzoselenazole compounds, pharmaceutically acceptable salts thereof and prodrugs thereof. The present invention further discloses pharmaceutical compositions containing the compounds and applications of the compounds in preparing medicines for the treatment and prevention of breast cancer in mammals.
Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd.

Certain chemical entities, compositions, and methods

Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of formula i, containing a diarylamide or diarylurea substructure that inhibit braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the braf inhibitor compound are described..
Neupharma, Inc.

Dna2 inhibitors for cancer treatment

Disclosed herein, inter alia, are compositions and methods for inhibiting dna2.. .
California Institute Of Technology

Salts and prodrugs of 1-methyl-d-tryptophan

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.. .
Newlink Genetics, Corp.

Multiple beamline position isocenterless positively charged particle cancer therapy apparatus and use thereof

The invention comprises a method and apparatus for treating a tumor with protons using multiple beamline positions not having an isocenter, including the steps of: (1) delivering the protons from a synchrotron along a redirectable beam transport path to yield a plurality of incident vectors, each of the plurality of incident vectors directed toward the treatment room and (2) redirecting the protons traveling along each of the plurality of incident vectors, with an output nozzle, to the tumor, where a first vector, of the plurality of incident vectors, comprises a first direction intersecting the tumor and where a second vector, of the plurality of incident vectors, comprises a second direction passing by the tumor without entering the tumor. The step of redirecting directs the protons traveling along the first and second incident vectors, respectively, to a first and second path intersecting a front and the back of the tumor..

Treatment delivery control system and operation thereof

The invention relates to a method and apparatus for control of a charged particle cancer therapy system. A treatment delivery control system is used to directly control multiple subsystems of the cancer therapy system without direct communication between selected subsystems, which enhances safety, simplifies quality assurance and quality control, and facilitates programming.

Systems and methods for determining optimum patient-specific antibody dose for tumor targeting

The present disclosure describes a non-linear compartmental model using pet-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., hua33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (mst) designed to further improve the therapeutic indices of rit..
Memorial Sloan Kettering Cancer Center

Radiolabeled grpr-antagonists for diagnostic imaging and treatment of grpr-positive cancer

The present invention relates to probes for use in the detection, imaging, diagnosis, targeting, treatment, etc. Of cancers expressing the gastrin releasing peptide receptor (grpr).
Advanced Accelerator Applications Usa, Inc.

Nano-devices for detection and treatment of cancer

Compositions and methods are described for detecting and treating conditions including cancer with target specific quantum dot nano-devices. In some aspects, nanoparticle conjugates are provided having multiple target specificities and include surface modified, water soluble quantum dot (qd) nanoparticles each of which are chemically conjugated to at least two different target specific ligands..
Nanoco Technologies Ltd.

Nanoparticle conjugates and uses thereof

The targeted delivery of therapeutic agents to specific cells remains a challenge in drug delivery. Provided herein are nanoparticle-targeting agent conjugates that can be used for the targeted delivery of therapeutic agents to certain cells and target tissues.
Massachusetts Institute Of Technology

A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for treatment of colorectal cancer

The present invention provides a novel complex for use in the prevention and/or treatment of colorectal cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one tlr peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of colorectal cancer, such as a pharmaceutical compositions and vaccines are provided..
Amal Therapeutics Sa

Site-specific dna-doxorubicin conjugates display enhanced cytotoxicity to breast cancer cells

Doxorubicin (dox) is widely used for breast cancer treatment but causes serious side-effects including cardiotoxicity that may adversely impact patient lifespan even if treatment is successful. The present invention relates to selective conjugation of dox to a single site in a dna hairpin resulting in a highly stable complex that enables dox to be used more effectively.

Conjugate including peptide molecule capable of self-assembly in cell organelle and pharmaceutical composition for preventing or treating cancer including conjugate

Disclosed are a conjugate including a mitochondria-targeting moiety and a peptide molecule capable of self-assembly; and a pharmaceutical composition for preventing or treating cancer including the conjugate as an active ingredient.. .
Unist (ulsan National Institute Of Science And Technology)

Cell penetrating peptides and complexes comprising the same

The present invention provides a cell penetrating peptide derived from zebra, which is optionally linked to a cargo molecule, such as at least one antigen or antigenic epitope. The present invention also provides a complex comprising the cell penetrating peptide and the cargo molecule.
Amal Therapeutics Sa

5-ala derivatives and use thereof

The present invention is directed to new 5-ala derivatives, particles and formulation thereof, related methods of preparation and methods of use thereof. In particular, the invention relates to compounds of the invention, particles and formulation thereof useful in the treatment of a cancer and/or the diagnosis of a cancer cell such as in photodynamic therapy or photodynamic diagnosis..
Universite De Geneve

Synergistic nanotherapy systems and methods of use thereof

The presently disclosed subject matter is directed to a method of treating cancer, such as (but not limited to) metastatic bladder and breast cancer. The disclosed method comprises using two treatment modalities to synergistically treat primary and secondary tumor cells in a subject.
Duke University

Enhanced plasmonic nanoparticles for cancer therapy and diagnostics

One or more techniques and/or products are disclosed using a process for preparing metallic nanoparticles. Resulting nanoparticles may comprise a gold-silver-gold core-shell-shell nanoparticles.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate

The present invention is directed to the combination therapy of an afucosylated anti-cd20 antibody with a cd79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of cd20 expressing cancers with an afucosylated humanized b-ly1 antibody and a cd79b antibody-drug conjugate.. .
Genentech, Inc.

Use of immune checkpoint inhibitors in central nervous systems neoplasms

This disclosure provides a method for treating glioma in a subject comprising administering to the subject an anti-programmed death-1 (pd-1) antibody. In some embodiments, this invention relates to methods for treating glioma in a subject comprising administering to the subject a combination of an anti-cancer agent which is an anti-programmed death-1 (pd-1) anti-body and another anti-cancer agent such as an anti-cytotoxic t-lymphocyte antigen-4 (ctla-4) antibody..
Bristol-myers Squibb Company

Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

We provide new methods of in vitro or in vivo enhancing the t-cell stimulatory capacity of human dcs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human dcs by contacting or modifying them with mrna or dna molecule(s) encoding cd40l, and cd70 or constitutively active tilr4 (catlr4)..
Vrije Universiteit Brussel

Cancer immunotherapy using virus particles

A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.. .
Case Western Reserve University

Early cancer detection and enhanced immunotherapy

A method of therapy for a tumor or other pathology by administering a combination of thermotherapy, immunotherapy, and vaccination optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time or original therapy and/or for later therapy.

Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

The disclosure features, inter alia, immunogenic xbp1-, cd138-, and cs1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or waldenstrom's macroglobulinemia).
Dana-farber Cancer Institute, Inc.

A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist

The present invention provides a novel complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one tlr peptide agonist, wherein the components a)-c) are covalently linked. Moreover, the present invention also provides a nucleic acid encoding such a complex, wherein the complex is a peptide or a protein.
Amal Therapeutics Sa

Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same

Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease..
University Of Kansas

Oncolytic hsv1 vector and methods of use

Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a second generation oncolytic virus rqnestin34.5v2 with less toxicity that is more effective at selective killing target cells, such as tumor cells.
The Brigham And Women's Hospital, Inc.

Composition comprising myoblasts for tumor growth inhibition and prevention of cancer cell metastasis by implantation

The invention is directed to a composition having a quantum of genetically normal non-host myoblasts and host serum, wherein the composition is adapted to induce myoblast proliferation. The invention is also directed to a composition for use as a medicament and a composition for use in inhibiting growth of a cancer tumor in a host and/or preventing cancer cells from metastasis in a host..

Treatment of cachexia using stem cells and products thereof

The current invention teaches the use of cells possessing regenerative properties, tissues associated with said cells possessing regenerative properties, and products derived from cells possessing regenerative properties for the treatment of cachexia. In one embodiment, cancer or hiv associated cachexia is treated by administration of tissues possessing regenerative cells that have been modified to allow for administration in a manner which is intravenous, subcutaneous or intramuscular while retaining properties associated with cellular regeneration..
Creative Medical Health, Llc

Methods for the storage of whole blood, and compositions thereof

Methods and compositions for improved clinical outcomes for trauma patients receiving whole blood transfusion. Methods and compositions for improved clinical outcomes for blood transfusions for cancer patients are also provided..
New Health Sciences, Inc.

Therapeutic ozone agent and treatment

The use of a medical therapeutic ozone agent in vivo to treat a variety of disorders including, but not limited to hypoxic conditions, autoimmune disease, fibrotic disease, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease, metabolic disease, and cancer, wherein the therapeutic ozone agent is administered in a therapeutically effective amount, which can convert carbon monoxide to carbon dioxide, thereby treating or preventing the disease in a patient.. .

Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound of formula (i) and (b) a mtor inhibitor for the treatment of a target of rapamycin (mtor) kinase dependent disease, especially a cancer disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.. .
Novartis Ag

Method for treating cancer

The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (mhc), or cancer, characterized by aberrant, misregulated, or increased enhancer of zeste homolog 2 (ezh2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an ezh2 inhibitor.. .
Epizyme, Inc.

Methods of treating pediatric cancers

A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (s)—n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof..
Loxo Oncology, Inc.

Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents

Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (uae) inhibitor such as ((1r,2r,3s,4r)-2,3-dihydroxy-4-(2-(3-(tri-fluoromethylthio)phenyl)pyrazolo [1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (compound 1) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents.
Millennium Pharmaceuticals, Inc.

Somcl-9112 solid dispersion and preparation method thereof and somcl-9112 solid preparation containing somcl-9112 solid dispersion

Disclosed is an somcl-9112 solid dispersion. The somcl-9112 solid dispersion is characterized by being prepared from the following raw materials in percentage by weight: 5 percent to 60 percent of somcl-9112, 5 percent to 90 percent of pharmaceutically acceptable matrix polymer, 0 percent to 20 percent of surfactant, 0 percent to 20 percent of flow aid and 0 percent to 20 percent of plasticizer.
Shanghai Acebright Pharmaceuticals Co., Ltd.

Pharmaceutical composition for treating cancer and a using the same

The invention provides a pharmaceutical composition and a method for treating cancer, and the composition comprises a proteasome inhibitor and a nuclear export inhibitor. The composition has synergistic effects on treating cancers, particularly a solid tumor cancer.
Suzhou Institute Of Systems Medicine

Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer

Provided herein are methods and compositions for the treatment of cancer. In particular, the methods include administration of a bcl-2 inhibitor and a bet inhibitor..
Gilead Sciences, Inc.

Cancer treatment via repositioned tricyclic anti-depressant-like drugs as anti-cancer agents and new combinations of such drugs

Methods and compositions for treating a lysosomal movement associated disease in an animal, in which the position of lysosomes can influence disease progression, comprising administering an effective amount of a first lysosome migration inhibitor or a pharmaceutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer or prodrug thereof.. .
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Fructose analogs and their combinations as anti-cancer agents

The present invention provides a fructose analogue and a composition thereof which can be used for cancer treatment, has a targeting effect and has little effect on normal cells, particularly when used in the treatment of acute myeloid leukemia (‘aml’) and pancreatic cancer and other types of cancer having similar metabolic characteristics. In the present invention, the fructose analog is selected from the group consisting of 2,5-anhydro-d-mannitol and the 5-anhydro-d-mannitol derivative substituted at the 1-position or 6-position by an amino group, an alkyl group or an aryl group, anhydro-d-mannitol tetraacetate and 2,5-anhydroglucitol and the like.

Cyp450 lipid metabolites reduce inflammation and angiogenesis

Methods for reducing angiogenesis, inflammation, and vascular permeability in a subject by administering an epoxymetabolite of docosahexaenoic acid (dha) and eicosapentaenoic acid (epa), e.g., as listed in table a, e.g., one or both of 17,18-epoxyeicosatetraenoic acid (eeq) and 19,20-epoxydocosapentaenoic acid (edp), e.g., for the treatment of conditions associated with inflammation or excess angiogenesis or neovascularization, including age-related macular degeneration, cancer, stroke, and arthritis.. .
Massachusetts Eye And Ear Infirmary

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one retinoic acid receptor or retinoid x receptor active agent.. .
Io Therapeutics, Inc.

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one retinoic acid receptor or retinoid x receptor active agent.. .
Io Therapeutics, Inc.

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one retinoic acid receptor or retinoid x receptor active agent.. .
Io Therapeutics, Inc.

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one retinoic acid receptor or retinoid x receptor active agent.. .
Io Therapeutics, Inc.

Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one retinoic acid receptor or retinoid x receptor active agent.. .
Io Therapeutics, Inc.

Pharmaceutical composition for treating cancer including 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol as active ingredient

The present disclosure relates to an anticancer use of a novel compound, i.e., 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol. The compound of the present disclosure effectively inhibits the growth of cancer cells and tumors in vitro and in a xenograft animal model.
Chungbuk National University Industry-academic Cooperation Foundation

Council Of Scientific & Industrial Research

. .

Sloan-kettering Institute For Cancer Research

. .

Tapestry Pharmaceuticals, Inc.

. .

. .

Diffusion ellipsoid mapping of tissue

Methods and devices for generating novel diffusion ellipsoid maps from diffusion tensor imaging (dti) scan data. One example method includes: (i) generating, from dti scan data, for each voxel in a plurality of voxels in one or more slabs of a target tissue, a respective diffusion tensor; (ii) generating, for each voxel, eigenvalues and eigenvectors of the respective diffusion tensor and a respective set of diffusion parameters; (iii) partitioning the voxels into two groups, wherein voxels, whose respective set of diffusion parameters is such that each element in the set is smaller than a corresponding element in a set of thresholds, are substantially all in a first group of the two groups; and (iv) providing a graphical representation of a diffusion ellipsoid map of at least one of the one or more slabs, wherein ellipsoids, associated with voxels in the first group, are displayed differently to the other ellipsoids.
Dde Mri Solutions Ltd.

Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample

A programmed computer functioning as a classifier operates on mass spectral data obtained from a blood-based patient sample to predict indolence or aggressiveness of prostate cancer. Methods of generating the classifier and conducting a test on a blood-based sample from a prostate cancer patient using the classifier are described..
Biodesix, Inc.

Methods of modulating cytokine activity; related reagents

Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of il-33 and il-33 receptor..
Merck Sharp & Dohme Corp.

Biological specimen evaluation methods using cytology and immunology

Information on cytokines and cytology obtained from a biological specimen are combined as a method of predicting the risk that dysplasia will progress to cancer.. .
Medite Cancer Diagnostics, Inc.

Methods of treating with tumor membrane vesicle-based immunotherapy and predicting therapeutic response thereto

Disclosed herein is a method for treating a subject having, or at risk of having, a triple negative breast cancer, comprising administering to the subject a therapeutically effective amount of an immunotherapeutic agent and a tumor membrane vesicle (tmv), wherein the tmv comprises a lipid membrane, and a b7-1 and/or il-12 molecule anchored to the lipid membrane. Also disclosed is method for predicting the likelihood a human subject having a cancer will respond therapeutically to a tmv immunotherapy, wherein the method comprises obtaining a blood or serum sample from the subject; measuring the amount of a set of biomarkers in the sample, wherein the biomarkers include at least ifn-gamma, tnf-alpha, and il-2, and wherein an increase in the level of the biomarkers as compared to a control indicates an increased likelihood the subject will respond therapeutically to the tmv immunotherapy..
Emory University

Il-6 signaling and breast cancer

The disclosure provides, inter alia, methods of detecting il-6 signaling activity in t cells in breast cancer patients, such as breast cancer patients in remission.. .
City Of Hope

Detection of human cytomegalovirus in breast cancer

Provided herein, inter alia, are methods for predicting the occurrence of metastasis in an individual affected with breast cancer as well as methods for determining the risk of metastasis in individuals diagnosed with breast tumors by assaying for the presence of viral interleukin-10 (cmvil-10) in individuals diagnosed with or suspected of having breast cancer that are seronegative for human cytomegalovirus (hcmv).. .

Reagents and methods for cancer treatment and prevention

The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects..
The Buck Institute For Age Research

Method of screening an agent for inhibiting recurrence or metastasis of breast cancer

The present invention relates to a method of screening preparations for inhibiting metastasis or recurrence of breast cancer using the change in the expression level of marker genes for breast cancer stem cells, wherein their expression levels are changed by the treatment with a wnt signaling inhibitor. The method of the present invention enables to screen preparations for preventing or treating the metastasis or recurrence of breast cancer with superior accuracy and thus the method can be widely used for the effective treatment of breast cancer..
Gil Medical Center

Gene expression signature for classification of tissue of origin of tumor samples

The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific micrornas and nucleic acid molecules relating thereto. Classification according to a microrna tree-based expression framework allows optimization of treatment, and determination of specific therapy..
Rosetta Genomics Ltd.

Predicting breast cancer treatment outcome

Methods and compositions are provided for the identification of expression signatures in er+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer the signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers.
The General Hospital Corporation

Cancer screening by detection of ultrastructural and molecular markers

The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject..
Northshore University Healthsystem

Algorithms for disease diagnostics

The present invention relates to compositions and methods for molecular profiling and diagnostics for genetic disorders and cancer, including but not limited to gene expression product markers associated with cancer or genetic disorders. In particular, the present invention provides algorithms and methods of classifying cancer, for example, thyroid cancer, methods of determining molecular profiles, and methods of analyzing results to provide a diagnosis..
Veracyte, Inc.

Circulating tumor and tumor stem cell detection using genomic specific probes

The present disclosure comprises a method of detecting circular tumor cells and methods of detecting, evaluating, or staging cancer in a patient, as well as a method of monitoring treatment of cancer in a patient using the claimed method. In other embodiments, the method provides for directed to a method of determining the level of circulating tumor cells (ctcs) in a sample having blood cells from a patient by contacting a sample having blood cells from a patient..
Board Of Regents, The University Of Texas System

Targeting micrornas for the treatment of liver cancer

Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a mirna.
Rosetta Genomics Ltd.

Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)

The present invention provides oligonucleotide inhibitors of mir-155 and compositions thereof. The invention further provides methods for treating cancer such as a t cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of mir-155.
Miragen Therapeutics, Inc.

Dldh, derivatives thereof and formulations comprising same for use in medicine

The invention provides methods for treating a proliferative disease or disorder such as cancer by administering to patients suffering from the disease or disorder dldh or a derivative thereof.. .
Ramot At Tel-aviv University Ltd.

Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality

Compositions and methods are provided for converting the predominant circulating classical monocytes to a non-classical and/or intermediate monocyte phenotype through cytokine stimulation via, for example, macrophage colony-stimulating factor. Once cultured into dendritic cells, these non-classical and/or intermediate monocyte derived cells have increased costimulatory molecule expression, which leads to improved immune and clinical responses in cancer patients receiving dendritic cell vaccination and other immunotherapies.
Health Research, Inc.

Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aapcs) are disclosed, including aapcs comprising a myeloid cell transduced with one or more viral vectors, such as a molm-14 or a em-3 myeloid cell, wherein the myeloid cell endogenously expresses hla-ab/c, icos-l, and cd58, and wherein the one or more viral vectors comprise a nucleic acid encoding cd86 and a nucleic acid encoding 4-1bbl and/or ox40l and transduce the myeloid cell to express cd86 and 4-1bbl and/or ox40l proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (tils) with aapcs and methods of treating cancers using tils after expansion with aapcs are also disclosed..
Iovance Biotherapeutics, Inc.

Antibodies against cd73 and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human cluster of differentiation 73 (cd73) with high affinity, and inhibit the activity of cd73, and optionally mediate antibody dependent cd73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided.
Bristol-myers Squibb Company

Internalizing moieties for treatment of cancer

In certain embodiments, the present disclosure provides compositions and methods for treating tumors and cancer.. .

Antigen-binding proteins that antagonize leptin receptor

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (lepr), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind lepr and antagonize lepr signaling.
Regeneron Pharmaceuticals, Inc.

Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy

An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (vegfr2; seq id no: 74) is disclosed. The epitope within the domain 3 of the vegfr2 is located between amino acid residues 250 and 270 of seq id no: 74.
Academia Sinica

Anti-ror2 antibodies

The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for receptor tyrosine kinase-like orphan receptors (ror), and to uses thereof for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules.
Memorial Sloan-kettering Cancer Center

Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the t cell immunoglobulin and mucin protein-3 (hm-3). The invention provides a tim-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Antibodies directed against lymphocyte activation gene 3 (lag-3)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the lymphocyte activation gene-3 (lag-3). The invention provides a lag-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Monoclonal antibodies against claudin-18 for treatment of cancer

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing cld18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.. .
Johannes Gutenberg-universitat Mainz

T cell receptors recognizing mhc class ii-restricted mage-a3

The invention provides an isolated or purified t-cell receptor (tcr) having antigenic specificity for mhc class ii-restricted mage-a3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells.
The United States Of America,as Represented By The Secretary,department Of Health And Human Services

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnology Gmbh

Template-fixed peptidomimetics

The template-fixed β-hairpin peptidomimetics cyclo(-tyr-his-cys-ser-ala-dpro-dab-arg-tyr-cys-tyr-gln-lys-d-pro-pro), disulfide bond between cys4 and gysl1, and pharmaceutically acceptable salts thereof, with x being ala or tyr, have cxcr4 antagonizing properties and can be used for where cancer is mediated or resulting from cxcr4 receptor activity. .
Polyphor Ltd.

Substituted purine compounds

The present invention relates to substituted purine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which dot1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof..
Epizyme, Inc.

Tricyclic compounds having antimitotic and/or antitumor activity and use thereof

The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example p-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells..
Duquesne University Of The Holy Spirit

Epoxyazulene derivatives useful for treating cancer and diabetes

Disclosed is a compound of formula (i) in which r1-r5 and x1 are as described herein. Also provided are methods of using a compound of formula (i), including a method of treating cancer and a method of treating diabetes..
Universitat Rovira I Virgili

Ethynyl derivatives

The compounds may be used for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .

Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds

Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or typanosoma cruzi infection in a mammal.. .
Array Biopharma, Inc.

Tricyclic compounds as anticancer agents

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.. .
Bristol-myers Squibb Company

Inhibitors of lysine specific demethylase-1

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

Benzothiazole or benzoxazole compounds as sumo activators

Provided are sumo activators, which can enhance sumoylation of serca2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.. .
Icahn School Of Medicine At Mount Sinai

Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (i) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix)..
Oryzon Genomics S.a.

Isoxazolyl substituted benzimidazoles

A compound which is a benzimidazolyl isoxazole of formula (i): wherein: r0 and r, which are the same or different, are each h or c1-6 alkyl; r9, r9 and r9, which are the same or different, are each h or f; x is -(alkn-, -alk-c(═o)—nr—, -alk-nr—c(═o)— or -alk-c(═o)—; r1 is selected from —s(═o)2r′; a 4- to 6-membered, c-linked heterocyclic group which is unsubstituted or substituted; and an n-linked spiro group of the following formula: r2 and r2′, which are the same or different, are each h or c1-6 alkyl, or r2 and r2′ form, together with the c atom to which they are attached, a c3-6 cycloalkyl group; r3 and r3, which are the same or different, are each h, c1-6 alkyl, oh or f; r4 is phenyl or a 5- to 12-membered, n-containing heteroaryl group and is unsubstituted or substituted; alk is c1-6 alkylene; r′ is c1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or cbp and is used to treat cancer, particularly prostate cancer..
Cellcentric Ltd

Pyrazolyl quinoxaline kinase inhibitors

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. Cancer..
Astex Therapeutics Ltd

Inhibitors of ras and methods of use thereof

Or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein a, b, r″, q, w, x, y, z, n2 and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of g12c mutant kras protein for treatment of disorders, such as cancer, are also provided..

Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists

Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.

Eckol derivatives, methods of synthesis and uses thereof

Provided herein are eckol derivatives, methods of synthesis thereof and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, alzheimer's disease, microbial infections, obesity, diabetes, cancer or inflammation using the compounds and pharmaceutical compositions disclosed herein..
Phloronol, Inc.

Novel class of quinolone heterocyclic aromatic molecules for cancer treatment

The invention is directed to new class of quinolone heterocyclic aromatic molecules (renotinibs) and their use in the treatment of cancer, in particular, cancer that harbor abnormal human epidermal growth factor receptors (egfrs).. .
Renotarget Therapeutics, Inc.

Imidazolyl tricyclic enones as antioxidant inflammation modulators

Disclosed herein are compounds of the formula: (i), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof.
Reata Pharmaceuticals, Inc.

Tetrasubstituted alkene compounds and their use

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an er-positive breast cancer and/or the subject in need of treatment may express a mutant er-α protein..
Eisai R&d Management Co., Ltd.

5-substituted indazole-3-carboxamides and preparation and use thereof

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of dyrk1a..
Samumed, Llc

Lsd1 inhibitors

The present invention relates to compounds that inhibit lsd1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention..
Mirati Therapeutics, Inc.

C5, c6 substituted and/or fused oxindoles as anti-cancer agents and process for preparation thereof

R2=h, alkyl, halogen, cn, no2, alkoxy, amino, oh. .

Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections

The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating viral diseases, cancer and diseases caused by intracellular protozoan infections. .
Romark Laboratories L.c.

Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof

Compositions and methods for improved delivery of active agents to the brain are provided. The compositions typically include a nanocarrier, such as a polymeric nanoparticle, liposome, or nanolipagel or are in the form of a conjugate.
Yale University

Radiotherapeutic and companion imaging agents to target mc1r

The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target mc1r and their use in the treatment of cancer.
Wake Forest University

Dendri-tac and their use as theranostics

The present invention relates to novel amphiphilic dendrimers, hereafter denoted dendri-tac. The present invention also relates to perfluorocarbon nanoemulsions stabilized by these amphiphilic dendrimers and their uses for in vivo diagnostic and/or for therapy, notably as theranostic tools, for detection and/or treatment of cancer..
Centre National De La Recherche Scientifique

Methods and compositions for theranostic nanoparticles

Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed.
Memorial Sloan Kettering Cancer Center

Antibody-vaccine engineered constructs (avec)

Hereby, we disclose and claim, the concept, designs, enabling technologies, and utility for therapy of patients suffering from cancer, of a novel class of biomolecularly engineered, synthetic molecules: antibody-vaccine engineered constructs (avec). They comprise the main functional domains (antibodies and vaccines) and the supporting domains (linkers and reporters).
Phoenix Biomolecular Engineering Foundation

Antibody drug conjugates

The present invention relates to anti-ckit antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. .
Novartis Ag

Trail receptor-binding agents and uses of same

The present invention discloses trail receptor-binding agents, their therapeutic effects on tumor inhibition in vitro and in vivo, alone or in combination with various chemotherapeutic agents. In particular, the present invention discloses methods for the treatment of cancer, comprising administrating a trail receptor binding agent of the present technology, alone or in combination with a chemotherapeutic agent..
Beijing Cotimes Biotech Company Limited

Compositions for treating cancer and methods for making the same

Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer.. .
The Brigham And Women's Hospital, Inc.

Multiple antigen binding molecular fusion, pharmaceutical composition, identifying linear epitope, and preparing multiple antigen binding molecular fusion

A multiple antigen-binding molecule fusion molecule containing a multiple antigen-binding molecule (α) having an immune cell antigen-binding region and a cancer antigen-binding region, a cancer tissue-specific protease-cleavable linker (β), and a masking molecule (γ) containing a polypeptide having the amino acid sequence qdgne, in which the multiple antigen-binding molecule (α) and the masking molecule (γ) are linked via the cancer tissue-specific protease-cleavable linker (β).. .
Chugai Seiyaku Kabushiki Kaisha

Methods for treating lung cancer

Provided herein are methods for predicting a likelihood of responsiveness to treatment with a folate receptor alpha (fra)-targeting agent in a patient having a fra-expressing lung cancer. Also provided are methods for treating a fra-expressing lung cancer in a patient with a fra-targeting agent.
Morphotek, Inc.

Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer..
Sotio A.s.

Placental vaccination therapy for cancer

The present invention discloses methods of stimulating an immune response to cancer tissue and biological effectors used by tumors to defeat the host, through the immunization of a mammal using placental tissue, cells, molecules, and combinations thereof. In one embodiment, the invention provides the utilization of syngeneic, allogeneic, xenogeneic, and combinations thereof as immunizing sources..

Virus-like particle with efficient epitope display

The invention relates to a virus-like particle (vlp) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject.
University Of Copenhagen

Prime-boost regimens involving administration of at least one mrna construct

The present invention relates to prime-boost regimens that involve the administration of at least one mrna construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen.
Curevac Ag

Modified chemokine peptide

The present invention provides a modified chemokine peptide, comprising (a) an “elr” characteristic sequence which is situated at the n-terminus of the modified chemokine peptide, (b) a “pasqf” characteristic sequence which is neighbored to the upstream of the third cysteine counted from n-terminus of the chemokine peptide, and (c) a modification at the 17th position counted from the n-terminus of the modified chemokine peptide. Additionally, the modified chemokine peptide can be used to treat cancer and inhibit tumor growth..
Rise Technology Co., Ltd.

Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects..
Heat Biologics, Inc.

Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway

Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated pd-1 variant polypeptide. The pd-1 variant polypeptide can inhibit the activity of pd-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type pd-1 and one or more of its ligands, pd-l1 and pd-l2..
The Board Of Trustees Of The Leland Stanford Junior University

Modified binding proteins inhibiting the vegf-a receptor interaction

The present invention relates to binding proteins specific for vegf-a, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits vegf-axxx binding to vegfr-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety.
Molecular Partners Ag

Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer.
Immatics Biotechnologies Gmbh

Method for enhancing effect of immunotherapy for cancer

Disclosed is a method for enhancing the effect of an immunotherapy for cancer in a subject, comprising administering to the subject an effective amount of a polysaccharide extract of astragalus membranaceus. Also disclosed is a method for increasing a subject's pool of m1 macrophages, wherein the subject is suffering from one or more conditions associated with undesirable m2 macrophage activation, the method comprising administering to the subject an effective amount of a polysaccharide extract of astragalus membranaceus..
Phytohealth Corporation

Treatment of cancer using chimeric antigen receptors

The invention provides compositions and methods for treating diseases associated with expression of cd20 or cd22. The invention also relates to chimeric antigen receptor (car) specific to cd20 or cd22, vectors encoding the same, and recombinant t or natural killer (nk) cells comprising the cd20 car or cd22 car.

Modified gamma delta t cells and uses thereof

The present invention provides composition and methods for the treatment of cancer or infectious diseases in a human. The invention includes the generation and administration of gamma delta t cells that express chimeric antigen receptors (cars) comprising an antigen binding domain, a hinge domain, a transmembrane domain, a costimulatory signalling domain with the inclusion or not of a cd3 zeta signalling domain.
Tc Biopharm Ltd

Immune modulation with tlr9 agonists for cancer treatment

The present invention relates to methods for treating a tumor, including a metastatic tumor, with tlr9 agonist in combination with an immune checkpoint inhibitor therapy.. .
Idera Pharmaceuticals, Inc.

Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells

In one embodiment, the invention provides a method of treating a subject who suffers from a neoplasm (including a cancer such as a radiotherapeutic-resistant cancer) by administering to the subject a therapeutically effective amount of (a) 5-formyl-2′-deoxyuridine (fdu or foudr) or a 5-formyl-2′-deoxyuridine derivative, optionally in combination with 5-hydroxy-2′-deoxyuridine (hudr); and (b) at least one composition selected from the group consisting of either 5-fluorouracil (5-fu), a 5-fu prodrug (e.g. 5-fluoro-2′-deoxyuridine (fdu)) or 5-fu metabolite.
Stc.unm

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
Volant Holdings Gmbh

Certain chemical entities, compositions, and methods

Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.. .
Suzhou Neupharma Co., Ltd.

Substituted quinazolines for inhibiting kinase activity

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.. .
Neupharma, Inc.

Therapeutically active compounds and their methods of use

Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic t-cell lymphoma (aitl).. .
Agios Pharmaceuticals, Inc.

Targeted therapies for cancer

Methods of treating, and for selecting a chemotherapy regimen for treatment of cancer in a patient (fig. 9).
Mayo Foundation For Medical Education And Research

Ergoloid for cancer

This enhancement results in better outcomes with lower cost and better quality of life.. .

Method for preventing lung diseases in smokers and non-smokers using antihypertensive drug

The present invention relates to a method for inhibiting lung diseases in smokers and non-smokers by blocking growth factor signaling using an antihypertensive drug, and more particularly, to a pharmaceutical composition for preventing lung cancer or emphysema, which contains an antihypertensive drug as an active ingredient. The present invention suggests a novel use of an antihypertensive drug which is being used in clinics, to prevent lung diseases, and therefore, may be readily applied to early lung cancer or a lung cancer high-risk group, and particularly may exclude safety concerns accompanying clinical application of novel drugs, thereby increasing clinical applicability.
Seoul National University R & Db Foundation

Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer

This invention is directed to prostaglandin e2 receptor 4 (ep4) antagonists useful in the treatment of nonalcoholic steatohepatitis (nash)-associated liver cancer in a human or animal. The method comprises administering one or more of compound a, compound b or compound c, or pharmaceutically acceptable salts thereof, as the ep4 antagonist(s).
Askat Inc.

Combination therapies for treating cancer

Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof..
Redhill Biopharma Ltd.

Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body

Combinations of an ido1 inhibitor (e.g., a 3-(5-fluoro-1h-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-pd1 antibody or anti-pd-l1 antibody, and an anti-4-1bb antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis..
Iteos Therapeutics

Cancer treatment method using ailanthone compounds

A pharmaceutical composition comprising an ailanthone (ail) compound or a derivative thereof, for the treatment of diseases or conditions caused by, dependent from, or associated with excessive androgen receptor activity. Ailantone compounds have been discovered to be a potent inhibitor of both full-length ar (ar-fl) and constitutively-active truncated ar splice variants (ar-vs), and are found to possess favorable drug-like properties such as good bioavailability, high solubility, lack of cyp inhibition, and low hepatotoxicity.
East China Normal University

Dehydroacetic acid (dhaa) and derivative for uses in treating cancer

This disclosure relates to methods of managing or treating cancer with agents that lower circulating acetoacetate levels, such as hypolipidemic agents, or other agents that antagonize acetoacetate-braf v600 mutant binding to attenuate braf v600 mutant tumor growth. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of an agent to a subject in need thereof, wherein the agent is dehydroacetic acid, derivative, prodrug, or salt thereof..
Emory University

Novel antitumoral use of cabazitaxel

Which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.. .

System and precision diagnosis and therapy augmented by cancer grade maps

An ultrasound system for performing cancer grade mapping includes an ultrasound imaging device (10) that acquires ultrasound imaging data. An electronic data processing device (30) is programmed to generate an ultrasound image (34) from the ultrasound imaging data, and to generate a cancer grade map (42) by (i) extracting sets of local features from the ultrasound imaging data that represent map pixels of the cancer grade map and (ii) classifying the sets of local features using a cancer grading classifier (46) to generate cancer grades for the map pixels of the cancer grade map.
Koninklijke Philips N.v.

Electromagnetic system and method

Differences of electromagnetic (em) properties between healthy and cancerous tissues allow detection of abnormal conditions occurring in a tissue of an animal, for example, intra-operative cancer detection. By using a time-varying em field, electrical eddy currents are generated in the tissue sample, and assessed using phase-sensitive detection.
Ohio State Innovation Foundation

Breast cancer recovery garment

The breast-cancer recovery system comprises a breast cancer recovery garment, an organizational subsystem and a needs kit. The breast cancer recovery garment comprises a body portion defining an opening, positioned, configured and dimensioned to allow the performance of a breast cancer treatment procedure and a closure device suitable for closing the opening when a procedure is not being performed.
Patient To Person, Llc

Taxane analogs for the treatment of brain cancer

Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at g2-m interface during mitosis but is not a substrate for mdr protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer..
Longwood Gardens, Inc.

Cdca1 epitope peptides for th1 cells and vaccines containing the same

Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Longwood Gardens, Inc.

Genetic alterations in ovarian cancer

According to various embodiments herein, methods for performing diagnosis and prognosis of ov have been provided. In embodiments, a method of determining an estimated outcome or predicting a clinical response to chemotherapy for a patient having ovarian serous cystadenocarcinoma (ov), comprises obtaining a biological sample from a patient diagnosed with ov, said sample comprising at least one of nucleic acids and proteins from the patient; detecting in said sample a value of an indicator of a differential expression; and calculating, by a processor, a weighted sum pattern based on the value of one or more of the indicators of differential expression; and estimating, by the processor and based on the weighted sum pattern, a predicted length of survival of the patient or a predicted clinical response to chemotherapy for the patient..
University Of Utah Research Foundation

System and lesion analysis and recommendation of screening checkpoints for reduced risk of skin cancer

A method for image analysis comprises receiving one or more current images of a lesion from a body of a person, wherein the one or more current images are electronically captured by and transmitted from a capture device, and analyzing the one or more current images, wherein the analyzing comprises performing image processing to compare the one or more current images captured at a first time to one or more previous images of the lesion captured at a second time prior to the first time, and determining at least one difference between the one or more current images and the one or more previous images based on the comparing. The method further comprises determining a probability that the lesion will become diseased based on the analysis, and recommending a time for a future image capture of the lesion and/or a consultation with a practitioner based on the determined probability..
Molemap Nz Ltd.

Simultaneous feature extraction and dictionary learning using deep learning architectures for characterization of images of heterogeneous tissue samples

Apparatus, methods, and computer-readable media are provided for simultaneous feature extraction and dictionary learning from heterogeneous tissue images, without the need of prior local labeling. A convolutional autoencoder is adapted and enhanced to jointly learn a feature extraction algorithm and a dictionary of representative atoms.
International Business Machines Corporation

Methods of diagnosing and treating cancer comprising me1

The present disclosure provides a method of determining treatment for cancer comprising identifying the absence of malic enzyme 1 (me1) and treating with an inducer of ferroptosis.. .
Washington University

Detection of cancer using antibody arrays

Disclosed are antibody arrays for the detection of cancer in a human or animal subject, comprising a solid support having disposed thereon in a predetermined spatial configuration, a panel of antibodies specific to biomarkers comprising ca-125, msp-α, timp-4, pdgf-rα and opg, wherein the panel comprises a first antibody or fragment thereof that specifically binds ca-125, a second antibody or fragment thereof that specifically binds msp-α, a third antibody or fragment thereof that specifically binds timp-4, a fourth antibody or fragment thereof that specifically binds pdgf-rα, and a fifth antibody or fragment thereof that specifically binds opg. Also disclosed are systems containing the arrays and methods of using the arrays to detect cancer such as ovarian cancer..
South China Biochip Research Center In Guangzhou

Diagnostic biomarkers and therapeutic targets for pancreatic cancer

We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins.
The Johns Hopkins University

Methods for diagnosis and prognosis of epithelial cancers

The present invention is based on the discovery that three proteins, cystatin b, chaperonin 10, and profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples.
The General Hospital Corporation

Method of diagnosis of cancer and uses thereof

The present invention concerns methods of identifying a cancer patient suitable for a treatment, for the treatment of cancer in a patient, for the prognosis of cancer outcome, or of diagnosing a cancer in a patient by determining with a biological assay an oncogenic potential of a sensitized cell contacted with a biological fluid derived from the patient, compared to a reference value, and if the oncogenic potential of the sensitized cell is above or below a reference value, a suitable identification, diagnosis or treatment may be performed.. .

Measuring a level of a 5-hydroxymethylcytosine in a sample from a subject having a cancer or suspected of having cancer

Provided herein are methods and kits for measuring a level of a 5-hydroxymethylcytosine in a nucleotide sequence from a subject, wherein the subject is a subject having a cancer or suspected of having cancer.. .
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servi

Grading, staging, and prognosing cancer using osteopontin-c

The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (dcis). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer.
University Of Cincinnati

Mutations of the pik3ca gene in human cancers

Phosphatidylinositol 3-kinases (pi3ks) are known to be important regulators of signaling pathways. To determine whether pi3ks are genetically altered in cancers, we analyzed the sequences of the pi3k gene family and discovered that one family member, pik3ca, is frequently mutated in cancers of the colon and other organs.
The Johns Hopkins University

Systems and methods for analyzing nucleic acid

Increased sensitivity and specificity of characterizing patient-specific variations as mutations that are indicative of a cancer or other disease by identifying patient-specific tumor mutations by comparing tumor and normal sequence reads from the patient and filtering for mutations that are unique to the tumor. By comparing tumor sequence to a normal sequence from the same patient, false-positive mutation calls are minimized in the analysis..
Personal Genome Diagnostics, Inc.

Methods for detecting prostate cancer

Methods for detecting a prostate cancer in a subject comprise detecting a marker selected from an endosomal associated marker and/or a lysosomal associated marker from the subject.. .
University Of South Australia

Point mutations in trk inhibitor-resistant cancer and methods relating to the same

Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a trk inhibitor, methods of predicting the efficacy of a trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a trk inhibitor-resistant cancer, and methods of determining the presence of a trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in ntrk1 and/or ntrk2 and/or ntrk3.. .
Array Biopharma, Inc.

Novel risk biomarkers for lung cancer

Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of n-methylpurine dna glycosylase (mpg), or apurinic/apyrimidinic endonuclease 1 (ape1), or both, or mpg and 8-oxoguanine dna glycosylase (ogg1), or mpg and ape1 and ogg1 in peripheral blood cells of a subject, wherein levels of mpg above a predetermined reference value, or ape1 or ogg1, or a integrated dna repair score below a predetermined reference value is indicative of an increased risk of developing lung cancer..
Yeda Research And Development Co. Ltd.

Methods of detecting signatures of disease or conditions in bodily fluids

Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided.
President And Fellows Of Harvard College

Method for analyzing 3' end sequence of messenger rna

The present disclosure provides a new protocol for sequencing the 3′ end of messenger rna (mrna). The present disclosure can be very favorably used in analyzing the repetitive sequences of nucleic acids, which are difficult to analyze by current sequencing methods, especially, homopolymeric sequences (poly[a] sequence) of mrna.
Institute For Basic Science

Methods, compositions and kits for high throughput kinase activity screening using mass spectrometry and stable isotopes

A mass-spectrometry-based method and substrates are provided herein for large scale kinome activity profiling directly from crude lysates using 90 chemically synthesized peptide substrates with amino acid sequences derived from known phosphoproteins. Quantification of peptide phosphorylation rates was achieved via the use of stable isotope labeled synthetic peptides.
President And Fellows Of Harvard College

Androgen receptor variant inhibitors and methods of using

This document relates to materials and methods for treating cancer (e.g., prostate cancer). For example, methods for using one or more androgen receptor variant (ar-v) inhibitors (e.g., morpholinos) to treat a mammal having prostate cancer (e.g., castration-resistant prostate cancer) are provided..
Regents Of The University Of Minnesota

Methods and compositions for diagnosis and treatment of cancer

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.. .
Johannes Gutenberg-universitat Mainz

Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom

The invention is directed to methods for identifying targets for antimicrobial and antiproliferative compounds as well as methods for identifying novel compounds for treating cancer and microbial infections.. .
Mimetics, Llc

Novel sustained release polymer

A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit.
Tolmar Therapeutics, Inc.

Anti-muc16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind muc16 and cd3, and uses thereof

Mucin 16 (muc16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human igg antibodies that bind to human and muc16 (monospecific antibodies).
Regeneron Pharmaceuticals, Inc.

Modifield antibodies to prostate-specific membrane antigen and uses thereof

Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (psma) are provided. The modified anti-psma antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human.
Cornell Research Foundation, Inc.

Disease therapy by inducing immune response to trop-2 expressing cells

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.

Flt3 directed car cells for immunotherapy

Car cells targeting flt3 relevant antigens are described as a new method of cancer treatment. It is proposed that flt3 car cells are safe and effective in patients and can be used to treat human tumors and cancer..
Precision Immunotherapy, Inc.

Combination therapy for cancer

This invention relates generally to a combination therapy for the treatment of cancer, particularly to a combination of (i) a bifunctional molecule comprising a tgfβrii or fragment thereof capable of binding tgfβ and an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as programmed death ligand 1 (pd-l1) and (ii) at least one additional anti-cancer therapeutic agent.. .
Merck Patent Gmbh

Car t-cells for the treatment of b7-h4 expressing solid tumors

Car cells and antibodies targeting human b7-h4 expressed on many human cancers including but not limited to breast ovarian, and renal cancers are described as a new method of cancer treatment. It is proposed that b7-h4 car cells are safe and effective in patients and can be used to treat human tumors expressing the b7-h4 surface protein..
University Of Southern California

Antibodies specific to glycosylated pd-l1 and methods of use thereof

Antibodies that bind specifically to glycosylated pd-l1 relative to unglycosylated pd-l1 are provided. Antibodies that recognize specific epitopes of glycosylated pd-l1 protein and can block the binding of pd-l1 to pd-1 are provided.
Board Of Regents, The University Of Texas

Antibodies to pd-1 and uses thereof

Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind pd-1.
Jounce Therapeutics, Inc.

Binding agents that modulate the hippo pathway and uses thereof

The present invention relates to agents that modulate the hippo pathway and hippo pathway signaling, such as antibodies and soluble receptors, as well as to methods of using the agents for the treatment of diseases such as cancer.. .
Oncemed Pharmaceuticals, Inc.

Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof

The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of cd3 and one binding site specific for an epitope of gpa33 (i.e., a “gpa33×cd3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin fc domain (“bi-specific monovalent fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpa33 and one binding site specific for an epitope of cd3 (i.e., a “gpa33×cd3 bi-specific monovalent fc diabody”).
Macrogenics, Inc.

Variant survivin vaccine for treatment of cancer

The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (apcs) such as dendritic cells, or apc precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or apc.. .
The Wistar Institute

Use of immunesuppressant receptor

Bir1 functions as an immunosuppressive receptor, and the antagonist of bir1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.. .

Mutant kras inhibitors

Compositions and methods for inhibits the binding of gtp to oncogenic mutant kras are disclosed. These compositions may be used in method to treat a subject with cancer.
Torrey Pines Institute For Molecular Studies

Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4h)-yl-piperidinonyl conjugates and methods of treating medical disorders using same

The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4h)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.. .
Deuterx, Llc

Substituted quinazolines as inhibitors of kras g12c

Or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein r1, r2a, r3a, r3b, r4a, r4b, g1, g2, l1, l2, m1, m2, a, b, w, x, y, z and e are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of g12c mutant kras protein for treatment of disorders, such as cancer, are also provided..

Ido inhibitors

Presently provided are ido inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (ido) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.. .
Newlink Genetics Corporation

Imidazo isoindole derivative, preparation method therefor and medical use thereof

The present invention relates to an imidazo isoindole derivative, a preparation method therefor and a medical use thereof. In particular, the present invention relates to the imidazo isoindole derivative as shown in the formula (i), a preparation method and pharmaceutical composition containing the derivative, and a use thereof for treating diseases with a pathological characteristic of the ido-mediated tryptophan metabolic pathways.
Shanghai Hengrui Pharmaceutical Co., Ltd.

Composition and methods for the treatment of camkk2-mediated disorders

The present disclosure provides compositions and methods for treating ocular disorders in mammals especially in and not limited to humans and mice. The present disclosure further provides methods of treating cancer and appetite suppression using the compositions which are novel small molecule inhibitors of camkk2.
Duke University

Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-idh) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the formula: (i) where y1, x1, x2, y2, w1, w2, w3, and r1-r5 are described herein.. .
Forma Therapeutics, Inc.

5-deutero-thiazolidinyldione compounds and methods of treating medical disorders using same

The invention provides deuterium-enriched thiazolidine-2,4-dione compounds (i.e., deuterium-enriched glitazone compounds), enantiopure forms of deuterium-enriched glitazone compounds, pharmaceutical compositions, and methods of treating medical disorders, such as a metabolic disorder, neurological disorders, cancer, or other disorder using deuterium-enriched glitazone compounds, which may be in enantiopure form.. .
Deuterx, Llc

Novel aryl-cyanoguanidine compounds

The present invention relates to protein-lysine n-methyltransferase smyd2 (set and mynd domain-containing protein 2) inhibitors, in particular smyd2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (i), wherein r1, r3, r4, r5 and n have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of smyd2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility..
Bayer Pharma Aktiengesellschaft

Pyrimidine derivatives

In which r1, x1 and x2 have the meanings indicated in claim 1, are mth1 inhibitors and can be employed, inter alia, in the treatment of cancer.. .

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

Substituted quinazoline derivatives as dna methyltransferase inhibitors

The present invention relates to compounds of the following formula (i) and pharmaceutically acceptable salts and solvates thereof, their methods of preparation, their use as a drug, notably in the treatment of cancer, and pharmaceutical compositions containing such compounds.. .
Sapienza Universita Di Roma

Combretastatin analogs

The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of formula (i), formula (ii), and formula (v) are provided..
Bioventures, Llc

Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof

And pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example p-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells..

Compounds for treatment of cancer

The present invention relates to colchicine-binding site compounds having anti-cancer activity, compositions comprising the same, and their use for treating various forms of cancer.. .
University Of Tennessee Research Foundation

Heterocyclic derivatives modulating activity of certain protein kinases

The present invention relates to novel heterocyclic derivatives having general formula (i) and their therapeutic use for diseases such as cancer, inflammation, pain, autoimmune diseases or neurodegenerative diseases like alzheimer's or parkinson's disease that can be treated by modulation of certain protein kinases. Compounds of formula (i) can be used for treatment of patients who do not respond to kinase inhibition therapy that comprises currently available medications..
Universita' Degli Studi Di Milano

Small molecule compounds targeting pbx1 transcriptional complex

In accordance with one or more embodiments, the present invention provides a compound of formulas i, ii, and iii, for use in methods of inhibition of pbx1-dna interaction in a mammalian cell or population of cells, and for use in the treatment of medical conditions including but not limited to cancers, developmental disorders, inflammatory disorders, autoimmune diseases, or neuro-degenerative disorders.. .
The Johns Hopkins University

Therapeutic agents

A compound of formula (i) or a compound of formula (ii) or pharmaceutically acceptable salts thereof, wherein r1-r7 and x are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the mdm2 protein with p53.. .
Cancer Research Technology Limited

Substituted hydroxystilbenes and their therapeutic applications

It discloses a compound of formula i that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.. .
Resolvex Pharmaceuticals Inc.

Selective androgen receptor degrader (sard) ligands and methods of use thereof

This invention provides novel 3-amino propanamide selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (ar-fl) including pathogenic or resistance mutations, ar-splice variants (ar-sv), and pathogenic polyglutamine (polyq) polymorphisms of ar in a subject.. .
University Of Tennessee Research Foundation

Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatment of tumorous pathologies

The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol or its derivatives/chemical variants in the manufacture of a medicament for the treatment of tumors or cancers.
Hong Kong Baptist University

Ion beam extraction apparatus and use thereof

The invention comprises an apparatus and method of use thereof for extracting ions from an ion source, such as for use in cancer treatment or tomographic imaging. The extraction apparatus uses a triode extraction system, with the ion source and/or first electrode held at a first potential; an extraction electrode held at a second potential; and a gating electrode, positioned between the ion source and the extraction electrode, oscillating and/or alternating between a first suppression potential proximate that of the ion source potential and a second extraction potential between the ion source potential and the extraction electrode potential.

Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity

Porous silicon (psi) microparticles (psm) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent psm-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies.
The Methodist Hospital

Drug conjugates comprising antibodies against claudin 18.2

The present invention provides anti-cldn18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing cldn18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.. .
Tron- Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg-univers

Sirna inhibition of human antigen r expression for treatment of cancer

Dna dendrimer linked to both a targeting moiety and a sirna which inhibits expression of human antigen r (hur), pharmaceutical compositions comprising the dna dendrimers and methods of treatment and use employing the dna dendrimers. Useful sirna sequences are also disclosed..
Lankenau Institute Of Medical Research

Covalent conjugates of bet inhibitors and alpha amino acid esters

The present invention relates to covalent conjugates of bet inhibitors and alpha amino acid esters, processes for their preparation, compositions containing them, and to their use in the treatment of various disorders in particular inflammatory and autoimmune diseases, such as rheumatoid arthritis; and cancers.. .
Glaxosmithkline Intellectual Property Development Limited

Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer

The invention described herein relates to methods and compositions for treating cancer in a patient or a tumor cell by administering an effective amount of an anti-fugetactic agent and an additional anti-cancer agent.. .
The General Hospital Corporation

Phase-change nanoparticle

Apparatus and methods are described for use with a subject suffering from cancer. A nanoparticle (22) includes an inner core (30) that comprises a phase-change material that is configured to absorb latent heat of fusion by undergoing a phase change.
New Phase Ltd.

Combination of anti-kir and anti-ctla-4 antibodies to treat cancer

Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-kir antibody in combination with an anti-ctla-4 antibody.. .
Innate Pharma

Egfr-directed car therapy for glioblastoma

Glioblastoma (gb) remains the most aggressive primary brain malignancy; brain metastasis, such as breast cancer brain metastases (bcbms), are also aggressive and are associated with poor prognosis. Adoptive transfer of chimeric antigen receptor (car)-modified immune cells has emerged as a promising anti-cancer approach, yet the potential utility of car-engineered cells to treat brain cancers has not been explored.
Ohio State Innovation Foundation

Targeted cytosolic delivery of antigenic compounds

The invention relates to engineered anthrax toxin compositions that can target antigen-presenting cells such as dendritic cells. Specifically, the compositions comprise (a) a native-receptor-ablated anthrax toxin protective antigen (pa) fused to a receptor-binding moiety specific for a target receptor on a dendritic cell and (b) a lethal factor (lf) or a fragment thereof fused to an active moiety comprising at least one repeat of a disease-specific antigen.
President And Fellows Of Harvard College

Method of treating cancer

The present invention provides a method of treating cancer in a subject wherein the method comprising administering to the subject an iap antagonist and a p38 and/or a mk2 inhibitor.. .
The Walter And Eliza Hall Institute Of Medical Research

Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer

The invention relates to a (i) vitamin a, a reaction product, a metabolite or a precursor of it and (ii) a plant extract of chamomile or an active component thereof, preferably for use in the treatment of cancer. The inventive composition may be provided as a medicament or a pharmaceutical composition.
Alpinia Laudanum Institute Of Phytopharmaceutical Sciences Ag

Cancer therapy with a parvovirus combined with a bcl-2 inhibitor

Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the bh3 mimetics abt-737 and abt-199..
Ruprecht-karls-universitÄt Heidelberg

Extracellular matrix compositions for the treatment of cancer or immunological diseases

The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ecm) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent.
Histogen, Inc.

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Therapy for malignant disease

Provided herein, inter alia, are methods and compositions directed to suppressing tumor cell growth in a subject as well as methods for sensitizing a proliferating cell for treatment with a cytotoxic agent via inhibiting expression of he4 and one or more immune checkpoint inhibitors (icis). Also provided herein are methods for determining whether a subject who has been diagnosed with cancer would benefit from immunotherapy as well as methods for determining whether a subject with cancer is responding to immunotherapy via assessment of levels of he4 gene and/or protein expression..
Women & Infants Hospital Of Rhode Island

Methods of treatment of cancer

The present invention provides a method of treating cancer with a proteasome inhibitor. The invention also provides a method of treating a patient with cancer based on elevated expression levels of nfκb, as measured by a h-score of the patients tumor sample using a nfκb p65 ihc assay.
Millennium Pharmaceuticals, Inc

System and diagnosis and treatment

This invention relates the use of cortisol blockers (glucocorticoid receptor [gr] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.. .
Pop Test Oncology Llc

Rationale-based design of a targeted therapy for cancer

The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an spop substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more spop substrates or signaling pathway activities thereof in a subject in need thereof..
Celestra Life Science Llc

Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase

Disclosed are methods for the treatment of proliferative disorders. Disclosed in particular, are methods for treatment of proliferative disorders such as cancer, by administering an mtorc1/2 inhibitor in combination with a selective inhibitor of aurora a kinase.
Millennium Pharmaceuticals, Inc.

Methods for treating egfr mutant cancers

Methods for the treatment of egfr mutated cancer. For example, treatment of non-small cell lung cancer (nsclc) with activating egfr mutations (e.g., l858r and ex19del) the acquired or resistant “gatekeeper” t790m mutation, or any combination of these mutations..
Novartis Ag

Composition for inhibiting growth or proliferation of chronic myelogenous leukemia cancer stem cells, and screening method therefor

Provided are a composition for inhibiting growth or proliferation of chronic myelogenous leukemia (cml) cancer stem cells, a pharmaceutical composition for preventing or treating cml, a method for preventing or treating cml, and a method of screening for a growth or proliferation inhibitor of cml cancer stem cells by blocking nutrient signaling in cml cancer stem cells.. .
Hiroshima University

The use for inhibitors of epidermal growth factor receptor variants ii, iii and vi

A panel of 12 egfr inhibitors were screened for inhibition of egfr phosphorylation in u87mg tumor cells engineered to express egfr-viii. Compounds elicited a range of activity against phosphoy1173-egfr.
Metastat, Inc.

Combination therapies for treating cancers

Provided herein are methods that relate to a therapeutic strategy for treatment of cancer, including hematological malignancies. In particular, the methods include administration entospletinib and a bcl-2 inhibitor, such as venetoclax, navitoclax, and abt-737..
Gilead Scienes, Inc.

6-amino-purin-8-one compounds

Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Combination therapy for cancer treatment

Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a parp inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor.
Ipsen Biopharm Ltd.

Pharmacologically active compounds

Wherein x, y, r2, r3, r4 and ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of monospindle 1 (mps1—also known as ttk) kinases either directly or indirectly via interaction with the mps1 kinase itself.

Bromodomain and extra-terminal protein inhibitor combination therapy

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (bet) inhibitor and at least one chemotherapeutic agent, which does not inhibit bet directly. The bet inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the bet inhibitor or the chemotherapeutic agent alone..
Celgene Quanticel Research, Inc.

Targeting metabolic vulnerability in triple-negative breast cancer

Methods for treating cancer in a subject by administering a therapeutically effective amount of a pyrimidine synthesis inhibitor and a genotoxic chemotherapeutic agent. In some embodiments, the cancer is triple negative breast cancer..
Beth Israel Deaconess Medical Center, Inc.

Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells

The invention relates to the use of substance p antagonists and, in particular, the use of non-peptidic nk1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human hodgkin's lymphoma km-h2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human burkitt's lymphoma, human lung carcinoma, human ewing's sarcoma, human glioma and human osteosarcoma.. .
Nk-1 Ip Limited

Treatment method by combined use of mdm2 inhibitor and btk inhibitor

It is intended to provide a medicament and a method for treating cancer comprising a compound having mdm2 inhibiting activity and a compound having btk inhibiting activity in combination. The present invention provides a medicament comprising (3′r,4′s,5′r)-n-[(3r,6s)-6-carbamoyltetrahydro-2h-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide or a pharmaceutically acceptable salt thereof and ibrutinib or a pharmaceutically acceptable salt thereof in combination, and a treatment method using these compounds or salts in combination..
Daiichi Sankyo Company, Limited

Demethylpenclomedine analogs and their use as anti-cancer agents

This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.
Dekk-tec, Inc.

Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment

Or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein..

Enzalutamide in combination with afuresertib for the treatment of cancer

A novel combination comprising an androgen receptor inhibitor, for example: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide or a pharmaceutically acceptable salt thereof, and an akt inhibiting compound, for example: n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which androgen receptor inhibition and/or akt inhibition is beneficial, e.g., cancer.. .
Novartis Ag

Shmt inhibitors

The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (shmt) inhibitor, and in particular the administration of pyrazolopyran compounds of formula (vi) as presently described, wherein the compounds are capable of inhibiting a mammalian shmt, such as human shmt1 and/or shmt2. The treatment method further comprises the optional administration of an additional agent as a rescue therapy to reduce toxicity, wherein said agent may be chosen from formate, a formate salt, folinic acid, formate ester, or leucovorin..
The Trustees Of Princeton University

Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer

The invention described herein relates to methods and compositions for treating cancer in a patient, or a tumor cell, by administering an effective amount of an anti-fugetactic agent and an immunotherapy agent.. .
The General Hospital Corporation

Compositions for the treatment of cancer

The invention described herein relates to compositions for treating cancer in a patient, or a tumor cell, by administering an effective amount of amd3100 over a period of time.. .
The General Hospital Corporation

Modulators of farnesoid x receptor and methods for the use thereof

Compounds, compositions and methods are provided for treating the fxr-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the fxr-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; inflammation, or cancer etc.. .
Xiamen University

Modulators of prostate-specific g-protein receptor (psgr/or51e2) and methods of using same

The present disclosure provides, in part, modulators of prostate-specific g-protein receptor (or51e2/psgr) and methods of treating, preventing, and diagnosing prostate cancer using the same.. .
Duke University

Novel treatment of prostate carcinoma

Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer..
Pellficure Pharmaceuticals, Inc.

Ferromagnetic shaped memory alloy nano-actuator and use

Nano-actuators having a helical member formed with a ferromagnetic shape memory alloy (fsma) are disclosed that are elastically deformable between a compressed state and an expanded state by the application of a magnetic field. The nano-actuators may include a ferromagnetic head portion, that may be formed from the fsma or from another material.
University Of Washington

Device and apparatus to facilitate cervix cancer screening

An apparatus for detecting cervical cancer comprising a mechanical structure configured to expose cervical region comprising a supporting rod, and an image capturing unit to capture cervix images and determine abnormalities in the cervix region based on preprogrammed instructions, wherein the image capturing unit is coupled to the mechanical structure on the supporting rod. The image capturing unit is coupled to the mechanical structure by means of a detachable unit mounted on the supporting rods of the mechanical structure.
M/s. Manipal University

Medical hyperspectral imaging for evaluation of tissue and tumor

Apparatus and methods for hyperspectral imaging analysis that assists in real and near-real time assessment of biological tissue condition, viability, and type, and monitoring the above overtime. Embodiments of the invention are particularly useful in surgery, clinical procedures, tissue assessment, diagnostic procedures, health monitoring, and medical evaluations, especially in the detection and treatment of cancer..
Hypermed Imaging, Inc.

Evaluating and calling sequences

Methods and systems for simultaneously evaluating genomic or biological sequences across multiple population members, and methods and systems for simultaneously calling normal and cancerous genomic or biological sequences from a mixed sample containing normal and cancerous material are disclosed. This may be achieved by evaluating the probability of one or more hypothesis being correct for a plurality of population members based on genomic or biological sequence information for the population.
Real Time Genomics Limited

Detectors of serum biomarkers for predicting ovarian cancer recurrence

Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay.
Wayne State University

Lipid markers for early diagnosis of breast cancer

Methods for measuring a panel of biomarkers in a subject suspected of having breast cancer are provided. The methods include obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample, the panel comprising at least 5 biomarkers selected from the group comprising lpc(18:3), lpc(20:2), lpc(20:1), lpc(20:0), pc(32:1), pc(34:4), pc(38:3), pc(40:5), pc(40:3), pc(44:11), epc(32:2), epc(38:3), c19:1 ce, c19:0 ce, and c20:0 ce, wherein the measurement comprises measuring a level of each of the at least 5 biomarkers..
Rush University Medical Center

Diagnostic and prognostic methods for barrett's esophagus

Provided are methods, compositions, kits, and systems for determining the risk that a subject who does not have dysplasia will develop dysplasia and/or esophageal cancer.. .
Miraca Life Sciences, Inc.

Rare cell isolation device and use thereof

This invention concerns patentable devices configured to capture cancer stem cells and cell clusters. After capturing such cells and/or clusters, the cancerous cells are subjected to whole genome sequencing.
Tumorgen Mdx Llc

Methods and kits for detecting subjects at risk of having cancer

The present invention relates to agents and methods for screening, diagnosis and surveillance of cancer, in particular pancreatic cancer.. .
Valley Health System

Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers

Mitochondrial dna deletions useful for the detection of cancers and sun exposure are provided. In particular, methods and kits for detecting mitochondrial dna deletions for the early detection, diagnosis and progression of prostate cancer, sun exposure and non-melonoma skin cancer are provided..
Mdna Life Sciences Inc.

Non-invasive determination of methylome of fetus or tumor from plasma

Systems, methods, and apparatuses can determine and use methylation profiles of various tissues and samples. Examples are provided.
The Chinese University Of Hong Kong

Selective inhibitors of tumor-initiating cells

Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors.
Children's Medical Center Corporation

Method for determining the survival prognosis of a patient suffering from pancreatic cancer

The present invention relates to pancreatic cancer, and more particularly to the survival prognosis of a patient suffering from pancreatic cancer. The invention also aims to determine the suitability of said patient to receive a treatment for pancreatic cancer, in particular a treatment with gemcitabine.
Acobiom

Microrna expression profile associated with pancreatic cancer

Methods are provided for diagnosing whether a subject has, or is at risk of developing pancreatic cancer. The methods include measuring the level of at least one mir gene product in a biological sample derived from the subject's pancreas.
Board Of Regents Of The University Of Oklahoma

Treatment of cancers with micro-rna inhibitors

The invention relates to the treatment and prevention of cancers, including blood-based cancers and breast cancers, by administering agents that inhibit the activity of micrornas, including mir-22. Inhibitors can include oligonucleotides that are at least partially complementary to these mirnas.
Beth Israel Deaconess Medical Center

Methods and systems for barcoding nucleic acid molecules from individual cells or cell populations

The present disclosure provides methods, compositions and systems for analyzing individual cells or cell populations through a partitioned analysis of contents of individual cells or cell populations, such as cancer cells and cells of the immune system. Individual cells or cell populations may be co-partitioned with processing reagents for accessing cellular contents, and for uniquely identifying the content of a given cell or cell population, and subsequently analyzing the content of the cell and characterizing it as having derived from an individual cell or cell population, including analysis and characterization of nucleic acid(s) from the cell through sequencing..
10x Genomics, Inc.

Antibodies that bind cell-associated ca 125/o772p

The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated ca 125/o772p polypeptides relative to shed ca 125/o772p polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a ca 125/o772p-related disorder.
Purdue Pharma L.p.

Tgfbeta receptor ii antibodies

The present invention relates to antibodies that bind tgfβ receptor ii (tgfβrii), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.. .
Eli Lilly And Company

Methods and compositions for using mhc class ii invariant chain polypeptides as a receptor for macrophage migration inhibitory factor

Methods and compositions for using the mew class ii invariant chain polypeptide, ii (also known as cd74), as a receptor for macrophage migration inhibitory factor (mif), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of mif which bind to this receptor, or which otherwise modulate the interaction of mif with cd74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered mif levels, particularly inflammatory conditions and cancer..
Baxalta Gmbh

Anti-cd47 antibodies and methods of use

Disclosed herein are anti-cd47 antibody molecules, their manufacture and use in treating disorders associated with cd47 expression, for example, certain hematological cancers and solid tumors.. .
Surface Oncology, Inc.

Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and producing antigen-presenting cells

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of seq id nos: 1 to 11 and consisting of 11 or less amino acid residues.. .
Cytlimic Inc,

Immune modulator for immunotherapy and vaccine formulation

A recombinant flagrp170 protein and pharmaceutical compositions comprising a flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The flagrp170 protein comprises an nf-κb-activating domain of flagellin and an atp-binding domain truncated grp170.
Health Research, Inc.

Novel cyclosporin derivatives and uses thereof

Or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.. .

Cytidine derivative dimers and applications thereof

By molecularly designing such cytidine-based compounds, the disclosed cytidine-based derivative dimers/salts show significant inhibiting effects on hct-116 human colon cancer cells, and exhibit strong growth inhibiting effects on hct-116 human colon cancer xenografts grown in nude mice. The disclosed cytidine derivative dimers/salts provide high anti-tumor activity with low toxicity and are useful for treating cancers..

Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient

Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity.
Duquesne University Of The Holy Spirit

Biologically active taxane analogs and methods of treatment by oral administration

The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.. .
Tapestry Pharmaceuticals, Inc.

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.

Methods and compositions for inhibiting the interaction of menin with mll proteins

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with mll1, mll2 and mll-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of mll1, mll2, mll fusion proteins, and/or menin..
The Regents Of The University Of Michigan

Preparation and use of novel protein kinase inhibitors

The invention provides novel compounds and methods of using such compounds to treat or prevent cancer.. .
Brandeis University

Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical compostion for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient

The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting pi3 kinases, thereby being useful in preventing or treating pi3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases..
Korea Research Institute Of Chemical Technology

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

Isoxazolyl substituted imidazopyridines

A compound which is an isoxazolyl imidazopyridine of formula (i): wherein: r0 and r, which are the same or different, are each h or c alkyl; r9′ and r9″, which are the same or different, are each h or f; x is -(alk)n-, -alk-c(═o)—nr—, -alk-nr—c(═o)— or -alk-c(═o)—; r1 is selected from —s(═o)2r′ and a 4- to 7-membered heterocyclic group which is unsubstituted or substituted; r2 and r2′, which are the same or different, are each h or c1-6 alkyl; or r2 and r2′ form, together with the c atom to which they are attached, a c3-6 cycloalkyl group; r3 and r3′, which are the same or different, are each h, c1-6 alkyl, oh or f; r4 is phenyl or a 5- to 12-membered n-containing heteroaryl group and is unsubstituted or substituted; alk is c1-6 alkylene; r′ is c1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or cbp and is used to treat cancer..
Cellcentric Ltd

Trka kinase inhibitors, compositions and methods thereof

The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (i): which are tropomyos-in-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trka.. .
Merck Sharp & Dohme Corp.

Pyridyl benzothiophenes as kinase inhibitors

This invention is directed to compounds, which are useful as protein kinase (pk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.. .
Allergan, Inc.

Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof

The present invention provides compounds pounds of formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, pro-drugs, and compositions thereof. Also provided are methods and kits involving the compounds of formula (i), (ii) or (iii) for treating diseases associated with the over-expression of phosphoglycerate dehydrogenase (phgdh) in a subject, such as proliferative diseases (e.g., cancers (e.g., breast cancer, er negative breast cancer, melanoma, cervical cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases).
Dana-farber Cancer Institute, Inc.

Glutathione-cleavable prodrug and methods of use thereof

A glutathione-cleavable prodrug is provided herein, as well as methods for its use in treating cancer, including triple negative breast cancer. The prodrug can be cleaved by glutathione under physiological conditions to generate a biologically active agent.
Georgetown University

N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same

The present invention provides an n1-cyclic amine-n5-substituted biguanide derivative compound represented by formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of ampk, even when administered in a small dose compared with conventional drugs..
Immunomet Therapeutics Inc.

Orthogonal double dipole cancer therapy treatment beam scanning apparatus and use thereof

The invention comprises a method and apparatus for scanning charged particles in a cancer therapy system, comprising the steps of: (1) providing a first and second dipole magnet system and a gap, the gap comprising a common gap length, along a path of the charged particles, within both the first and second dipole magnet systems, the gap comprising a progressively increasing x/y-plane cross-section area from an entrance area of the charged particles into the double dipole magnet system to an exit area of the double dipole magnet system, the x/y-plane perpendicular to a z-axis from a center of the entrance area to a center of the exit area; (2) scanning the positively charged particles along a first axis of the x/y-plane using the first dipole magnet system; and (3) scanning the positively charged particles along a second axis of the x/y-plane using the second dipole magnet system.. .

Cold atmospheric plasma treatment of actinic keratosis and non-melanoma skin cancer

The present invention relates to a new method of treating patients with the skin conditions including actinic keratosis and non-melanoma skin cancer using cold atmospheric plasma (cap).. .

Apparatus and treating cancer using discontinuous fractional alternative electric field

The present invention relates to an apparatus and a method for treating cancer using a discontinuous fractional alternative electric field, and more particularly, to an apparatus and a method for treating cancer using a discontinuous fractional alternative electric field capable of providing the same treatment effect on tumor while minimizing an effect on normal tissues by reducing time for which an electric field is applied over the existing electric field treatment. According to the exemplary embodiments of the present invention, the discontinuous fractional alternative electric field shows the same effect as applying the continuous electric field to the cancer cells while reducing the effect on the normal cells, and as a result the method for treating cancer using an optimized alternative electric field may be constructed by the treatment using the discontinuous fractional alternative electric field..
Korea University Research And Business Foundation

Drug coated balloon catheters for nonvascular strictures

Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (bph) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (bph), prostate cancer, asthma, and chronic obstructive pulmonary disease (copd).
Urotronic, Inc.

Radiotracer derivatives of trimethoprim for diagnositc imaging

The present invention provides radiolabeled trimethoprim which are useful in imaging tests such as pet scans. The compounds show robust bacterial uptake in vitro and identify infections from inflammation or tumor when administered to a subject.
The Trustees Of The University Of Pennsylvania

Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof

The protein known as six-transmembrane epithelial antigen of prostate 2 (steap2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human igg antibodies that bind to human steap2 (monospecific antibodies).
Regeneron Pharmaceuticals, Inc.

Methods of treatment for epcam positive bladder cancer

The present disclosure provides compositions and methods for treatment of bladder cancer. The methods include administering an immunoconjugate having a binding protein that specifically binds to ep-cam and a toxin to a subject in need of treatment for bladder cancer..
Viventia Bio Inc.

Dosing strategies for targeting epcam positive bladder cancer

The present disclosure provides methods for treatment of bladder cancer. The methods include administering an immunoconjugate to a subject in a dosing regimen that includes an induction phase with twice weekly followed by once weekly dosing, and optionally a maintenance phase.
Viventia Bio Inc.

Pharmaceutical formulations containing lipoic acid derivatives

Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer..
Cornerstone Pharmaceuticals, Inc.

Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies

The present invention concerns methods and compositions related to t cells redirected against cd70 for the immunotherapy of cd70-positive malignancies. In aspects of the invention, t cells that are cd70-specific are employed.
Baylor College Of Medicine

Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy

The present invention relates to combinations and pharmaceutical compositions comprising an igf inhibitor and a chemotherapeutic agent, and their use in treating a proliferative disorder such as cancer (for example a solid cancer such as pancreatic cancer). The invention also provides an igf inhibitor for use in treating such proliferative disorders in combination with a chemotherapeutic agent, and a chemotherapeutic agent for use in treating such proliferative disorders in combination with an igf inhibitor and a biomarker for identifying proliferative disorders which have increased responsiveness to the combined treatment..
The University Of Liverpool

Autoimmune antibodies for use in inhibiting cancer cell growth

The present disclosure provides, among other things, compositions (e.g., autoantibodies) that inhibit the growth, viability, or mobility of (invasion by) a cancer cell. Also provided are applications, such as therapeutic and diagnostic methods, in which the agents are useful, as well as screening methods for identifying autoantibodies useful in the applications..
The Johns Hopkins University

Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds

A nanoparticle comprising at least one sterol, e.g. Cholesterol and a component from quillaja saponaria molina (quilq) selected from quillaja saponin, characterized in that said nanoparticles do not comprise a phospholipid and in that the sterol molecule is bound by a hydrophobic bond between a hydroxyl group of the sterol and terpene moieties in a quil a micelle and by an hydrophilic ester bond between a sterol oh− and cooh− or aldehyde groups in the quila micelle.
Moreinx Ab

Treatment of cancer using recall antigens delivered by attenuated bacteria

Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.. .
Albert Einstein College Of Medicine, Inc.

Therapeutic compositions and methods of use for treating cancer

The present invention relates to compositions and methods for treating cancer. More specifically, the present invention relates to compositions of engineered oncolytic viruses for administration to a subject with cancer that specifically lyse tumor cells and actively target tumor cells and cell debris to antigen presenting cells, in order to generate anti-tumor immunity..
Agalimmune Limited (gb/gb)

Histamine-producing bacterial strains and their use in cancer

The invention herein discloses histamine-producing bacterial strains for use in the prophylaxis, inhibition, treatment or reducing a risk of relapse of cancer, including colorectal cancer. The present invention also discloses the use of histamine-producing bacterial strains for manufacturing a medicament for treatment of cancer, including male colorectal cancer..
Biogaia Ab

Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof

The present invention relates to compositions comprising a recombinant attenuated listeria strain expressing a truncated acta and fusion proteins thereof and methods of using the same for inducing anti-disease immune responses, and treatment of the same, including a tumor growth or cancer. In particular, the invention relates to the treatment of a tumor growth or cancer using a live attenuated recombinant listeria strain that expresses a fusion protein of a truncated acta fused to an antigen..
Advaxis, Inc.

Pyrrolopyrimidine compounds for the treatment of cancer

Wherein: one of x and x′ is n and the other of x and x′ is c, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.. .

4-(2-amino-tetrahydronaphthalenyl)pyrimidine derivative, preparation method therefor, and pharmaceutical composition for preventing or treating cancer, containing same as active ingredient

The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (alk) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (alk) fusion proteins such as eml4-alk and npm-alk, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer..
Korea Research Institute Of Chemical Technology

Combination therapy for cancer

The present invention provides a method of treating squamous histology cancers and pi3k pathway activated large cell lung and colorectal cancers in a patient comprising administering to a patient in need of such treatment an effective amount of 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2s)-2-methoxypropyl]-3-methyl-1,3-dihydro-2h-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of necitumumab.. .
Eli Lilly And Company

Methods of treatment and pharmaceutical compositions using bcn057 or bcn512

The present disclosure is directed to method of treatment for treating or ameliorating various conditions pertaining such as bone marrow recovery (or blood cell production), fibrosis, inflammatory diseases, inhibition of cancer cell growth, propagation or malignancy, thrombocytopenia, wound healing, and conditions related to stem cells by the administration of bcn057, 512, or an analog thereof.. .
Bcn Biosciences L.l.c.

Methods for determining prognosis for breast cancer patients

Described herein are methods for treating breast cancer and for providing a prognosis for metastatic-free survival of breast cancer patients. Aspects relate to treating a patient determined to be at high risk for developing or having metastatic breast cancer comprising administering adjuvant or neoadjuvant therapy to the patient determined to be at high risk for developing or having metastatic breast cancer, wherein the patient was determined to be at high risk for developing or having metastatic breast cancer by determining that the expression level of rkip was reduced and/or the expression level of one or more of hmga2, ccl5, tn-fr2, grn, and ccl7 was elevated in a biological sample from the patient compared to a control non-metastatic tissue sample..
The University Of Chicago

Method of treating skin disorders

In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism.
Mymd Pharmaceuticals, Inc.

Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers

The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-erk mapk pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an erk inhibitor and methods for inhibiting phosphorylation of rsk in a cancer cell that is refractory or resistant to a non-erk mapk pathway inhibitor..
Biomed Valley Discoveries, Inc.

Pharmaceutical composition, methods for treating and uses thereof

Wherein r1 to r6, and x are as defined herein, and an sglt2 inhibitor. In addition the present invention relates to methods for preventing, slowing the progression of, delaying or treating fibrotic disorders, metabolic disorders, inflammation disorders, ocular diseases, neuroinflammatory disorders or cancer in a patient in need thereof characterized in that the pharmaceutical combination according to the invention is administered to the patient..

Endoxifen for local transdermal therapy to the breast

Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (dcis) using local transdermal therapy (ltt). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, n-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or enx) for treating breast cancer.
Northwestern University

Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer

This invention is related to use of exosomes for biomarker analysis for early detecting and characterizing of disease progression of cancer. Further, the invention provides bioengineered exosomes for use in methods of targeting and treating cancer..
Case Western Reserve University

Treatment devices and methods

The present invention is directed to a medical device for providing treatment to diseased tissue and cells. The medical device is configured to ablate a target tissue surface, optionally within a resection cavity, and further deliver a therapeutic that targets diseased (e.g., cancer) cells via a marker whose expression is upregulated by the ablation.
Innoblative Designs, Inc.

System and identifying cancerous tissue

A system and method for identifying a characteristic of a region of a subject, such as whether a region is cancerous, which includes an ultrasonic imaging device that acquires a first and second set of time series data from a region of a subject during a first and second time period. The system includes a comparison device (120) that receives first and second sets of time series data (116, 118) and computes differential data (119) therebetween at one or more features.
The University Of British Columbia

Light emitting ornament assembly

A light emitting ornament assembly is provided for publicly displaying breast cancer awareness. The assembly includes an ornament structured to resemble a breast cancer ribbon.

Asavi, Llc

. .

Surrogate functional biomarker for solid tumor cancer

The present invention relates to diagnostic methods that are relevant to various solid tumor cancers that are not amenable to traditional bih3 profiling diagnostic methods. In some embodiments, the methods described herein are useful in the evaluation of a patient, for example, for evaluating diagnosis, prognosis, and response to treatment.
Eutropics Pharmaceuticals, Inc.

Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Disclosed herein are panels related to the diagnosis or recognition of advanced adenoma and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient.
Applied Proteomics, Inc.

Adenoviral tumor diagnostics

Compositions and methods for detecting a cancer in a subject using a recombinant reporter adenovirus are described. In particular, recombinant adenovirus is used to diagnose a cancer in a patient and further used for screening compounds effective in treating the cancer in said patient..
Salk Institute For Biological Studies

Method for identifying or detecting genomic rearrangements in a biological sample

A method for detection, visualization and/or comparison of polynucleotide sequences of interest using specially designed sets of long and short probes that enhance resolution and simplify visualization and detection. Probe compositions useful for practicing this method and procedures for identifying useful probes and probe combinations.
Genomic Vision

Method for determining prognosis of breast cancer patient by using gene expression data

A method for determining prognosis of a breast cancer patient according to an embodiment includes: collecting information on cancer tissue in a patient group from patient information determined to have breast cancer, collecting gene expression information of each patient group, sorting genes by performing a test for a group having a high expression level and a group having a low expression level based on gene expression of each patient group, clustering genes based on expression patterns of the sorted genes, defining a prognostic score using a gene expression ratio for a gene, and deriving prognosis for breast cancer in a patient group by using the prognostic score.. .
Gwangju Institute Of Science And Technology

Methods for predicting drug responsiveness in cancer patients

The present invention features methods, devices, and kits for detecting expression in a patient having cancer or determining responsive of a patient having cancer to a treatment, such as irofulven. The invention further includes methods of treating a patient having cancer by administering, e.g., irofulven..
Oncology Venture Aps

Dna methylation markers for metastatic prostate cancer

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer.
The Johns Hopkins University

Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer..
Engenelc Molecular Delivery Pty. Ltd.

Reduction of tgf beta signaling in myeloid cells in the treatment of cancer

Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing tgfβ signaling, for example, by reducing tgfβ receptor ii expression in myeloid cells. Vectors comprising a tgfβ receptor ii rnai nucleic acid sequence operably linked to a myeloid specific promoter also are provided.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Method and kit for use in inhiiting tumor progression, predicting or determining tumor progression state in vgf expressing cancers

The present invention provides a method of inhibiting tumor progression in a subject suffering from vgf expressing cancers. The present invention also provides a method and a kit of predicting or determining tumor progression state in a subject suffering from vgf expressing cancers..
Truebio Llc

Organic compositions to treat epas1 - related diseases

The present disclosure relates to methods of treating epas1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, rheumatoid arthritis, using a therapeutically effective amount of a rnai agent to epas1.. .
Arrowhead Pharmaceuticals, Inc.

Cancer cell enrichment system

The present invention describes a method for the propagation of a subpopulation of cells. The subpopulation of cells can be grown in specific culture conditions to promote growth and enrichment of the subpopulation of cells.
Xcell Biosciences, Inc.

Prostate-specific membrane antigen binding proteins and related compositions and methods

The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (psma) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (bph). In one embodiment, the multi-specific poly-peptide therapeutics bind both psma-expressing cells and the t-cell receptor complex on t cells to induce target-dependent t-cell cytotoxicity, activation and proliferation..
Aptevo Research And Development Llc

Use of car-modified human natural killer cells to treat cancer

The invention provides a natural killer cell, which may be a nk92 cell that is modified to express one or more types of chimeric antigen receptor (car) on its surface, and administering said cell to a subject for a cancer treatment. Said engineered car comprises an antigen binding domain, which may bind cd19 or gd2, a transmembrane domain, a co-stimulatory signaling region, which may be all or a portion or variant of 2b4, and a signaling domain, which may be all or a portion or variant of cd3ζ..

Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target

The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Bifunctional stapled polypeptides and uses thereof

The invention relates to bifunctional stapled or stiched peptides comprising a targeting domain, a linker moiety, and an effector domain, that can be used to tether, or to bring into close proximity, at least two cellular entities (e.g., proteins). Certain aspects relate to bifunctional stapled or stiched peptides that bind to an effector biomolecule through the effector domain and bind to a target biomolecule through the targeting domain.
President And Fellows Of Harvard College

Novel compounds as rearranged during transfection (ret) inhibitors

This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. .
Glaxosmithkline Intellectual Property Development Limited

Compounds useful for inhibiting metastasis from cancer and methods using same

The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one cx3cr1 or fractalkine antagonist..
Alliance Discovery, Inc.

3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives

In which w, r1, r2 and r3 have the meanings indicated in claim 1, are inhibitors of alk1, al2 and alk5, and can be employed for the treatment of diseases such as cancer.. .

Quinazoline derivatives as vegf inhibitors

The invention relates to quinazoline derivatives of formula (i), wherein m is an integer from 1 to 3; r1 represents halogeno or c1-3alkyl; x1 represents —o—; r2 is selected from one of the following three groups: 1) c1-5alkylr3 (wherein r3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, c1-4 alkyl, c1-4hydroxyalkyl and c1-4alkoxy; 2) c2-5alkenylr3 (wherein r3 is as defined hereinbefore); 3) c2-5alkynylr3 (wherein r3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (i) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (i) and the pharmaceutically acceptable salts thereof inhibit the effects of vegf, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis..
Genzyme Corporation

Process for the preparation of androgen receptor antagonists and intermediates thereof

The present invention relates to an improved process for the preparation of carboxamide structured androgen receptor (ar) antagonists such as n—((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide (1a) and key intermediates thereof such as 2-chloro-4-(1h-pyrazol-3-yl)benzonitrile (v). Ar antagonists are useful in the treatment of cancer, particularly prostate cancer and other diseases where ar antagonism is desired..
Orion Corporation

Novel aryl-cyanoguanidine compounds

The present invention relates to protein-lysine n-methyltransferase smyd2 (set and mynd domain-containing protein 2) inhibitors, in particular smyd2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (i), wherein r1, r2, r3, r4 and r5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of smyd2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility..
Bayer Pharma Aktiengesellschaft

Double dipole cancer therapy treatment beam scanning apparatus and use thereof

The invention comprises a method and apparatus for steering/scanning charged particles, comprising: a double dipole scanning system, comprising: (1) a beam path chamber comprising an entrance side and an exit side, the entrance side comprising a smaller area than the exit side; (2) a first dipole magnet, the first dipole magnet comprising a first coil and a third coil on first opposite sides of the beam path chamber; and (3) a second dipole magnet, the second dipole magnet comprising a second coil and a fourth coil on second opposite sides of the beam path chamber, the beam path chamber further comprising a truncated square/rectangle pyramid shape, the smaller entrance side of the charged particles comprising a top of the truncated pyramid shape, the exit side of the charged particles comprising a larger bottom of the truncated pyramid shape.. .